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Abstract 
Background: Cardiac fibrosis, a component of pathological remodelling, often arises 
secondary to hypertension or myocardial infarction. It leads to systolic and diastolic cardiac 
dysfunction, since the increased collagen deposition increases myocardial stiffness. Reactive 
oxygen species (ROS) are implicated in this pathology and NADPH oxidase-2 (NOX2), a major 
producer of ROS, is elevated in heart failure settings. Previous work showed that global NOX2 
knockout (KO) mice had reduced generation of cardiac fibrosis, but the cell-type specific role 
of NOX2 is yet to be investigated in this context.  
Aim: This research aimed to determine the role of fibroblast and endothelial cell NOX2 in the 
development of cardiac fibrosis in mice. In addition, the extent of endothelial-mesenchymal 
transition (EndoMT) in the development of cardiac fibrosis was to be assessed using a lineage 
tracing approach. 
Methods and Results: Tamoxifen-inducible fibroblast-specific NOX2 KO mice were generated 
by crossing novel NOX2 floxed mice with Collagen 1α2 (Col1α2)-Cre mice. Cardiac NOX2 
protein expression was reduced by 60% in these mice. Cardiac fibrosis was induced using 
chronic angiotensin II (Ang II) infusion (1.1mg/kg/day) and blood pressure was monitored by 
ambulatory telemetry. Fibroblast NOX2 KO mice had a significantly delayed hypertensive 
response and less cardiac fibrosis compared to wildtype (WT), as determined by histological 
analysis of cardiac sections. In contrast, fibroblast NOX2 KO mice were not protected from 
cardiac fibrosis when subjected to chronic pressure overload by transverse aortic constriction 
(TAC), nor were they protected from systolic and diastolic dysfunction as determined by serial 
echocardiography.  
Similarly, endothelial cell-specific NOX2 KO mice were generated by crossing floxed NOX2 
mice with VE-Cadherin (Cdh5)-Cre mice, with a 60% reduction in aortic NOX2 protein levels. 
These mice were also not protected from developing cardiac fibrosis or cardiac dysfunction 
when subjected to TAC.  
The Col1α2 and Cdh5 Cre-recombinase efficiencies were assessed by crossing with a 
tdTomato “STOP” floxed reporter mouse, showing high tdTomato expression in specific cell 
types and estimated high efficiency of ≥70% using flow cytometry. The extent of EndoMT was 
assessed in Cdh5 tdTomato (EndoTom) mice subjected to TAC using a lineage tracing 
approach. There was no convincing evidence of EndoMT in cardiac or lung tissue, since the 
percentage of tdTomato+ (Cdh5 lineage traced) cells expressing the fibroblast marker CD140α 
was not augmented by TAC (determined by flow cytometry). 
Conclusion: Although fibroblast NOX2 contributes to the development of Ang II-induced 
cardiac fibrosis it is dispensable for TAC-induced fibrosis. Endothelial cell NOX2 is also 
dispensable for TAC-induced fibrosis.  These results suggest that the cell-specific role of NOX2 
in cardiac fibrosis is stimulus dependent. The activation of NOX2 in other cell types may be 
required for the development of cardiac fibrosis in response to chronic pressure overload. 
Furthermore, EndoMT appears to be at most a minor contributor to the development of 
cardiac fibrosis after TAC. Taken together, this work provides new insights into the cell-
specific roles of NOX2 in the development of cardiac fibrosis.  
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CreER(T) - Inducible Cre recombinase 
Ct (values) - Cycle threshold (values) 
CTGF  - Connective tissue growth factor 
CVF  - Collagen volume fraction 
DAPI  - 4',6-diamidino-2-phenylindole 
DDR2  - Discoidin domain receptor 2 
DMEM  - Dulbecco’s Modified Eagle’s Medium 
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DNA  - Deoxyribonucleic acid 
DPX  - Distyrene, a plasticizer and xylene (mixture of) 
DsRed  - Discosoma sp. Red 
E wave  - Early ventricular filling velocity (Doppler-derived) 
E/A ratio - Early/late ventricular filling velocity ratio (Doppler-derived) 
E/E’  - Mitral valve ‘E’ wave velocity to annular motion ratio 
E’  - Early mitral valve diastolic annular motion 
ECM  - Extracellular matrix 
EDTA  - Ethylenediaminetetraacetic acid 
eGFP  - Enhanced green fluorescent protein 
EndoMT - Endothelial to mesenchymal transition 
EndoTom - Endothelial cell reporter mice (Cdh5CreER(T2):ROSA26R- 
   tdTomatoflox/flox) 
eNOS  - Endothelial nitric oxide synthase 
ERK1/2   - Extracellular-signal-regulated kinase type 1/2  
FBS  - Foetal bovine serum 
FibroTom - Fibroblast reporter mice (Col1α2CreER(T):ROSA26R-tdTomatoflox/flox) 
FITC  - Fluorescein isothiocyanate 
FSC-A/H - Forward scatter area/height 
FSP-1  - Fibroblast-specific protein-1 
GDP  - Guanosine diphosphate 
GFP  - Green fluorescent protein 
GTP  - Guanosine triphosphate 
HFpEF  - Heart failure with preserved ejection fraction 
HW  - Heart weight 
HW: BW - Heart weight to body weight ratio 
IVCT  - Isovolumic contraction Time 
IVRT  - Isovolumic relaxation time 
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KO  - Knockout 
LA  - Left atrium 
LacZ  - Beta-galactosidase (β-galactosidase) 
LoxP  - Locus of X-over P1 
LV  - Left ventricle 
MAP  - Mitogen activated protein 
MI  - Myocardial infarction 
MMP(s) - Matrix metalloproteinase(s) 
mRNA  - Messenger ribonucleic acid 
NADPH  - Nicotinamide adenine dinucleotide phosphate 
NaOH  - Sodium hydroxide 
NOS  - Nitric oxide synthase 
NOX  - NADPH oxidase 
PBS  - Phosphate buffered saline 
PCR  - Polymerase chain reaction 
PDGFR1α - Platelet-derived growth factor receptor 1-alpha 
PE  - Phycoerythrin 
PFA  - Paraformaldehyde 
PI3Kγ  - Phosphoinositide 3-kinase gamma 
Postn  - Periostin gene 
qPCR  - Quantitative polymerase chain reaction 
RA  - Right atrium 
RAAS  - Renin angiotensin aldosterone system 
RNA  - Ribonucleic acid 
ROS  - Reactive oxygen species 
RV  - Right ventricle 
SDS  - Sodium dodecyl sulfate 
SOD  - Superoxide dismutase 
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SPARC  - Secreted-protein, acidic and rich in cysteine 
SSC-A/H - Side scatter area/height 
TAC  - Transverse aortic constriction 
TAE  - Buffer containing 40mM Tris, 20mM acetic acid, and 1mM EDTA 
Taq  - DNA polymerize derived from Thermus Aquaticus 
tdTomato - Tandem dimer tomato 
TGFβ  - Transforming growth factor beta 
Tie1  - Tunica intima endothelial kinase 1 gene 
Tie2  - Tunica intima endothelial kinase 2 gene 
TIMP(s)  - Tissue inhibitors of metalloproteinase(s) 
TNFα  - Tumour necrosis factor alpha 
VE-Cadherin - Vascular endothelial cadherin 
WGA  - Wheat germ agglutinin 
WT  - Wildtype 























CHAPTER 1: General Introduction 
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1.1 Cardiovascular Disease, Cardiac Fibrosis and Cardiac 
Function 
The heart is central to the cardiovascular system, operating without rest and with 
limited regenerative capacity. Pathological stresses on the heart can be either acute 
or chronic in nature, but both will lead to initially compensatory changes in the 
geometry, function and composition of the heart, known as cardiac remodelling. 
Cardiac hypertrophy, for example, is the growth of cardiomyocytes, either concentric 
(thickening) or eccentric (elongation) and may result in dilated cardiomyopathy.1 
Functional changes will occur as a consequence and may affect overall cardiac 
pumping efficiency. 
Cardiac fibrosis is a component of pathological cardiac remodelling, described as the 
excessive deposition of collagen and the formation of scar tissue.2 It is seen in a wide 
range of cardiovascular pathologies and diseases, including chronic hypertension, 
aortic stenosis, cardiac valve disease, diabetes and after more acute events such as 
myocardial infarction (MI) and myocarditis.3-7 Cardiovascular disease is now a major 
cause of morbidity and age-related mortality in the developed and increasingly in the 
developing world,8, 9 with most leading to some form of cardiac fibrosis.5, 10 
Hypertension, for example, has a high prevalence of 26% and is itself a promoter of 
ischaemic heart disease and MI events.11  
One important functional consequence of cardiac fibrosis is diastolic dysfunction, 
which describes impairment of the filling function of the heart. This occurs in many 
cardiac conditions but is especially relevant to the relatively new concept of heart 
failure with preserved ejection fraction (HFpEF). Of all heart failure cases around 50% 
are thought to be HFpEF, for which there is no proven therapy.12 In mechanical terms, 
an increase in interstitial cardiac collagen deposition will lead to myocardial 
stiffening,13 thereby reducing ventricular elasticity, or compliance, culminating in 
compromised ventricular filling.12, 14, 15 Cardiac fibrosis also involves the deposition of 
a range of extracellular matrix components, further discussed in chapter 1.2. 
Impaired relaxation will cause an increase in ventricular and atrial filling pressures 
and over time may lead to secondary pulmonary hypertension and other symptoms 
of heart failure, including congestion and lung oedema.16 Although ventricular 
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ejection fraction and cardiac output are preserved at rest, patients with HFpEF may 
have a reduced capacity to augment these indices during exercise, severely impacting 
quality of life.12, 17, 18  
Cardiac fibrosis can also directly cause systolic cardiac dysfunction. Electrical 
conduction during systole follows two paths; conduction along myocardial fibres and 
conduction across fibres to adjacent fibres. Collagen deposition between adjacent 
myocardial fibres delays electrical conduction velocities, whereas conduction along 
an individual bundle will be largely undisturbed.19 In simple terms, this fibrosis-
induced difference in conduction velocities uncouples electrical signalling between 
cardiomyocytes, causing ventricular dyssynchrony and reduced systolic pumping 
efficiency.20, 21 There is also an increased propensity towards cardiac arrhythmias and 
sudden cardiac death.19, 22 
Cardiac fibrosis, diastolic dysfunction and HFpEF currently have no specific treatments 
and together demonstrate an area of high unmet medical need; hence understanding 
the processes involved in the development of cardiac fibrosis is an important and 
urgent research goal. 
1.2 The Cardiac Extracellular Matrix in Health and Disease 
Cardiac fibrosis develops in the extracellular matrix (ECM), a diverse and dynamic 
network of structural and non-structural proteins responsible for maintaining cell 
organisation and tissue structure.23 The ECM provides anchoring points for 
cardiomyocytes, essential for mechanical force transmission during systole, whilst 
preventing overstretching during diastole.7 The ECM also provides support and 
flexibility for coronary vessels operating under high pressures10 and further functions 
as a modulator of electrical signalling between cardiac cells and between atria and 
ventricles, providing insulation to prevent premature contractions.5, 10  
A delicate balance of ECM synthesis and degradation exists in a healthy heart, 
allowing for normal growth and remodelling.24 During adaptive cardiac hypertrophy, 
such as in elite athletes in training, proportionate growth, remodelling and expansion 
of the ECM occurs as a homeostatic mechanism in order to support cardiomyocyte 
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growth.25, 26 Key to this process are the matrix metalloproteinases (MMPs) and tissue 
inhibitors of metalloproteinases (TIMPs) which are discussed later in chapter 1.2.1. 
In contrast, during diseases such as chronic hypertension or in experimental models 
of pressure overload, a disproportionate increase in ECM deposition is observed, 
upsetting the delicate balance and promoting cardiac fibrosis.24, 27, 28 The deposition 
of ECM is excessive and sustained, collagen chains also become cross-linked, leading 
to progressive detrimental effects on cardiac structure and function. 
Cardiac fibrosis can be divided into two broad categories. Replacement fibrosis occurs 
predominantly after an acute inflammatory event such as MI; the sudden death of 
cardiomyocytes after infarction causes a spike in inflammatory signalling, leading to 
the eventual replacement of dead myocytes with collagen.27, 28 In contrast, reactive 
fibrosis has mechanical stress origins and is more diffuse throughout the 
myocardium.24 Replacement and reactive fibrosis can be easily modelled in animal 
models using myocardial infarction and chronic angiotensin II or pressure overload 
surgical models, respectively, where cardiac fibrosis is evident both in the interstitial 
and perivascular regions.29-34 
1.2.1 ECM Components 
The ECM contains a plethora of different cells, enzymes, structural and non-structural 
components, as well as growth factors and cytokines.28 Fibrillar collagen, with its 
triple helix structure, is the most abundant non-cellular component in the heart, with 
types I and III providing tensile strength and elasticity, respectively.24 Collagen I forms 
thick fibres and accounts for around 85% of total cardiac ECM collagen, with thinner 
collagen III as the next most abundant.28 Fibrillar collagen is synthesised as 
procollagen, before undergoing post-translational processing to form collagen fibrils 
and eventually thicker collagen fibres.24 In addition to collagens I and III, there over 20 
collagens exist, many of which are expressed in heart. In particular, collagen IV and 
collagen VI are shown to have increased expression following myocardial infarction or 
chronic pressure overload. Some collagens, such as collagen XVIII, even play a 
protective role during cardiac pathology.24 It is also worth noting that a number of 
cardiac cells produce collagen and increase production during pathological cardiac 
stress, including MI and pressure overload. 
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Another major structural component is fibronectin, a fibril-forming glycoprotein 
secreted by fibroblasts. Fibronectin forms large, complex, cross-linked networks and 
interacts with ECM components such as collagen and fibroblasts via integrin 
receptors, a process important for cell adhesion, migration, growth and 
proliferation.28 Similar to collagen, the expression of fibronectin is increased during 
cardiac pathologies and is a marker of cardiac fibrosis.32, 35 
Elastin is important in tissues required to stretch and recoil, such as the heart, lungs 
and aorta. It is a fibrous, elastic polymer, giving rise to flexibility in cardiac tissue 
during diastole and also plays a role in cell adhesion, migration, differentiation and 
survival.36 Elastin has been shown as essential, since elastin knockout (KO) mice die 
shortly after birth.37 In pathology, recombinant elastin can prevent cardiac 
dysfunction and reduce fibrotic scar expansion in a model of rat myocardial 
infarction.38 A reduction in cardiac fibrosis following chronic pressure overload was 
also shown to be associated with increased elastin expression in mice.39 
Tissue MMPs and TIMPs are groups of non-structural proteins involved in ECM 
turnover. As with the structural ECM components, MMPs and TIMPs also have altered 
expression during cardiac stress and remodelling.40 MMPs are expressed by 
cardiomyocytes, endothelial cells and fibroblasts and are the major proteolytic 
enzymes in collagen, fibronectin and other structural ECM component breakdown.24 
Over 20 MMPs have been identified and grouped according to their primary targets, 
for example MMPs 1, 8 and 13 are regarded as collagenases, involved in the digestion 
of collagen types I and III amongst others. MMPs are synthesised as pro-MMPs and 
must first be activated by cleavage of an amino domain, either by another proteolytic 
enzyme or by auto-proteolysis. 
Indiscriminate breakdown of the ECM is avoided by specific inhibitors of MMPs, 
known as TIMPs. TIMPs are small molecules which essentially act like a plug to block 
the active proteolytic sites of MMPs. Together, the 4 TIMP subtypes inhibit virtually 
all MMPs, though there are reported differences in affinity for specific MMPs.24 
TIMPs may also have MMP-independent functions, for example TIMP-2 is believed to 
be inhibitory to cell proliferation.41  
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Matricellular proteins are non-structural, but bind to structural components and 
cardiac cells to aid stability.42 For example, secreted-protein-acidic and rich in 
cysteine (SPARC) expression is increased after infarction and is particularly important 
in post infarct cardiac stability, since targeted deletion in mice (SPARC KO) results in 
increased post infarct mortality by cardiac rupture.43 The authors also showed a 
reduction in systolic function in SPARC KO mice accompanied by abnormal and 
immature collagen deposition. In chronic pressure overload, a model less likely to 
result in cardiac rupture, it was shown that SPARC KO mice had less cardiac fibrosis, 
less myocardial passive stiffness and a non-significant improvement in mortality 
compared to controls.44 Another key matricellular protein is osteopontin, a secreted 
protein expressed during cardiac stress and remodelling.24 In contrast to SPARC KO, 
mice with deletion of osteopontin (osteopontin KO) did not have reduced cardiac 
fibrosis in response to chronic pressure overload,45 but a reduction was observed in a 
chronic angiotensin II model.42 Interestingly, similar to SPARC KO, osteopontin KO 
appears detrimental in infarcted mouse models,42 suggesting that these matricellular 
proteins are most important in post-infarct stability and remodelling. 
1.3 Cardiac Cells in Cardiac Fibrosis 
Multiple cell types and cell-cell interactions are involved in both ECM homeostasis 
and cardiac fibrosis pathology, notably cardiomyocytes, endothelial cells, 
inflammatory cells and cardiac fibroblasts.46  
1.3.1 Cardiac Fibroblasts 
The adult human heart is thought to be composed of approximately 70% non-
cardiomyocytes, of which fibroblasts are assumed to be the most abundant. 
Fibroblasts help to maintain ECM structure, function and integrity through autocrine 
and paracrine signalling, as well as physically through cell-cell and cell-ECM 
interactions.46 Resident cardiac fibroblasts are therefore key players in ECM 
homeostasis (Figure 1-1), since they produce mainly types I and III collagen, in 
addition to degradative enzymes MMPs for remodelling.5  
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Figure 1-1: The roles of a cardiac fibroblast in the extracellular matrix. Cardiac 
fibroblasts are central to extracellular matrix (ECM) homeostasis, able to promote 
both synthesis and degradation of ECM components. Cardiac fibroblasts are able to 
respond to various activation stimuli, transforming to highly active myofibroblasts 
with proliferative and migratory tendencies. Image adapted from Krenning et al., 
2010.5 
Upon activation by pathological stimuli, fibroblasts transform and take on a slightly 
different phenotype, displaying stress fibres and markers similar to those of smooth 
muscle cells, such as smooth muscle actin alpha (αSMA; Figure 1-1).7 Fibroblasts may 
become activated by a range of stimuli including, A: growth factors (e.g. transforming 
growth factor-β (TGFβ), connective tissue growth factor [CTGF], endothelin-1) 
released by cardiomyocytes or endothelial cells; B: cytokines (e.g. tumour necrosis 
factor-α [TNFα] and interleukins) released by infiltrating inflammatory cells; C: 
neurohumoral stimuli such as angiotensin-II (Ang II); or D: mechanical stimuli such as 
stretch.5 Activated fibroblasts, known as myofibroblasts, are highly migratory and 
proliferative and themselves secrete pro-inflammatory growth factors and cytokines, 
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in addition to increased ECM synthesis such as collagen.46 The combination of 
persistent fibroblast activation and increased rates of proliferation and accumulation 
is the main contributor to pathological ECM deposition and the progression of cardiac 
fibrosis towards heart failure.5, 46  
1.3.2 Cardiomyocytes 
In addition to inflammatory signalling due to cardiomyocyte death, cardiomyocytes 
can directly activate interstitial fibroblasts via the release of factors such as TGFβ and 
Ang II (discussed later in section 1.5). This so-called paracrine signalling from 
cardiomyocytes to fibroblasts promotes pro-fibrotic signalling and is proving to be a 
key mechanism in the development of cardiac fibrosis.47 A number of studies have 
used gene knockout (KO) mice to successfully disrupt cardiomyocyte signalling and 
the development of cardiac fibrosis, indicating a major role for this cell type. For 
example, mice deficient in cardiomyocyte TGFβ-2 receptor had significantly reduced 
cardiac fibrosis following TAC,48 with similar results for mice deficient in 
cardiomyocyte RhoA.49 In addition, an overexpression approach was used to show 
that TAK1 in cardiomyocytes, a target for TGFβ, mediates cardiac fibrosis and other 
deleterious effects.50 
1.3.3 Endothelial Cells 
Endothelial cells may contribute to cardiac fibrosis at least in part due to endothelial-
mesenchymal transition (EndoMT).51 Limited studies have shown that endothelial 
cells may convert to a fibroblast-like phenotype, synthesize collagen and contribute 
to cardiac fibrosis.30, 52, 53 The role of endothelial cells in EndoMT is further discussed 
in chapter 5.1 and chapter 6.1. Endothelial cells are further implicated due to their 
signalling through endothelin-1, a pro-fibrotic mediator shown as essential for cardiac 
fibrosis in a mouse model of chronic Ang II.54 
1.3.4 Inflammatory Cells 
Inflammatory cells are present in low numbers under basal conditions in cardiac 
tissue. Following an ischaemic event or cardiomyocyte cell death, inflammatory 
leukocytes, mainly neutrophils, are attracted to sites of damage from the circulation 
and further release pro-inflammatory mediators such as interleukins and TGFβ.55 
Chronic angiotensin II acting via the angiotensin II type 1 receptor is known to 
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promote the release of chemoattractant molecules such as MCP-1 by 
monocyte/macrophages.56 Various studies have shown a role for mast cells, T-
lymphocytes and macrophages in the development of cardiac fibrosis in response to 
both chronic angiotensin II and pressure overload.57 It is suggested that signalling 
from these inflammatory cells causes the activation of cardiac fibroblasts which then 
secrete ECM. A possible role for inflammatory cells in the development of cardiac 
fibrosis is exemplified by interleukin-6 KO mice, which develop less inflammation and 
cardiac fibrosis as a result of chronic Ang II treatment.58  
1.3.5 Fibrocytes 
Fibrocytes are similar in shape to fibroblasts, produce collagen and other structural 
fibres and are elevated in cardiac fibrosis.59 They are found in the circulation where 
they can respond quickly to sites of damage such as skin wounds. Fibrocytes therefor 
cannot be overlooked with regard to the development of cardiac fibrosis. 
Furthermore they are capable of differentiating into myofibroblasts allowing it to 
carry out functions detailed in chapter 1.3.1.60  
1.4 Mouse Models of Cardiac Fibrosis 
Mouse models of cardiovascular disease have made it possible to elucidate 
mechanisms and a more thorough understanding of cardiac fibrosis and its drivers. As 
in humans, both reactive and replacement cardiac fibrosis exist in mice, resulting in 
fibrillar collagen deposition and increased myocardial stiffness.61 It is worth noting 
that both chronic renin-angiotensin and chronic pressure overload models will have 
rapid onset of pathology (<2 weeks) in mouse models, compared to progressive onset 
(>40 years) in humans. This limitation is further discussed in chapter 7.4. 
1.4.1 Experimental Renin-Angiotensin-Aldosterone Chronic Stimulation 
Chronic stimulation of the renin-angiotensin-aldosterone system (RAAS) leads to 
hypertension. Hypertension is a precursor for cardiac fibrosis and experimental 
mouse models have been designed to chronically target specific aspects, such as 
chronic infusion with angiotensin II35, 62, aldosterone35, 63 or the synthetic mimetic 
deoxycorticosterone acetate,64, 65 all of which induce hypertension and cardiac 
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fibrosis in mice. These models can often lead to systolic and diastolic dysfunction as a 
result of cardiac fibrosis, depending on the angiotensin II dose and duration. 
1.4.2 Experimental Chronic Pressure Overload  
In contrast to replacement fibrosis, reactive fibrosis occurs in the absence of major 
myocyte necrosis and is characterised by diffuse ECM deposition and accumulation of 
collagens in the interstitial or perivascular space.61, 66  
The suprarenal abdominal aortic banding (AAB) and transverse aortic constriction 
(TAC) mouse models mimic vascular stenosis and are both regularly used to generate 
profound pressure overload-induced cardiac fibrosis and even lung fibrosis.29, 31, 67-72 
Cardiac pressure overload causes fibrosis since fibroblasts can become activated due 
to mechanical stress, e.g. stretch, leading to fibroblast differentiation, proliferation, 
pro-fibrotic signalling and excessive collagen deposition.5 Chronic pressure overload 
invariably leads to severe systolic and often diastolic dysfunction, particularly after 
longer durations. 
1.4.3 Experimental Myocardial Infarction (MI)  
Replacement or reparative fibrosis occurs as a result of cardiomyocyte loss due to 
necrosis, where dead cells are replaced by fibrotic scar tissue.73 This can be induced 
by the MI model in mice, since permanent cardiomyocyte loss occurs, followed by the 
formation of a discrete scar.74 The MI surgical mouse model mimics human 
myocardial infarction by permanently ligating the left anterior descending coronary 
artery. This results in an ischaemic, infarcted zone and cardiomyocyte death. The 
ischaemic area will become akinetic and surrounding fibrotic regions may affect 
border zone contractility.75 
1.5 Pro-fibrotic Signalling 
A range of interconnected, pro-fibrotic signalling pathways and mediators have been 
described in the heart. Studies have used receptor blockade and various gene 
modification techniques to show significant reductions in the development of cardiac 
fibrosis. Key targets are given in Table 1-1.  
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Table 1-1: Signalling pathways targeted to prevent the development of cardiac 
fibrosis. *Rho-kinase (ROCK) inhibitor involved in the TGF-β-TAK1 pathway, 
#traditionally an angiotensin converting enzyme inhibitor. 
Target/ Inhibitor Outcome Models Ref. 
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1.5.1 Activation of the Renin-Angiotensin-Aldosterone System 
The RAAS is a potent hormone system involved in salt regulation and arterial blood 
pressure homeostasis. Under physiological conditions, a reduction in arterial and 
therefore renal blood pressure is detected by the juxtaglomerular apparatus in the 
kidney, leading to the cleavage and secretion of renin.87 Renin is an enzyme which 
cleaves circulating hepatic angiotensinogen to angiotensin I, which is further cleaved 
to angiotensin II by angiotensin-converting enzyme (ACE) in the lungs. Angiotensin II 
is a potent vasoactive peptide, acting primarily on AT1 receptors to induce 
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constriction of blood vessels.88 AT1 receptor activation also promotes the 
upregulation of the pro-fibrotic cytokine TGFβ.2  
Release of anti-diuretic hormone (ADH) is also stimulated by angiotensin II, as well as 
release of aldosterone, a hormone which acts on the distal collecting tubes of the 
kidney to increase sodium and water reabsorption.88 The net result of RAAS 
stimulation is an increase in effective circulating volume, through sodium and water 
retention, as well as an increase in arterial blood pressure (in part mediated via 
vasoconstriction). Chronic activation of the RAAS therefore causes hypertension and 
each RAAS effector such as Ang II and aldosterone, or downstream mediators such as 
TGFβ, have been shown experimentally to contribute to cardiac fibrosis (Table 1-1).  
In addition to the classical circulating RAAS, mounting evidence suggests that the 
RAAS can be found locally in individual tissues, capable of producing and responding 
to Ang II, most likely initiated by tissue uptake of circulating renal renin and hepatic 
angiotensinogen.87, 89 The so-called local tissue RAAS operates alongside circulating 
RAAS in the heart, where it is thought to be involved in the inhibition of cell growth 
and proliferation.87 The implications of local tissue RAAS are currently unknown, but 
the classical circulating RAAS is a common target for the clinical and experimental 
reversal of chronic hypertension, cardiac dysfunction and the management of 
fibrosis.24, 88  
It is worth noting that the metabolites of angiotensin II, Ang1-7 and Ang1-9, are 
thought to oppose the pathological signalling of angiotensin II and Ang1-9 has 
recently been shown to attenuate cardiac fibrosis in mice.90 
1.5.2 TGFβ-dependent Signalling 
Often at the heart of pro-fibrotic signalling is TGFβ, a pleiotropic cytokine, regarded 
as a master switch in the initiation of cardiac fibrosis following inflammation.91 TGFβ 
has enhanced expression in a range of pathologies, including cardiac fibrosis and its 
expression can be induced experimentally by Ang II or by the application of 
mechanical stretch.66, 91, 92 Following synthesis, TGFβ is secreted in an inactive form 
and must be proteolytically cleaved for activation. MMP-2, MMP-9, plasmin and 
thrombospondin have all been recognised as activators, allowing TGFβ to associate 
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with its type II receptor which dimerises with and activates the type I receptor.66 
TGFβ signalling can be through Smad transcription factors (canonical) or Smad-
independent (non-canonical) pathways. Canonical pathways involve Smad3 activation 
of TGFβ response elements to induce collagen transcription and synthesis, whereas 
non-canonical pathways involve activation of kinases such as p38 MAP kinase and 
ERK1/2 kinases.66 The net result of TGFβ signalling in this context is fibroblast 
differentiation to myofibroblasts, cardiomyocyte hypertrophy, collagen synthesis and 
cardiac fibrosis through both autocrine and paracrine mechanisms.93 Although 
incompletely understood, a direct link between nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase (NOX)-derived reactive oxygen species (ROS) signalling 
and TGFβ activation has been described, a mechanism in which ROS and TGFβ induce 
the production and activation of each other.86 In addition, TGFβ has been shown to 
play a role in EndoMT.30, 86, 94  
The diversity of signalling by TGFβ highlights its importance and appears to link 
together the variety of studies listed in table 1. 
1.5.3 Endothelin-1 
Endothelin-1 is a protein secreted predominantly by endothelial cells, but also by 
fibroblasts and other cardiac cell types.95 It is downstream of TGFβ signalling and can 
be induced by Ang II and ROS; with evidence of reciprocal activation.52, 95-97 Acting 
through its endothelin-A and –B receptor subtypes, endothelin-1 is a potent 
vasoactive peptide, elevated in hypertension and is able to induce fibroblast 
differentiation to myofibroblasts as well as collagen synthesis and ECM deposition.95  
Mice with vascular endothelial cell-specific deletion of endothelin-1 were shown to 
be resistant to developing both perivascular and interstitial cardiac fibrosis in 
response to chronic Ang II54 and streptozotocin-induced diabetes.52 Endothelin-1 is 
upregulated in diabetic cardiomyopathy and may promote EndoMT, since endothelin-
1 KO mice did not show co-localisation of endothelial and mesenchymal markers in 
hearts of diabetic mouse hearts.52 Endothelin-1 upregulation is also associated with 
aging and age-related cardiac fibrosis; histological analysis of aged human cardiac 
tissue showed profound upregulation with accompanying fibrosis compared to 
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young.83 Similar results were obtained in aged mice and senescent cultured fibroblast 
studies.83  
These studies indicate an important role for endothelin-1 and highlight a viable 
therapeutic target for receptor blockade. 
1.5.4 Reactive Oxygen Species  
Reactive oxygen species (ROS) were originally thought only to cause oxidative 
damage to cell membranes, proteins and DNA, leading to cellular dysfunction and 
death via apoptosis and necrosis.98 It is now accepted that ROS such as superoxide 
and hydrogen peroxide are also involved in cell signalling and recent evidence points 
towards ROS signalling in the generation of cardiovascular pathologies, including 
cardiac fibrosis.99 Indeed, the redox-sensitive activation of p38 mitogen-activated 
protein (MAP) kinase and extracellular-signal-regulated kinase-1/2 (ERK1/2) in 
fibroblasts, ROS-dependent generation of TGFβ and CTGF, and redox-dependent 
enhancement of TGFβ signalling have all been experimentally demonstrated to be 
involved in fibroblast proliferation or ECM synthesis, key processes in the initiation of 
cardiac fibrosis.100-103  
Under physiological conditions, ROS are maintained at very low levels via antioxidant 
systems, including glutathione, superoxide dismutase (SOD), catalase and 
peroxiredoxins.104, 105 For example, SOD, which comprises a family of three isoforms, 
is primarily responsible for the dismutation of superoxide into hydrogen peroxide and 
molecular oxygen in cells and tissues.106 Glutathione, catalyses the reduction of 
hydrogen peroxide into water at high peroxide concentrations, whereas catalase 
appears more important at low peroxide levels.98, 107 In addition, the body controls 
ROS levels using non-enzymatic methods with vitamin C and vitamin E, which are ROS 
scavengers.106 Despite this, some pathological states are characterised by a 
combination of increased ROS production and decreased antioxidant systems, 
contributing to oxidative stress. Oxidative stress is defined as a localised imbalance in 
ROS production and anti-oxidant capacity and the imbalance has been described as 
pro-fibrotic in a number of tissues including the heart, likely through promotion of 
pro-fibrotic signalling pathways.102, 108  
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The importance of ROS signalling in oxidative stress has been highlighted by a number 
of animal studies in which antioxidants or endogenous antioxidant overexpression 
were used to reduce cardiac fibrosis and/or pathological cardiac remodelling and to 
improve cardiac function.31, 33, 35, 109-111 Whilst antioxidants such as N-acetylcysteine112 
and resveratrol65 have often been used successfully in animals, these effects rarely 
translate to human clinical studies, or do so with conflicting results.113 This not only 
indicates possible species differences, but also a need for greater mechanistic 
understanding, especially concerning the nature and source of ROS generation. 
1.6 NADPH Oxidases as ROS Sources 
Different sources of ROS exist within the cardiovascular system, including xanthine 
oxidases, mitochondria, uncoupled nitric oxide synthases and NOX enzymes.99 NOXs 
are of particular importance in cardiovascular disease, being described as a major 
source of ROS, and especially important in redox signalling.102 
NOXs are a family of multi-subunit enzymes, each containing a catalytic core which 
gives rise to the name. There are 7 isoforms, NOX1-5 and Duox1 and 2,  each based 
on a distinct catalytic subunit.114 Of the 5 known NOX isoforms, NOX2, NOX4 and 
NOX5 are expressed in the human heart, however only NOX2 and NOX4 exist in mice. 
NOX2 and NOX4 are expressed in endothelium, cardiomyocytes and cardiac 
fibroblasts, but appear to have distinct roles due to differences in their activation 
mechanism, subcellular location and nature of ROS species generated.103, 115 Both 
NOX2 and NOX4 form a membrane-bound heterodimer with a p22phox subunit, but 
NOX2 is normally quiescent whereas NOX4 is constitutively active.114 The catalytic 
subunit of NOX2 is gp91phox, which contains a flavoprotein domain essential for 
complex assembly and activation. NOX2 is activated upon cell stimulation by agonists 
such as Ang II or TNFα in a process that involves the translocation and binding of 
cytosolic regulatory subunits (p47phox, p67phox, p40phox, Rac1/2; Figure 1-2A and B).114 
Once assembled at the cell membrane, these subunits support full activation of NOX2 
and the catalytic transfer of electrons from NADPH to molecular oxygen to generate 
superoxide (Figure 1-2C).102 In contrast, NOX4 does not require the binding of 
regulatory subunits and when expressed is constitutively active to produce hydrogen 
peroxide.116  
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Figure 1-2: Subunit assembly of NOX2. A: The gp91phox subunit of NOX2 (red) is found 
associated with p22phox where they co-stabilise each other in cell membranes. Upon 
activation, B: the GDP bound to Rac is exchanged for GTP causing Rac activation. The 
p47phox subunit becomes phosphorylated in the cytosol, causing conformational 
changes which facilitate binding to p22phox and association of the entire NOX2 enzyme 
complex. C: this marks full activation of the NOX2 enzyme and allows the transfer of 
electrons from NADPH to molecular oxygen to form the superoxide anion. 
The involvement of NOX in the activation of cardiac fibroblasts can be studied in vitro 
using TGFβ or other applied stimuli. Whilst this is useful in determining changes in 
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activity and superoxide generation, as well as downstream signalling, the complexity 
of cardiac fibrosis development demands that the role of NOX is studied in vivo to 
better understand the processes at play. In addition, functional consequences such as 
cardiac contractility and relaxation properties are ultimately important when 
considering the clinical relevance of these studies and unfortunately cannot be 
determined in culture. 
1.6.1 NOX2 in the Development of Cardiac Fibrosis  
In recent years, a key finding was that NOX2 seemed to be essential for the 
development of cardiac fibrosis in an Ang II infusion model.62 Global NOX2 KO mice 
were subjected to chronic Ang II infusion for two weeks at a subpressor (non-
hypertensive) dose. Interstitial cardiac fibrosis developed in wildtype (WT) littermates 
as expected, but fibrosis was significantly attenuated in NOX2 KO mice.62 Subsequent 
studies from our group and others found a similar inhibition of fibrosis in several 
different mouse models, including pressor (hypertension-inducing) Ang II infusion,35, 
117 TAC-induced pressure overload,31, 118 chronic aldosterone treatment,35 MI32, 119 and 
chronic genetic renin-angiotensin activation.117 This supported the early finding that 
expression of gp91phox, the catalytic subunit for NOX2, was elevated in failing human 
hearts and accompanied by increased oxidase activity.118, 120 
Whilst both NOX2 and NOX4 increase their expression in response to stress, it was 
found that NOX4 mediates beneficial adaptive effects during chronic pressure 
overload induced by TAC.34 This study used both loss and gain of function gene-
modified mice, showing that NOX4 KO mice experienced exaggerated cardiac 
hypertrophy and fibrosis in response to TAC compared to WT controls, whereas NOX4 
overexpressing mice appeared to be partially protected.34 Taken together, these 
results strongly suggest a pivotal, detrimental role for NOX2 in the development of 
cardiac fibrosis and shift the focus away from non-selective antioxidant therapy. 
Indeed, the beneficial effects of NOX4 in chronic pressure overload may provide an 
explanation for why antioxidant therapies have been less than successful in the clinic, 
since although pathological NOX2 effects would be blocked, so would the beneficial 
NOX4 effects.  
 
Page | 34  
 
1.6.2 Cellular Sources of NOX2 
NOX2 is present in a range of cardiovascular cell types such as cardiac fibroblasts, 
inflammatory cells, endothelial cells and cardiomyocytes, any of which could be 
drivers of cardiac fibrosis. Previous studies used global NOX2 KO mice and therefore 
could not identify the important cell type responsible for the pro-fibrotic effects of 
NOX2. Given the importance of fibroblasts in the development of fibrosis, NOX2 in 
these cells would be expected to be important, but this has not previously been 
investigated in vivo. 
NOX2 is basally present in cardiomyocytes, with increased expression in patients with 
MI.121 A series of in vitro experiments on H9c2 (rat cardiomyocyte) cells show nuclear 
expression of NOX2 during ischaemic stress, activating apoptosis via caspase-3.122 The 
non-specific NOX inhibitors apocynin (an antioxidant) and diphenyleneiodonium (a 
general flavoprotein enzyme inhibitor)  were used to show a reduction in apoptosis, 
highlighting a role for NOX2 in cardiomyocyte cell death.122 Since reactive fibrosis 
occurs largely as a consequence of cardiomyocyte cell death, it is possible that NOX2 
in cardiomyocytes indirectly contributes to the development of cardiac fibrosis. 
Indeed, it has recently been shown that overexpression of cardiomyocyte NOX2 
induced more severe cardiac fibrosis in response to myocardial infarction in vivo.123 
Inflammatory cells are high expressers of NOX2 and invade myocardial tissue during 
cardiac stress. To study the effect of NOX2 in inflammatory cells, bone marrow 
chimeric mice were generated, in which WT mice were irradiated and the bone 
marrow was reconstituted with either NOX2 KO or WT cells.53 The fibrotic response to 
chronic Ang II infusion was then investigated, showing similar levels of cardiac fibrosis 
in WT mice with either (a) NOX2-deficient or (b) NOX2-intact bone marrow cells 
(Figure 1-3)53. These data indicated that NOX2 in inflammatory cells may be 
dispensable in Ang II-induced cardiac fibrosis.  
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Figure 1-3: Quantification of Ang II-induced cardiac fibrosis in chimeric mice. WT or 
global NOX2 KO mice were irradiated, then bone marrow reconstituted with either 
WT or NOX2 KO cells. Cardiac fibrosis is the same, independent of bone marrow type 
(BMT).  Horizontal lines above bars indicate a significant difference (*P<0.05) by 1-
way ANOVA; n≥5/group. Reproduced from Murdoch et al., 2014.53 
By contrast, endothelial cell NOX2 appears to play an important role in cardiac 
fibrosis development. A novel transgenic mouse overexpressing NOX2 specifically in 
endothelial cells was developed124 and, when subjected to chronic Ang II infusion, 
displayed significantly more interstitial cardiac fibrosis than WT mice (Figure 1-4).53 
This was shown to be due in part to enhanced EndoMT in transgenic mice. The 
enhancement of cardiac fibrosis was confirmed as ROS-dependent, since treatment of 
transgenic mice with N-acetylcysteine abolished the enhancement. Unfortunately 
however, the effect of N-acetylcysteine treatment was not investigated in the context 
of EndoMT, which could feasibly also be ROS-dependent.   
 
Figure 1-4: Quantification of Ang II-induced cardiac fibrosis in endothelial cell NOX2 
transgenic mice. Picrosirius Red-stained sections from mice infused with saline (Sal) 
or Ang II. Scale bars 100μm. Sal: saline infused controls; TG: transgenic endothelial 
NOX2 overexpressing mice. Reproduced from Murdoch et al., 2014.53 
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1.7 Summary 
Cardiac fibrosis is seen in a variety of cardiovascular pathologies, leading to cardiac 
dysfunction and increased mortality. Cardiac fibrosis is multifactorial, with many 
contributing pro-fibrotic pathways, many of which are stimulated by ROS. The current 
literature suggests a key role for NOX2 in the development of cardiac fibrosis and in 
particular, NOX2 in fibroblasts and endothelial cells. This is owing to the central role 
in ECM homeostasis and EndoMT for fibroblasts and endothelial cells, respectively. 
Identification of a crucial cellular ROS source in the development of cardiac fibrosis 
could yield more specific and targeted ROS-directed therapies. 
1.8 Research Aims and Objectives 
The aim of this thesis is to determine the role of fibroblast and endothelial cell NOX2 
activation in the generation of cardiac fibrosis in mice.  
To address this aim, the following specific objectives were set out: 
1. Establish a suitable and reproducible mouse model of cardiac fibrosis. 
2. Generate tamoxifen-inducible fibroblast and endothelial cell-specific NOX2 
knockout mice and induce cardiac fibrosis via surgical intervention. 
3. Determine the effects of fibroblast and endothelial cell NOX2 deletion on the 
generation of cardiac fibrosis by assessing cardiac function by 
echocardiography, cardiac fibrosis by histological analysis and the biochemical 
profile of these knockout mice in the disease setting.  
4. Investigate the contribution of EndoMT to the development of cardiac fibrosis 
using a novel reporter mouse and lineage tracing techniques.  
It was hypothesised that specific deletion of NOX2 in fibroblasts and endothelial cells 
would reduce the development of cardiac fibrosis. 
  












CHAPTER 2: General Methods 
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2.1 Introduction to Genetic Alteration in Mice 
Specific signalling pathways in experimental models of heart failure and fibrosis can 
be investigated by using gene-modified mice. Commonly, loss-of-function, i.e. gene 
knockout (KO),34 or gain-of-function, i.e. gene overexpression,53 approaches are used, 
providing an insight into the roles of proteins and pathways of interest.  
The Cre-LoxP system for gene KO allows for conditional cell type-specific and 
temporal-specific analysis of genes of interest.125 For example, two distinct gene-
modified mouse lines can be crossed to generate temporal KO in fibroblast or 
endothelial cell gene “X”. In the first mouse line, mice are generated harbouring two 
small DNA recognition sites flanking critical components of gene “X” for gene 
function.125 These recognition sites are known as Locus of X-over P1 or simply LoxP. 
This involves gene targeting and recombination and the resulting mice are so-called 
“floxed” mice (Figure 2-1A). In the second transgenic mouse line, the tamoxifen-
inducible Cre-recombinase is placed under the control of the Col1a2 or CD144 gene 
promoter in a transgene construct, conferring fibroblast or endothelial cell specificity 
(Figure 2-1B). The transgene construct is integrated into the mouse genome either by 
simple microinjection (random transgenesis) or by targeting to a specific locus (e.g. 
the ROSA26 locus). The advantage of the latter approach is that a single copy of the 
transgene is integrated at a specific site but it involves gene targeting. In contrast, the 
random approach, while simpler, could result in more than one copy of the transgene 
being integrated, while the site of integration is unpredictable and could in principle 
disrupt other genes and their function.126 
Cre-recombinase is a tyrosine kinase which performs site-specific recombination 
between DNA recognition sites. Upon crossing the two mouse lines, Cre recombinase 
will recognise and excise any gene region between the two LoxP sites.125 Cre 
recombinase will only be expressed in fibroblasts or endothelial cells, hence only 
fibroblast or endothelial cell gene “X” will be disrupted or “knocked out” (Figure 2-
1C).   
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Figure 2-1: Cre-LoxP system for generating knockout mice. A: Component of gene 
“X” critical to gene function (red) is “floxed” by two LoxP sites (blue). The expression 
of gene “X” is ideally unaffected. B: Cre recombinase gene (green) under the control 
of the fibroblast- or endothelial cell-specific (Col1a2 or CD144) promoter (yellow). C: 
When mice A and B are crossed, the floxed gene will be disrupted and therefore 
“knocked out” in Col1a2+ or CD144+ cells. 
Inducible Cre-recombinase (CreER(T/2)) allows for spatial and temporal control of 
target gene excision, with high specificity. In brief, CreER(T/2) is a tyrosine 
recombinase fused to a modified oestrogen receptor.127 Under basal conditions the 
recombinase associates with cytoplasmic chaperone proteins, e.g. heat shock protein-
90, rendering it inactive.125, 128 Upon binding of 4-hydroxytamoxifen, these 
associations are broken, such that Cre can relocate to the nucleus and bind to LoxP 
sites which flank genes of interest.125, 127 Modified tamoxifen (4-hydroxytamoxifen) 
can be given in the diet,129 or as a course of intraperitoneal injections.130  
Successful recombination in mouse progeny can then be confirmed by polymerase 
chain reaction (PCR) methods, as well as western blotting, quantitative real-time PCR 
in tissue samples or crossing to a fluorescent reporter strain.130-132 
2.2 Generation of Experimental Mice 
All animal experiments were performed according to the Home Office Guidance on 
the care and use of animals in science (Scientific Procedures Act, 1986, UK). All mice 
were on a C57BL/6J background and bred under licence at King’s College London, 
  












of gene “X” 
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with ad libitum access to food and water. All mouse lines were maintained in house 
and appeared to breed normally without obvious basal phenotype. 
Experimental mice in these studies were generated by taking advantage of the 
inducible Cre-recombinase transgenic mouse breeding strategy as outlined above. 
Four distinct transgenic mouse lines were established before being specifically 
crossed to generate experimental mice, details of which are given in individual 
chapters. 
Line 1 (NOX2 flox) have LoxP insertions flanking exons 1 and 2 on the NOX2 locus 
(Figure 2-2A). Crossing with a Cre recombinase-expressing mouse results in disruption 
of NOX2 function in the specific cell type. 
Line 2 (ROSA26-CAG-LoxP-STOP-LoxP-tdTomato or simply ROSA26-tdTomatoflox/flox) 
mice are prevented from ubiquitously expressing tandem dimer tomato (tdTomato) 
fluorescent protein (which is targeted to the ROSA26 locus) by an upstream STOP 
codon (Figure 2-2B). The STOP codon is flanked by LoxP sites so that Cre-mediated 
excision of the STOP codon allows permanent expression of tdTomato fluorescence. 
This mouse line has been used extensively owing to its favourable bright 
fluorescence.133-136 
Line 3 (Col1α2-CreER(T)) harbour a transgenic DNA construct containing a subcloned 
6kb transcriptional enhancer from the far upstream regulatory element of the mouse 
Col1α2 gene, which drives the expression of CreER(T) (Figure 2-2C).132 Importantly, 
this enhancer region is reported to confer specificity to fibroblasts rather than to 
other collagen 1-expressing lineages.132, 137 This Col1α2-CreER(T) line has been used in 
previous studies, including a cardiac study.136, 138 Daily treatment with intraperitoneal 
injections of 1mg tamoxifen for 10 consecutive days induces Cre activity in this mouse 
line.136 
Line 4 (Cdh5-CreER(T2)) harbour a transgenic DNA construct containing CreER(T2) 
subcloned downstream of the 2.5kb mouse Cdh5 promoter (Figure 2-2D).130 This 
Cdh5-CreER(T2) mouse line expresses Cre-recombinase in endothelial cells and has 
been fully characterized and reported in cardiac endothelial cell lineage tracing 
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experiments.130, 131, 139 Daily treatment with intraperitoneal injections of 1mg 
tamoxifen for 3 consecutive days induces Cre activity in this mouse line.130 
 
Figure 2-2: Transgenic mouse lines used to generate experimental mice. A: NOX2 
floxed mice have LoxP sites flanking critical exons 1 and 2. B: ROSA26-tdTomato mice 
have LoxP sites flanking a STOP codon, preventing tdTomato expression in the 
absence of Cre recombinase. C: Col1α2-CreER(T) mice express tamoxifen-inducible 
Cre recombinase driven by an enhancer region of the Col1α2 gene. D: Cdh5-CreER(T2) 
mice express tamoxifen-inducible Cre recombinase driven by a promoter region of 
the Cdh5 gene. 
In addition, wildtype (WT) C57Bl/6 mice (Harlan, UK or Charles River, UK) were used 
in some experiments where stated. 
2.3 Surgical Procedures 
All mice were given 10µL Vetergesic (buprenorphine hydrochloride) i.m. from 
0.03mg/mL stock and 50µL finadyne (flunixin meglumine) s.c. from 1mg/mL stock as 
prophylactic pain relief prior to any surgical procedure. Full surgical plane was 
ensured by toe pinch reflex. Any incision sites were first shaved and swabbed with 
iodine then chlorhexidine.  
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2.3.1 Transverse Aortic Constriction (TAC) Surgery  
Minimally invasive TAC surgery without intubation was used to induce cardiac fibrosis 
and hypertrophy over 14 days, based on methods previously described.140, 141 All TAC 
operations were performed by Dr. Greta Sawyer, a highly experienced and consistent 
microsurgeon at King’s College London. Briefly, mice were anaesthetised with 
isoflurane and maintained at 1.5% at 1.5L/min. A small suprasternal incision was 
made through which the thymus was retracted and the strap muscles were bluntly 
dissected to expose the aortic arch. A mini proximal sternotomy was made to assist 
passing a small, hook-shaped needle with 6-0 silk suture under the aorta between the 
brachiocephalic and left common carotid arteries. The needle was then removed. An 
angled 27-gauge needle was placed alongside the aorta and the 6-0 silk suture tied 
snugly around the 27-gauge needle to constrict the aorta. The needle was then 
promptly removed and the incision closed by suturing. Sham operated mice 
underwent the same procedure without constriction. Mice were then placed in a 
heated recovery chamber.  
2.4 Physiological Measurements 
2.4.1 Echocardiography 
Echocardiography was performed as previously described142 both prior to surgical 
intervention for baseline cardiac function and again on a weekly basis following mini-
osmotic pump implantation or TAC surgery. Briefly, mice were weighed and 
anaesthetized with 5% isoflurane in medical oxygen at 1L/minute, then maintained 
on a nose cone at 1-2% isoflurane on a heated stage in the supine position. Heart and 
respiration rates were continuously monitored throughout via the stage. Hair was 
removed on the abdomen using hair removal cream (Veet, UK), ensuring that any 
residual cream was removed fully with water. Ultrasonic gel (Skintact, DE) was 
applied to the 22-55MHz echocardiography transducer (MS550D; Vevo 2100, 
FUJIFILM VisualSonics, Canada) and scanning initiated with long and short axis views 
in B-Mode and M-Mode, according to a standard protocol, with a target heart rate of 
>400bpm for systolic cardiac function. Pulsed-wave Doppler and tissue Doppler 
imaging were also used to determine diastolic function, using mitral valve flow for the 
following indices: early and late filling velocities (E and A wave), E/A ratio, E wave 
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deceleration time, isovolumic relaxation time (IVRT), isovolumic contraction time 
(IVCT) and total ejection time (Figure 2-3). E’ and A’ indices were obtained by tissue 
Doppler imaging at the mitral annulus (Figure 2-4). 
 
Figure 2-3: Pulsed-wave Doppler imaging by echocardiography for Doppler-derived 
indices.  
 
Figure 2-4: Tissue Doppler imaging by echocardiography for mitral annular 
displacement during early and late diastole (E’ and A’, respectively). The 
simultaneous recording of mouse electrocardiogram (green trace) aids interpretation. 
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TAC pressure gradients were estimated using trans-TAC aortic pulsed-wave Doppler 
imaging (Figure 2-5). The MS550D transducer was used to visualise the TAC site in 
standard B-Mode (yellow arrow; Figure 2-5). Colour Doppler was then used, showing 
either laminar blood flow (sham) or disrupted, turbulent blood flow (TAC). Lastly, a 9-
18MHz transducer (MS200) was used to detect higher blood velocities through the 
TAC constriction using pulsed-wave Doppler. The peaks could then be measured and 
a peak pressure TAC gradient could be calculated using the modified Bernoulli 
equation (Pressure gradient = 4*velocity2).141 
Strain and strain rate measurements were completed using a semi-automated border 
tracking technique as previously described.142 Briefly, tracking points were added to 
the endocardial and epicardial borders of the left ventricle from a parasternal long 
axis view in B-Mode. These points are described as a guide for the automated 
software (VevoStrain) to provide frame-to-frame tracking of ventricular walls 
throughout the cardiac cycle.142 Six cardiac ‘segments’ are assigned to regions of the 
ventricular wall (e.g. anterior apex) and their delineation during the cardiac cycle is 
converted to a data curve with positive and negative values for peak radial and 
longitudinal strain and strain rate, in addition to calculated ventricular volumes and 
ejection fraction.142  
All images were analysed using Vevo 2100 software (v1.5.0, FUJIFILM VisualSonics, 
Canada), taking an average of 3 measurements per variable per animal. 
Page | 45  
 
 
Figure 2-5: Strategy for TAC gradient assessment at 1 day post TAC surgery by 
echocardiography. First, B-Mode is used to confirm TAC (upper panel), followed by 
colour Doppler to visualise blood flow through the TAC site (middle panel). Lastly, 
pulsed wave Doppler is used to determine the maximal blood velocity through the 
TAC site (lower panel). Measurement of the pulse profile provides an estimate for 
trans-TAC gradient using the Bernoulli Equation. 
2.5 Tissue Harvest and Processing 
Mice were weighed then killed according to a schedule 1 method. An abdominal 
incision was made and continued up to the thorax to expose the heart. The heart was 
arrested in diastole by injecting approximately 200µL of 5% potassium chloride/ 0.9% 
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sodium chloride directly into the apex. The whole heart was quickly excised and 
gently palpated in ice cold phosphate buffered saline (PBS) to remove blood prior to 
weighing. All four chambers (left and right ventricles and atria) were separated and 
weighed individually. The left ventricle was divided transversely into apical, mid and 
basal sections, before being either snap frozen in liquid nitrogen or placed into 4% 
paraformaldehyde (PFA) for biochemical or histological analysis respectively (Figure 
2-6). 
 
Figure 2-6: Division of the left ventricle for biochemical and histological analysis. 
Apical, mid and basal sections were used for RNA extraction, histology and protein 
extraction respectively. 
Total liver and lung weights were also recorded, as well as left tibia length for 
normalization. Lastly, a small ear biopsy was taken for genotype confirmation.  
2.5.1 Histology 
After 24 hours fixation in 4% PFA, hearts (histology portion; Figure 2-6) were washed 
in PBS then placed in 70% ethanol. Tissues were prepared for embedding using an 
automated tissue processor (Shandon Hypercentre XP; Thermo Scientific, UK), then 
embedded in molten paraffin wax. 6µm tissue sections were cut onto glass slides 
using a microtome (≥3 sections/slide). After 24 hours drying, slides were de-waxed in 
xylene and rehydrated through a series of decreasing ethanol concentrations 
followed by distilled water.  
2.5.2 Cardiac Fibrosis Assessment 
For the assessment of fibrosis, slides were submerged in 0.1% phosphomolybdic acid 
for 2 minutes, rinsed in distilled water then stained with Picrosirius red for 2 hours. 
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Slides were washed in acidified water then dehydrated by successive baths of 
increasing ethanol. Slides were cleared with xylene before a cover slip was mounted 
with DPX mounting medium (a mixture of Distyrene, a Plasticizer and Xylene).  
Picrosirius red-stained hearts were imaged with both bright field and circularly 
polarised light on a light microscope (Axioskop 2, Carl Zeiss or DM2000, Leica). 
Interstitial cardiac fibrosis was determined by taking images of four distinct regions of 
each cardiac section, imaged at 5x magnification. To determine perivascular fibrosis, 
four individual coronary vessels per section were identified and imaged such that 
they occupied the central field of view at 20x magnification. Picrosirius red is used to 
determine fibrosis as it enhances the birefringency of collagen.143 Standard bright 
field images report total collagen content, whereas polarised light is said to increase 
the stain specificity by showing mainly abnormally cross-linked collagen, therefore 
naturally reducing false positives.143 Images were analysed using ‘Red-Green-Blue-
based’ detection for total tissue area and fibrosis, and region of interest tracing for 
vessel lumen size (Volocity v6.3, PerkinElmer). Images were acquired and analysed in 
a blinded fashion. Interstitial fibrosis is expressed as a percentage of total tissue and 
perivascular fibrosis is expressed as percentage of tissue in the perivascular region 
(up to 450µm from the vessel wall). For perivascular fibrosis attempts were made to 
analyse similarly-sized vessels. 
2.5.3 Cardiomyocyte Hypertrophy Assessment  
To determine cardiomyocyte area, rhodamine-conjugated wheat germ agglutinin 
(WGA) was used to outline cardiomyocytes. Briefly, the antigen was unmasked by 
heating slides in a steamer of unmasking solution (H3300; Vector Labs, UK) for 10 
minutes and left to cool for a further 20 minutes. Slides were washed in PBS, then 
sections blocked for 45 minutes in 10% goat serum, before being incubated for 2 
hours with 2% WGA-rhodamine in 10% goat serum in a humidity chamber at room 
temperature. Slides were washed with PBS, stained with 4’,6-diamino-2-phenylindole 
(DAPI), then cover slips mounted with mowial.  
WGA-stained hearts were imaged using a fluorescence microscope (IX81-2, Olympus) 
at 40x objective. The average cross-sectional area was determined by tracing the area 
congruent to the WGA stain in ≥100 cells per slide. Cell exclusion criteria included a 
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non-transverse orientation and/or an absence of a DAPI-stained nucleus. Images 
were analysed using Volocity software (v6.3, PerkinElmer).  
2.5.4 Protein Preparation and Western Blotting 
Tissue samples were placed in liquid nitrogen and crushed using a cryogenic pestle 
and mortar. The resulting powder was collected and placed directly into an eppendorf 
containing lysis buffer with 1% proteinase inhibitors (roughly 10µL/µg tissue). 
Samples were sonicated briefly before being centrifuged at maximum speed for 5 
minutes. The supernatant was transferred to a fresh eppendorf. Total protein 
concentration was determined using the Bicinchoninic acid Protein Assay Reagent kit 
(Thermo Fisher Scientific, IL, USA). Two dilutions of each sample was made with lysis 
buffer (1:10 and 1:20), then 25µL of each sample was pipetted into a microplate well 
(Thermo Fisher Scientific, UK). Concentration standards were prepared according to 
manufacturer’s protocol and a working reagent was made (50 parts Reagent A, 1 part 
Reagent B). 200µL of working reagent was added to each diluted sample on the 
microplate. The microplate was then covered and incubated at 37°C for 30 minutes, 
before being cooled to room temperature and absorbance measured at 562nm on a 
spectrophotometric plate reader. The absorbance of each standard was blank-
corrected by subtraction and a standard curve constructed to determine 
experimental sample concentrations in µg/mL. Proteins were diluted appropriately 
into Laemmli sample buffer to yield 30µg/mL. 
Sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis was carried out 
using the Bio-Rad Mini-PROTEAN system (Bio-Rad Laboratories, Hertfordshire, UK) 
using 8% resolving gels. For electrophoresis, gels were loaded into the Bio-Rad Mini-
PROTEAN system (Bio-Rad Laboratories, Hertfordshire, UK) and the electrophoresis 
chamber filled with running buffer solution (100mL 10x running buffer stock [30g Tris 
Base and 144g Glycine in 1L deionized water] and 10mL 10% SDS made up to 1L with 
deionized water) to fully submerge gels. A protein standard (PageRuler, Thermo 
Scientific, UK) was first loaded and run alongside up to 9 protein samples 
simultaneously. Electrophoresis was started at 120V initially and run until the dye 
front had just run off.  
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Gels were transferred to a nitrocellulose membrane using wet transfer (BioRad, UK) 
at 70V for 45 minutes, followed by membrane blocking in 5% milk-PBS-Tween 
(0.001%) solution (w/v; Marvel, Chivers Ireland LTD, Ireland) for 1 hour. NOX2 
(mouse; anti-gp91phox; 1:1000 dilution; BD Biosciences) and β-actin (rabbit; 1:1000 
dilution; Sigma) primary antibodies were applied in 5% milk solution overnight. Anti-
mouse and anti-rabbit secondary antibodies (1:15,000; LI-COR Biosciences) were 
applied for 45 minutes. Membranes were washed with PBS-Tween for 1 hour on a 
shaker after each antibody to remove non-specific binding. Detection of protein was 
completed using the Odyssey CLx detection system and quantified using Image Studio 
Software (LI-COR Biosciences, UK). 
2.5.5 RNA Isolation and Reverse Transcription Polymerase Chain 
Reaction 
Approximately 20mg of apical left ventricle tissue was first homogenised with metal 
beads in 300µL of RLT lysis buffer containing 1% β-mercaptoethanol (Qiagen; GmbH, 
DE), using a tissue homogeniser (Precellys 24; Bertin Technologies). Ribonucleic acid 
(RNA) was extracted using the Qiagen RNeasy Fibrous Tissue Mini Kit (Qiagen, UK) 
according to manufacturer’s protocol. After the final centrifugation step, 30µL of 
RNase-free water was added directly to the spin column membrane and RNA was 
eluted by centrifuging at maximum speed for 1 minute. The concentration of 
extracted RNA was determined using a spectrophotometer (NanoDrop ND-1000; 
Thermo Scientific, UK).  
1µg of RNA was reverse transcribed by PCR in 20µL final volume. The volume of RNA 
required for 1µg/20µL was added to a PCR tube, made up to 11µL with water and 
1.5µL of 100µg/mL oligodeoxythymine primers added to each tube. Tubes were 
heated to 70°C for 5 minutes, then immediately placed on ice. 7.5µL of mastermix 
(4µL 5x reaction buffer, 1µL deoxyribose nucleoside triphosphate, 0.5µL RNasin, 1µL 
water and 1µL reverse transcriptase) was added to each tube and the solution 
incubated at 42°C for 90 minutes for reverse transcription. A negative control was 
included, lacking reverse transcriptase. Resultant complimentary deoxyribonucleic 
(cDNA) was diluted with 80µL of water and stored at 4°C.   
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2.5.6 Quantitative real-time Polymerase Chain Reaction (qPCR)  
Relative expression of messenger RNA (mRNA) was determined by quantitative PCR 
(qPCR) using a SYBR green detection system, with β-actin mRNA for normalization as 
previously described,32 performed in duplicate. All qPCR primers are detailed in Table 
2-1 and were used at a working concentration of 10µM (Sigma, UK or IDT DNA, UK).  
Table 2-1: Primer sequences for qPCR. All sequences are shown as 5’-3’.  
Gene of interest Forward primer sequence Reverse primer sequence 
NOX2 (gp91phox) ACTCCTTGGGTCAGCACTGG GTTCCTGTCCAGTTGTCTTCG 
p47phox GGACACCTTCATTCGCCATA CTGCCACTTAACCAGGAAC 
   
Collagen 1α1 CCTCAGGGTATTGCTGGACAAC TTGATCCAGAAGGACCTTGTTTG 
Collagen 3α1 CCTGGTGGAAAGGGTGAAAT CGTGTTCCGGGTATACCATTAG 
CTGF TGACCCCTGCGACCCACA TACACCGACCCACCGAAGACACAG 
Fibronectin CCGGTGGCTGTCAGTCAGA CCGTTCCCACTGCTGATTTATC  
   
CD31 CAAACAGAAACCCGTGGAGAT ACCGTAATGGCTGTTGGCTTC 
   
β-actin CTGTCGAGTCGCGTCCACCC ATGCCGGAGCCGTTGTCGAC 
 
A separate mastermix for each gene of interest was made (per well: 10μL SYBR 
Green, 6μL RNase/DNase-free water and 1µL of both forward and reverse primer) 
before being loaded into an appropriate well on the 96-well plate (ABI Prism, Life 
Technologies, UK). 2µL of each sample cDNA was added to an appropriate well and 
finally a plastic film placed on top to seal all wells. The plate was centrifuged briefly at 
1000rpm, then loaded into the qPCR machine (Mastercycler ep Realplex2, Eppendorf 
or StepOnePlus, Applied Biosystems) and run according to the protocol given in 
Figure 2-7. 
 
Figure 2-7: Programme to determine gene expression by qPCR using detection of 
SYBR Green. Samples were heated to 95°C for 10 minutes, then 40 cycles of 95°C for 
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15 seconds, followed by 60°C for 30 seconds, then 95°C for 15 seconds, 60°C for 15 
seconds, then increased slowly to 95°C over 20 minutes and lastly held for 15 seconds 
at 95°C. 
Data was converted to log scale and cycle threshold (Ct) values were obtained after 
thresholding and drift correction. Ct values were normalised to their respective β-
actin Ct values, then expressed in relative terms to percentage of control (vehicle or 
sham) samples.  
2.6 Mouse Genotyping and Polymerase Chain Reaction (PCR) 
DNA isolation was performed using small ear punch samples taken from each mouse. 
Samples were placed into eppendorf tubes, to which 300µL of 50mM sodium 
hydroxide (NaOH) was added and heated to 95°C for 10-15 minutes. The sample was 
vortexed and 25µL of 1M Tris HCl (pH8) was added. The final sample (purified DNA) 
was left to stand for 10 minutes at room temperature, and then stored at 4°C. For 
PCR, a mastermix was prepared to detect flox insertions (for NOX2 or tdTomato), Cre 
recombinase or recombined NOX2 (to indicate cell-specific KO mice) given in Tables 
2-2, 2-3, 2-4 and 2-5, respectively.  
Table 2-2: PCR mastermix used to detect flox insertions in mouse tissue. Red 
Thermus Aquaticus (Taq) and nuclease-free water are from Readymix Kit (Red Taq 
PCR reaction mix, Sigma-Aldrich, UK), ASHL1 and ASHL2 are primers designed to 
recognise flox insertions (Sigma- Aldrich, UK). 
Reagent Volume per sample 
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Table 2-3: PCR mastermix used to detect tdTomato ‘STOP’ flox insertions in mouse 
tissue. Red Taq and nuclease-free water are from Readymix Kit (Red Taq PCR reaction 
mix, Sigma-Aldrich, UK), wildtype and mutant forward and reverse are primers 
designed to recognise ‘STOP’ flox insertions (IDT DNA, UK). 
Reagent Volume per sample 
Red Taq 12.5µL 
Wildtype Forward 
5’-AAG GGA GCT GCA GTG GAG TA-3’ 
1µL 
Wildtype Reverse 
5’-CCG AAA ATC TGT GGG AAG TC-3’ 
1µL 
Mutant Forward 
5’-CTG TTC CTG TAC GGC ATG G-3’ 
1µL 
Mutant Reverse 
5’-GGC ATT AAA GCA GCG TAT CC-3’ 
1µL 
Nuclease-free H2O 6.5µL 
 
Table 2-4: PCR mastermix used to detect Cre recombinase in mouse tissue. 
MerCreMer and GAPDH are DNA primers (Sigma-Aldrich, UK). 
Reagent Volume per sample 













Nuclease-free H2O 9µL 
Table 2-5: PCR mastermix used to detect the presence of recombined NOX2 in 
mouse tissue after tamoxifen treatment. 
Reagent Volume per sample 
Red Taq 12.5µL 
NOX2 Cre Forward 
5’-GGAATTGAGTTGTAAGAATCAAATGAC-3’ 
0.5µL 
NOX2 Cre Reverse 
5’- ATGATGTGTCCCAAATGTGC-3’ 
0.5µL 
NOX2 Cre [Wildtype] Forward 
5’-GGGGCTGAATGTCTTCCTCT-3’ 
0.5µL 
Nuclease-free H2O 9.5µL 
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After mixing, a 23-24µL aliquot of mastermix was added to appropriately labelled PCR 
tubes, followed by sample DNA for a total reaction volume of 25µL. PCR was then 
performed as detailed in Table 2-6.  
Table 2-6: Detailed PCR cycle protocols for genotyping mice.  

























































DNA gels were made by heating agarose solution [3g of Agarose in 200mL TAE buffer 
(40mM Tris, 20mM acetic acid, and 1mM ethylenediaminetetracetic acid (EDTA)] in a 
microwave for 2-3 minutes. 10µL ethidium bromide or Nancy-520 (Cat# 01494, 
Sigma, UK) was added and the solution was poured into the gel tank with well combs 
already inserted. The gel took approximately 20 minutes to set. Well combs were 
then removed and the gel transferred to a running tank, ensuring full submersion in 
TAE buffer. 15µL of each DNA sample was run alongside a 7.5µL aliquot of 1Kb DNA 
ladder (Promega, WI, USA) at 150-170V for 20-25 minutes, ensuring the samples did 
not run out of the gel. Lastly, gels were exposed under UV light and images saved 
and/or printed for analysis. 
2.7 Statistical Analysis 
Data are presented as mean ± S.E.M where applicable. Data are presented and 
analysed using GraphPad Prism (v6.0, La Jolla, CA, USA), with the statistical test and 
replicate number (n=) detailed in individual figure legends. In general, 2way analysis 
of variance (ANOVA) was used for data involving two variables (genotype and surgical 
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intervention) and 2way ANOVA with repeated measures was used for data also 
including time as an additional variable e.g. echocardiography. P<0.05 was considered 
as statistically significant.  












CHAPTER 3: Angiotensin II-induced 
Cardiac Fibrosis 
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3.1 Introduction 
As discussed in chapter 1, Ang II plays a major physiological role in cardiovascular 
homeostasis. Once cleaved by angiotensin converting enzyme, circulating Ang II acts 
as a potent vasoconstrictor and signals to increase water and sodium retention, with 
a net effect of increasing arterial blood pressure.88 Ang II signalling is a homeostatic 
response; however the chronic presence of Ang II disrupts this balance and quickly 
increases blood pressure and haemodynamic load on the heart and other organs. 
3.1.1 Chronic Angiotensin II as a Mouse Model 
Chronic stimulation with Ang II in mice is amongst the most common models in 
cardiovascular research. One approach is to use surgically implanted subcutaneous 
mini-osmotic pumps to administer Ang II over 2 to 4 weeks. A dose of 1.1mg/kg/day 
has been reported in a number of cardiovascular research studies,35, 53 causing 
varying degrees of hypertension, cardiac hypertrophy, fibrosis and dysfunction. In 
addition to pressor doses of Ang II (hypertension-inducing), subpressor doses in the 
absence of hypertension can also drive cardiac pathologies including fibrosis, 
oxidative stress and hypertrophy. This has been reported in a number of studies62, 144, 
145 and most likely reflects direct effects of Ang II-receptor-mediated signalling.  
3.1.2 Fibroblast-Myofibroblast Conversion, NADPH Oxidases and Fibrosis  
As discussed in chapter 1, the conversion of fibroblasts to active myofibroblasts is a 
primary step in the development of fibrosis. This conversion involves Ang II/TGFβ-
signalling, but importantly also involves reactive oxygen species generated by 
NOXs.146 Studies have highlighted the importance of NOX2- and NOX4-mediated 
fibroblast-myofibroblast conversion in subsequent fibrosis, including in renal 
fibrosis147, 148 and hepatic fibrosis, where p47phox KO mice had reduced liver injury 
and fibrosis following a model of experimental liver fibrosis.149 
Interestingly, NOX4 activity specifically in lung fibroblasts was increased in cells 
isolated from patients with idiopathic pulmonary fibrosis.150 Furthermore, the TGFβ-
induced increase in collagen 1α1 expression (indicative of fibroblast-myofibroblast 
conversion) was reduced in isolated fibroblasts pre-treated with the antioxidant N-
acetylcysteine, showing the importance of ROS-mediated signalling.150 
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In general, the majority of evidence shows NOX2 activation to be detrimental in the 
context of cardiac remodelling and fibrosis, whereas the role of NOX4 is disputed. As 
previously discussed, the global NOX2 KO mouse was shown to be resistant to 
developing cardiac fibrosis in response to chronic Ang II,35, 62, 117 pressure overload31, 
118 and myocardial infarction.32 In addition, NOX2 overexpression led to increased 
cardiac fibrosis in response to chronic Ang II.53 In contrast, global NOX4 KO mice were 
shown to have exacerbated cardiac fibrosis and hypertrophy in response to pressure 
overload, indicating a protective role for NOX4.34 Furthermore, mice with 
cardiomyocyte-specific NOX4 overexpression were resistant to pressure overload-
induced cardiac dysfunction and fibrosis. However, work from another group shows 
almost the exact opposite, with cardiomyocyte NOX4 deletion improving pressure 
overload-induced cardiac dysfunction and reducing fibrosis. The authors then went 
on to show NOX4 overexpression as detrimental.151 
Taken together, fibroblast NOX2 activity is likely to be involved and possibly 
detrimental in the development of cardiac fibrosis, warranting further investigation.  
3.1.3 Chapter Aim 
The aim of this chapter was to investigate the contribution of fibroblast NOX2 in the 
development of Ang II-induced cardiac fibrosis. Owing to the central role of 
fibroblasts in extracellular matrix homeostasis and the involvement of NOX2, it was 
hypothesised that specific deletion of NOX2 would reduce subsequent cardiac 
fibrosis. 
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3.2 Methods 
3.2.1 Generation of Experimental Mice  
Male Col1α2CreER(T) Cre-positive mice were crossed with Cre-negative female 
NOX2flox/flox mice to generate experimental Col1α2CreER(T)/NOX2flox/y or 
Col1α2CreER(T)/NOX2flox/flox male or female mice respectively, or Cre-negative 
littermates. Cre-positive progeny are deficient in fibroblast NOX2 following daily i.p. 
injection with 1mg tamoxifen in peanut oil for 10 days.136  
All experimental mice were NOX2 floxed (Figure 3-1A). Cre-negative male littermates 
were used as flox controls. Cre recombinase expression is indicated by the presence 
of a lower band in Figure 3-1B. Figure 3-1C shows recombination of disrupted NOX2 
in heart tissue, (following 10-day 1mg i.p. tamoxifen injections), indicated by the 
presence of a lower band. Mice with recombined NOX2 are referred to as “knockout 
(KO)” and those without are referred to as “flox”. 
 
Figure 3-1: PCR-based genotyping of mice using DNA gel analysis. A: Primers to 
recognise floxed and wildtype (WT) NOX2 in ear tissue. B: Primers to recognise 
GAPDH (upper band) and Cre recombinase (lower band) in ear tissue. The presence of 
the lower band indicated that mice are Cre expressers and that genetic 
recombination is likely following tamoxifen treatment. C: Primers to recognise WT 
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NOX2 or recombined NOX2 in heart tissue following tamoxifen treatment. The upper 
band indicated WT NOX2, whereas the lower band indicated the presence of a 
disrupted (non-functional) NOX2 gene, so-called knockout.  
Flox and KO mice were viable, had a normal life expectancy, bred normally and did 
not show any obvious basal phenotype. Earlier investigations showed that cultured 
primary cardiac fibroblasts from KO mice are difficult to maintain, making it difficult 
to determine the extent of fibroblast specific deletion of NOX2 by western blot or 
qPCR, however whole heart western blotting showed a 50-60% reduction in NOX2 
protein levels in mice aged 10+ weeks, a time point commensurate with fibrosis study 
mice (Figure 3-2).   
 
Figure 3-2: NOX2 protein expression in whole heart following mouse treatment 
with tamoxifen. A: Western blot for NOX2, with β-actin for normalisation, 
representative image. B: Quantification of western blot expressed as fold change 
compared to flox controls. n=3; P<0.05; student’s t-test. Reproduced from Harrison et 
al., 2017; manuscript in preparation.  
3.2.2 Blood Pressure Measurement by Telemetry 
For the on-going measurement of blood pressure in conscious, unrestrained mice, 
telemetry units were implanted subcutaneously. Here, surgery was performed by 
Greta Sawyer and Helena Zhang. Key aspects of the surgical procedure are shown in 
Figure 3-3. Mice were weighed then anaesthetised with 4% isoflurane in oxygen and 
air at 4L/min. The neck and chest area was shaved and the mouse moved to an 
operating table on a heated pad, maintained with 1-2% isoflurane in 1L/min medical 
oxygen via nose cone in the supine position. An incision into the suprasternal region 
was made, followed by blunt dissection to form a pocket down towards the lower 
Flox     KO 
Flox               KO 
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abdomen (right side). Approximately 200µL of saline was used to maintain the 
pocket, delivered by a 1mL syringe. Blunt dissection was again used to separate tissue 
and locate and isolate the left carotid artery. Two 6-0 silk ligatures were used to 
obstruct blood flow, followed by the application of a surgical clamp. A small incision 
was made to the left carotid artery and the area flushed with saline to remove blood 
from the vessel. The telemeter (placed in saline for 15 minutes prior to implantation) 
was then inserted into the artery, down to the aortic arch. The telemeter probe was 
tied in place with 3-4 braided silk ligatures (6-0), followed by removal of the surgical 
clamp. Lastly, the telemeter unit was inserted into the previously created 
subcutaneous pocket in the lower right abdomen and the incision closed by suturing. 
Mice were then placed in a heated (26-28°C) recovery chamber. 
 
Figure 3-3: Surgical implantation of telemetry devices. A: after an initial incision, the 
left carotid is isolated and tied off. B: with a 1cm segment of the vessel completely 
tied off and clamped, a small incision is made in the left carotid. C: the telemeter 
probe is inserted down to the aortic arch via the small incision. D: lastly the telemeter 
probe is secured in place using 6-0 braided silk ligatures. 
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Following recovery from anaesthesia, telemetry units were tested using static 
detection on an amplitude modulation (AM) radio. The telemeter was activated by 
magnet and the telemeter amplitude tested using a plate reader (usually 
approximately 20mmHg). Telemeters were then deactivated by magnet until needed. 
Blood pressure was recorded and analysed using Dataquest A.R.T.™ System 
acquisition and analysis software respectively (DSI, Data Sciences International), 
acquiring at 1000Hz for 10 second durations at 5 minute intervals over 24 hours.  
3.2.3 Angiotensin II Infusion by Mini-Osmotic Pump 
Mice were infused s.c. with subpressor Ang II (0.3mg/kg/day62; Human, Cat# A9525, 
Sigma-Aldrich, MO) for 28 days or pressor Ang II (1.1mg/kg/day)152 for 14 days or 
vehicle control via mini-osmotic pumps (model 1002/1004, Alzet Durect, CA). Using 1-
3% isoflurane anaesthesia, an incision was made on the mouse dorsum proximal to 
the scapula. Blunt dissection was used to create a subcutaneous mini-osmotic pump 
pocket. The pump was inserted according to manufacturer’s instructions and the 
incision closed using 6-0 silk suture. Mice were placed in a recovery chamber and 
further perioperative care was rarely required. 
3.2.4 Blood Pressure Cuff Plethysmography 
Blood pressure was acutely measured in conscious mice receiving subpressor Ang II 
using tail cuff plethysmography (MK-2000ST, Muromachi Kikai, Japan). A 3-day 
acclimatisation period was used to reduce future stress artefacts, in which mice were 
placed into the restraint for at least 10 minutes each day followed by 10 blood 
pressure measurements. Systolic, mean and diastolic blood pressures and heart rate 
were recorded from an average of 5-10 readings per mouse at baseline and 3-times 
per week following Ang II treatment. 
3.2.5 Echocardiography 
Basic echocardiography was performed to include B- and M-Mode systolic function in 
mice at before and 14 days following treatment with pressor Ang II, performed by Dr. 
Craig Harrison. As described in chapter 2, full echocardiographic assessment was used 
for mice receiving subpressor Ang II, measured at baseline and every 7 days up to 28 
days following Ang II pump implantation.  
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3.2.6 Histology 
Histological analysis of cardiac tissue was performed as described in chapter 2. 
Additionally, Masson’s Trichrome was also used for the assessment of cardiac fibrosis 
in mice treated with subpressor Ang II, using the Masson’s Trichrome Light Green 
Variant Kit (RAL Diagnostics, France). Briefly, following treatment and rehydration of 
tissues as described in chapter 2, sections were stained with Mayer’s Haematoxylin 
for 10 minutes, rinsed in distilled water, stained with Ponceau Fuchsin solution for 5 
minutes and rinsed again in distilled water. Sections were then stained with 
Phosphomolybdic acid for 3 minutes and transferred to Light Green Solution for 5 
minutes. Slides were then rinsed in two changes of 1% acetic acid solution, before 
being dehydrated rapidly through increasing concentrations of ethanol. Finally, cover 
slips were mounted with DPX.   
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3.3 Results – Pressor Angiotensin II (1.1mg/kg/day) 
To investigate the role of fibroblast NOX2 in the generation of cardiac fibrosis, chronic 
Ang II infusion, a well-established model of blood pressure driven cardiac fibrosis, was 
used at a dose of 1.1mg/kg/day for 14 days. This dose has been previously reported 
to cause hypertension, leading to cardiac fibrosis and variable cardiac hypertrophy in 
WT mice.35, 53  
3.3.1 Cardiac Fibrosis 
Treatment with 1.1mg/kg/day Ang II led to a significant increase in interstitial cardiac 
fibrosis in flox mice (1.2 ± 0.1% with vehicle, up to 2.6 ± 0.2% after 14 days Ang II 
treatment; P<0.001; Figure 3-4). In contrast, fibroblast NOX2 KO mice treated with 
Ang II did not develop significant cardiac fibrosis (1.2 ± 0.2% with vehicle vs. 1.6 ± 
0.2% after 14 days Ang II treatment; P=0.28). As such, there was a significant 
interaction between flox and fibroblast NOX2 KO mice receiving Ang II (#P<0.05). 
These data support the hypothesis that NOX2 activation in fibroblasts contributes to 
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Figure 3-4: Interstitial cardiac fibrosis following 2 week treatment with Ang II. Upper 
tiles: representative Picrosirius red stained heart sections visualised in brightfield 
light. Lower graph: quantification of fibrous tissue determined by polarised light 
analysis. Images are representative from n=6, 4, 4, 5, mice respectively per group 
with a minimum of 4 sample frames/mouse. Scale 200µm. #P<0.01; significant 
interaction between angiotensin II-treated flox and knockout mice, ***P<0.001 
compared to vehicle; 2way ANOVA with Bonferroni’s multiple comparison post-test.   
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3.3.2 Gene Expression 
The expression of fibronectin, CTGF, collagen 1α1 and collagen 3α1 mRNA in 
myocardial tissue was significantly increased in all mice receiving Ang II (Figure 3-5). 
Bonferroni post-tests revealed significant increases in fibronectin and collagen 3α1 in 
flox mice, but not in fibroblast NOX2 KO mice receiving Ang II (Figure 3-5A and D) 
which goes some way towards supporting the cardiac fibrosis data shown in Figure 3-
4. It must be noted however, that the usefulness of a post-test is limited in the 
absence of a significant interaction.  
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Figure 3-5: Angiotensin II-induced fibrotic gene expression. A: fibronectin, B: CTGF, 
C: collagen 1α1 and D: collagen 3α1 in hearts following Ang II treatment. Each sample 
is normalised to its own β-actin mRNA control and then expressed as a percentage of 
vehicle controls. 2way ANOVA shows significant increase vs. vehicle for both groups. 
*P<0.05, **P<0.01; 2way ANOVA with Bonferroni’s multiple comparison post-test; 
n=5, 4, 4, 4, respectively for groups.  
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Interestingly, the expression of NOX2 in myocardial tissue was significantly increased 
in KO mice following Ang II treatment, with p47phox following a similar, although 
non-significant trend (Figure 3-6). This could suggest a significant contribution of 
NOX2 from other cell types, for example infiltrating leukocytes. The expression of 
NOX4, the other major cardiac isoform, was not investigated, but was believed to be 
unchanged owing to data from previous studies, discussed further in chapter 7.2. In 
support of this, expression of p22phox, required for NOX4 activity, was similar in flox 
and fibroblast NOX2 KO mice (Figure 3-6C).  
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Figure 3-6: Angiotensin II-induced changes in NOX2 and p47phox gene expression. 
A: NOX2, B: p47phox and C: p22phox gene expression in hearts following Ang II 
treatment. Each sample is normalised to its own β-actin mRNA control and then 
expressed as a percentage of vehicle controls. n=5, 4, 4, 4 respectively for groups; 
*P<0.05; 2way ANOVA with Bonferroni’s multiple comparison post-test. 
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3.3.3 Cardiac Function 
Echocardiography was used to determine the effects of Ang II on cardiac function. 
The left ventricular ejection fraction and fractional shortening did not significantly 
differ after treatment with Ang II for 14 days or between genotypes (Figure 3-7). This 
is somewhat unexpected, since the majority of reports suggest a reduction in cardiac 
function following chronic Ang II. This is discussed further in chapter 3.5.1.  
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Figure 3-7: Systolic cardiac function determined by echocardiography. A: Left 
ventricular ejection fraction and B: Left ventricular fractional shortening were 
calculated over at least 3 cardiac cycles. n=3, 6, 4, 5, respectively; P>0.05; 2way 
ANOVA with repeated measures.  
3.3.4 Cardiac Hypertrophy and Remodelling 
Morphological analysis of the left ventricle by echocardiography showed that septal 
and posterior wall thicknesses did not increase in Ang II treated hearts, and there was 
no significant difference between genotypes (Figure 3-8A-B). In addition, left 
ventricular end systolic and diastolic volumes did not change in either genotype 
following Ang II treatment (Figure 3-8C-D). 
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Figure 3-8: Left ventricular wall thicknesses and chamber volumes determined by 
echocardiography. A: Intraventricular septal wall thickness during systole (IVS;s), B: 
Left Posterior wall thickness during systole (LVPWT), C: end systolic volume (LVESV) 
and D: end diastolic volume (LVEDV). n=3, 6, 4, 5 respectively; P>0.05; 2way ANOVA 
with repeated measures.  
These data suggest that there is no evidence of systolic dysfunction in flox or 
fibroblast NOX2 KO mice after receiving Ang II for 14 days. Wall thicknesses were also 
similar amongst all groups, suggesting an absence of significant cardiac hypertrophy. 
This was confirmed by assessing heart weight and with histological analysis of 
cardiomyocyte cross sectional area (Figure 3-9).  
Page | 68  
 
 
Figure 3-9: Assessment of cardiac hypertrophy following Angiotensin II treatment. 
A: Total heart weight normalised to body weight, B: Mean cardiomyocyte cross 
sectional area in WGA-stained heart sections and C: Representative WGA-stained 
heart sections; scale 30µm. n=3, 4, 2, 5, respectively.   
3.3.5 Blood Pressure 
Ang II (1.1mg/kg/day) caused a significant increase in systolic, diastolic and mean 
blood pressures in both flox and fibroblast NOX2 KO mice after 14 days (Figure 3-10A-
C). This increase however, was significantly blunted in fibroblast NOX2 KO mice, 
occurring only on day 14, compared to as early as day 2 as seen in flox controls. The 
mean increase in systolic blood pressure in Ang II treated flox controls was from 108.7 
± 0.5mmHg to 163.8 ± 2.1mmHg, compared to 108.2 ± 1.8mmHg up to only 140.7 ± 
11.6mmHg in fibroblast NOX2 KO mice (P<0.05). Differences in blood pressure were 
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Figure 3-10: Angiotensin II-induced changes in blood pressure. A: Daytime 
ambulatory systolic B: diastolic and C: mean arterial blood pressures and D: heart rate 
in mice fitted with telemeters during treatment with 1.1mg/kg/day Ang II. Telemetry 
devices were fitted one week prior to mini-osmotic pump implantation. Data was 
acquired from each mouse every 5 minutes during each 24 hour sample period, with 
the group average being used for each data point. Mice were not restrained or 
disturbed during the acquisition of data. n=7, 4, 3, 6, respectively; a, b, c P<0.05 as 
indicated; 2way ANOVA with repeated measures with Tukey’s multiple comparison 
test. 
The data presented in part 1 indicate an important role for fibroblast NOX2 in the 
development of cardiac fibrosis. Differences in flox and KO blood pressure responses 
to Ang II may in part be an important contributor and suggest a possible indirect, 
pressor-dependent effect. This is discussed further in chapters 3.5.1, 4 and 7.  
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3.4 Results – Subpressor Angiotensin II (0.3mg/kg/day) 
To assess the blood pressure-independent effects of Ang II, experiments were 
performed using a chronic subpressor dose of Ang II for 28 days.62 Here, wildtype 
mice (C57/BL6) were used to verify the model.  
3.4.1 Blood Pressure 
To verify the model of subpressor Ang II, it was essential to ensure an absence of 
blood pressure effects during treatment. Serial tail cuff plethysmography revealed 
that 0.3mg/kg/day Ang II did not alter systolic, diastolic or mean blood pressures in 
mice compared to vehicle treated control mice over 28 days (Figure 3-11).  
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Figure 3-11: Subpressor angiotensin II-induced changes in blood pressure. Systolic, 
mean and diastolic blood pressures in mice treated with subpressor Ang II. Blood 
pressure (BP) was measured by tail cuff plethysmography in trained mice before and 
during subpressor Ang II treatment via implanted mini-osmotic pump. n=4 and 9, 
respectively; P>0.05; 2way ANOVA.  
In addition, heart rate, also measured by tail cuff plethysmography, and body weights 
did not differ between vehicle and Ang II-treated mice at any time point (Figure 3-12). 
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Figure 3-12: Subpressor angiotensin II had no effect on heart rate or body weight. 
Heart rate (left) and body weight (right) in mice treated with subpressor Ang II. Heart 
rate was measured by tail cuff plethysmography in trained mice before and during 
Ang II treatment via implanted mini-osmotic pump. n=4 and 9, respectively; P>0.05; 
2way ANOVA.  
3.4.2 Cardiac Fibrosis 
The level of interstitial cardiac fibrosis was determined by staining with Picrosirius 
red, with analysis of both bright field and circularly polarized light images. 
Unexpectedly, subpressor Ang II did not lead to a significant increase in cardiac 
fibrosis after 28 days (Figure 3-13). Mean collagen content was 1.02 ± 0.06% and 0.98 
± 0.09% for vehicle and subpressor Ang II treated hearts respectively (P>0.05).  
 
Figure 3-13: Subpressor angiotensin II did not induce cardiac fibrosis. Interstitial 
cardiac fibrosis visualised with Picrosirius red staining under bright field (upper panel) 
and circularly polarised light (lower panel). Scale 200µm; n=4 and 5, respectively; 
P>0.05; Student’s t-test. 
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Masson’s trichrome staining was also used qualitatively, confirming these findings, 
using a sample from a 14-day chronic pressure overloaded heart by transverse aortic 
constriction (Figure 3-14). 
 
Figure 3-14: Representative images of Masson’s Trichrome-stained left ventricle 
sections. Upper tiles: Negative (-ve) sham-operated and positive (+ve) transverse 
aortic constriction control images. Lower tiles: Vehicle and Ang II treated heart 
sections. Scale bar 200µm.   
3.4.3 Gene Expression  
The expression of fibrotic gene markers was determined by qPCR, showing that there 
was no significant induction of collagen 1α1, collagen 3α1, CTGF or fibronectin 
following treatment with subpressor Ang II for 28 days (Figure 3-15). This is in stark 
contrast to gene expression following pressor Ang II.  
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Figure 3-15: Subpressor angiotensin II did not induce the expression of fibrotic gene 
markers. A: Collagen 1α1, B: collagen 3α1, C: CTGF and D: fibronectin. n=4 and 5, 
respectively; P>0.05; Student’s t-test. 
3.4.4 Cardiac Function 
Cardiac fibrosis can lead to deleterious effects on cardiac function over time, notably 
diastolic and eventually systolic dysfunction before progressing to heart failure,28 
therefore serial echocardiography was used to assess in vivo cardiac function in mice.  
Subpressor Ang II did not lead to a reduction in left ventricular ejection fraction or 
fractional shortening compared to vehicle treated mice, suggesting an absence of 
systolic dysfunction (Figure 3-16).  
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Figure 3-16: Subpressor angiotensin II did not cause systolic dysfunction. A: Left 
ventricular ejection fraction and B: fractional shortening following subpressor Ang II 
infusion. Subpressor Ang II did not lead to a significant difference between groups 
over the 28 day period. n=4 and 5, respectively; P>0.05; 2way ANOVA.  
Left ventricular filling indices such as mitral A wave velocity, E/A ratio and mitral valve 
E’, A’ and E/E’ ratio were not significantly different between treatment groups (Figure 
3-17A-E). These indices are reported to correlate with ventricular filling pressures, 
with an increase indicating potential myocardial stiffening due to fibrosis and diastolic 
dysfunction.153 Since increased left ventricular filling pressures often feeds back to 
the left atrium, leading to atrial enlargement, left atrial area was also measured by 
echocardiography, however no evidence of left atrial enlargement was found (Figure 
3-17F).  
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Figure 3-17: Subpressor angiotensin II did not alter left ventricular filling indices or 
left atrial area. Indices measured by echocardiography following Ang II treatment. 
n=4 and 5, respectively; P>0.05; 2way ANOVA.  
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Furthermore, other mitral Doppler indices including mitral valve E wave deceleration 
time, IVCT, IVRT and overall ejection time were similar between Ang II and vehicle 
treated mice at each time point, indicating an absence of diastolic dysfunction (Figure 
3-18A-D).  
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Figure 3-18: Subpressor angiotensin II did not alter cardiac mitral valve Doppler 
indices. Indices measured by echocardiography following Ang II treatment. n=4 and 5, 
respectively; P>0.05; 2way ANOVA. 
Subpressor doses of Ang II have previously been reported to cause cardiac 
hypertrophy in mice. In the current experiments, however, subpressor Ang II treated 
mice did not show any increase in echo-derived left ventricular posterior wall or 
septal wall thickness compared to vehicle controls, during systole or diastole (Figure 
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3-19A-B). There was also an absence of cardiac remodelling in Ang II-treated mice, 
shown by end systolic and diastolic left ventricular chamber volumes (Figure 3-19C-
D). 
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Figure 3-19: Subpressor angiotensin II did not alter left ventricular wall thickness 
and chamber volumes. Indices measured by echocardiography. A: Posterior wall 
thickness, B: internal diameter, C: end diastolic volume and D: end systolic volume. 
n=4 and 5, respectively; P>0.05; 2way ANOVA with repeated measures.  
Strain and strain rate analyses take into account regional stresses experienced by the 
ventricular wall (wall motion/displacement) during systole and diastole.142 Both radial 
and longitudinal peak % and time to peak strain were comparable between vehicle 
and Ang II treated mice (Figure 3-20A-D). In addition, radial and longitudinal strain 
rate indices did not significantly differ between treatment groups (Figure 3-20E-H). 
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Figure 3-20: Subpressor angiotensin II did not alter left ventricular strain and strain 
rate indices. Analysis of B-Mode, parasternal long axis images by echocardiography. 
n=4 and 5, respectively; P>0.05; 2way ANOVA with repeated measures. 
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Taken together, these results indicate that 0.3mg/kg/day Ang II for 28 days did not 
have any deleterious effects on systolic or diastolic cardiac function in these mice, 
with no evidence for adverse cardiac remodelling. 
3.4.5 Cardiac Hypertrophy 
In support of the echocardiographic data, subpressor Ang II did not lead to cardiac 
hypertrophy vs. vehicle control (P=0.177) as determined by normalized heart weight 
(Figure 3-21A). This was further supported by histological analysis of cardiomyocyte 
cross-sectional area, revealing similar mean cross-sectional areas of 334.2 ± 37.45µm2 
and 342.0 ± 41.71µm2 for vehicle and Ang II treated hearts respectively (Figure 3-21B-
C). Suitable cross-sections were defined as having a near circular profile, with nuclear 
staining (blue, DAPI).154 











































































Figure 3-21: Subpressor angiotensin II did not induce cardiac hypertrophy. A: Total 
heart weight normalised to tibia length, B: mean cardiomyocyte cross-sectional area 
in WGA-stained heart sections and C: representative WGA-stained heart sections; 
scale 30µm. n=4 and 5, respectively; P>0.05; Student’s t-test.  
Taken together, subpressor Ang II treatment in the current study did not cause any 
functional, morphological or histological changes in wildtype mice.   
Page | 80  
 
3.5 Discussion 
Chronic administration of Ang II is a well-established model for the induction of 
cardiac fibrosis in mice.35, 43, 53, 62 Ang II (1.1mg/kg/day) induces significant 
hypertension and in the current study we were able to show consistent hypertension 
in floxed mice from 10 days onwards. In agreement with published reports, we were 
also able to show significant interstitial cardiac fibrosis and an elevation in supporting 
gene expression markers, including collagen 1α1,53 collagen 3α1 and fibronectin after 
14 days of chronic Ang II at 1.1mg/kg/day.35  
This study aimed to build on the landmark study by Bendall et al,62 by deleting NOX2 
in a cell specific manner, namely fibroblasts. It was hypothesised that NOX2 deletion 
in fibroblasts would mitigate the generation of cardiac fibrosis. By taking advantage of 
a collagen 1α2-promoted CreER system, the current study has shown successful NOX2 
recombination in hearts of 10-day tamoxifen-treated mice, as well as a 50-60% 
reduction in whole heart NOX2 protein levels. Importantly, we observed that 
fibroblast NOX2 KO mice were protected from a significant increase in interstitial 
cardiac fibrosis following chronic pressor Ang II, as determined by Picrosirius red 
histological analysis. This result was strengthened by fibrotic gene expression 
analysis, in particular fibronectin and collagen 3α1.  
Whilst this result supports the original hypothesis, mice in the KO group did not 
become hypertensive until approximately day 14 of Ang II, the final day of the study. 
Since Ang II-induced cardiac fibrosis is reported to be largely dependent on 
hypertension,155 it is possible that the reduced tendency towards cardiac fibrosis in 
KO mice is explained, at least in part, by the delayed development of hypertension. 
This concept is supported by studies showing a reduction in cardiac fibrosis after 
treatment to reduce angiotensin II-induced hypertension in mice, for example using 
resveratrol.156  
Owing to the observed blood pressure phenotype, it is therefore difficult to 
definitively determine the role of fibroblast NOX2 deletion in isolation on the 
development of cardiac fibrosis using the chronic pressor angiotensin II model. It is 
for this reason that we sought to use a blood pressure-independent model of cardiac 
fibrosis. 
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3.5.1 Angiotensin II-based mouse models 
In addition to its well-known effects on blood pressure, Ang II has been reported to 
induce cardiac fibrosis and hypertrophy, independent of hypertension, when used at 
a lower dose.62 A subpressor dose of Ang II (0.3mg/kg/day) has previously been 
shown not to alter blood pressure in WT mice up to 14 days.62, 124 We opted to use 
this dose for 14 and 28 days in WT mice to first determine the maximum achievable 
level of cardiac fibrosis. The results of the current study however, showed that this 
subpressor dose of Ang II did not cause significant interstitial cardiac fibrosis after 14 
(data not shown) or 28 days of chronic treatment.  
Cardiac hypertrophy (both increased heart: body weight (HW: BW) ratio and 
increased cardiomyocyte cross-sectional area) and cardiac fibrosis has been 
previously reported following 0.3mg/kg/day Ang II for 14 days, independent of blood 
pressure.62 A thorough search of the literature reveals conflicting data regarding the 
effects of low dose Ang II in mice. In another study using a similar dose 
(0.28mg/kg/day for 28 days), the authors reported an absence of hypertrophy in 
terms of both HW: BW ratio and cardiomyocyte cross-sectional area.144 They went on 
to use echocardiography, showing normal systolic function and no increases in left 
ventricular wall thicknesses.144 Another group reported 0.28mg/kg/day to in fact be a 
pressor dose of Ang II, showing a 14% increase in systolic blood pressure after 13 days 
chronic treatment.157 Interestingly, a lower dose of subpressor Ang II 
(0.144mg/kg/day) was shown to cause cardiac hypertrophy without detectable 
fibrosis158 and an even lower dose (0.006mg/kg/day for 3 weeks) reported increases 
in systolic blood pressure, left ventricular wall thicknesses, cardiac hypertrophy and 
interstitial and perivascular fibrosis, with complementary gene expression data 
showing elevated collagen 1, collagen 3 and fibronectin expression.145  The reasons 
for these differences are difficult to be certain about, but may reflect mouse diet and 
housing, gender159 and possibly age and starting weight differences,145 as well as 
method of drug administration e.g. impregnated pellet vs. mini-osmotic pump. 
Indeed, the study by Bendall and colleagues62 from our lab was performed many 
years ago, since which mouse diet formula and housing conditions have changed. 
These variables offer some explanation. Regardless, based on the current methods 
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and results, the subpressor Ang II infusion model would not be very useful to 
investigate our hypothesis. 
A reduction in cardiac function following chronic pressor Ang II in mice is a commonly 
held view. Whilst the variables listed above may also explain the absence of cardiac 
dysfunction, it has been suggested that in the absence of another stimulus, such as 
simultaneous aldosterone infusion or prolonged hypertension, Ang II may be 
incapable of causing morphological or functional changes.160, 161 
3.5.2 Collagen1α2 Cre and Fibroblasts  
Here, we describe a novel mouse model of NOX2 deletion specifically in fibroblasts, 
allowing insights into the cell-specific role of NOX2 in vivo for the first time.  
The Col1α2-promoted Cre-recombinase transgenic mouse has been extensively 
characterised in a few studies. Inducible control with tamoxifen has been previously 
described by Zheng and colleagues, showing β-galactosidase (LacZ) reporter 
expression in tamoxifen-treated, but not oil/vehicle-treated or wildtype mouse 
embryos.132 The authors went on to show that postnatal administration of tamoxifen 
produced LacZ expression in skin, lung and pericardial tissue, as expected, as well as 
sustained expression in older mice.132 Similar results were obtained from Florin and 
colleagues.162  
This Col1α2 Cre mouse was used to identify fibroblasts following cardiac injury using a 
LacZ reporter cross and a discoidin domain receptor 2 (DDR2) antibody.136 In addition 
it has been used to show accelerated wound healing and skin fibrosis in a dermal 
injury model when a protein, glycogen synthase kinase 3 beta, was deleted 
specifically in fibroblasts.138 Importantly, the authors first characterized the extent of 
knockout, showing an approximate 90% reduction in isolated fibroblast protein levels 
following 10 days of tamoxifen treatment. Replicating such an experiment in 
fibroblast NOX2 KO mice proved difficult, since fibroblasts from KO mice did not 
adhere and grow well in vitro following isolation, however the studies discussed, in 
addition to our own characterization, provides confidence in the ability of Col1α2-
promoted Cre-recombinase to delete NOX2 in fibroblasts. 
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3.5.3 Detection of Cardiac Fibrosis  
Of the many methods available for the determination of fibrosis, histological analysis 
of tissue sections stained with Picrosirius red is one of the most simple, reliable and 
accurate techniques.163 Picrosirius red is linear and a mix of Sirius red dye and picric 
acid. Collagen contains basic amino groups with which Sirius red sulphonic acid 
groups will react and align in a parallel orientation.163 The result is a highly visible red 
stain (fibrosis), on a pale yellow non-fibrotic background. A great advantage of 
Picrosirius red is how it responds to circularly polarised light. The parallel 
arrangement of dye and collagen, combined with polarised light enhances the 
birefringency and emitted light intensity of collagen by about 700%, providing a 
highly collagen-specific stain.163, 164 Picrosirius red-stained tissue sections viewed 
under polarised light range from green-yellow to orange-red, thought to correspond 
to collagen fibre thickness or collagen type, although these reports are disputed.165, 
166 This method also allows for the detection of very thin collagen fibres, missed with 
traditional bright-field analysis, due to the high contrast against the black 
background.163, 164 
Other methods include Masson’s Trichrome, an Aniline blue or light-green fibrosis 
stain on a red, non-fibrous background. This method gives high contrast (red vs. blue) 
and should in theory give very similar results to non-polarized analysis with Picrosirius 
red. Masson’s Trichrome is however, based solely on acid-base interactions and 
therefore not exclusively selective for collagen, a problem Picrosirius red staining can 
overcome by polarization.143 
Hydroxyproline is a modified amino acid, found largely in collagen, and can be used to 
give an estimation of total collagen content in tissues. The hydroxyproline assay can 
be performed using a kit, in which a reaction gives rise to a product quantifiable by 
calorimetry.143 The hydroxyproline assay is commonly used, but tissue must be 
homogenised, removing information on tissue distribution or maturity of collagen. In 
addition to kit costs, it also requires more expensive apparatus. 
Antibody-based staining is also used, but is more costly, requires antibody titration 
and may have problems with tissue autofluorescence.143 
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Picrosirius red is therefore a sensitive, cheap, easy and reliable method, published to 
be able to pick up differences in a range of human and animal models.32, 53, 163-166 We 
opted to use this method based on the relative ease, sensitivity and cost compared to 
other methods. 
3.5.4 The use of Echocardiography - Diastolic function 
Despite the failure of the subpressor Ang II model, this study provided an invaluable 
opportunity to explore the range of measurable indices by non-invasive 
echocardiography.153 Current literature and in house preliminary studies show that 
subtle functional changes can be detected in more severe heart failure models, such 
as chronic pressor angiotensin II31, 33 or chronic pressure overload.167 In particular, a 
number of new and emerging techniques in mouse echocardiography are aimed 
towards assessing diastolic function (further discussed in chapter 4).  
Trans-mitral Doppler flow can provide values for mitral valve E and A wave velocities, 
reflecting diastolic early filling driven by left ventricular suction and late filling driven 
by atrial contraction, respectively.153 Impaired left ventricular relaxation is indicated 
by firstly a reduction in E wave magnitude, followed by an increased reliance on the 
atrial A wave component. As such, the E/A ratio decreases and indicates stiff or 
fibrotic cardiac tissue and overall diastolic dysfunction.153  
Isovolumic relaxation time (IVRT) describes the interval between aortic valve closure 
and mitral valve opening, that is, the time between end systole and the start of left 
ventricular diastolic filling. A prolonged IVRT indicates impaired left ventricular 
isovolumic relaxation,168 and this finding has also been described in mice following 
chronic pressor Ang II (2.8mg/kg/day), which showed a 62% prolongation.33  
3.5.5 The use of Echocardiography - Systolic function 
Ejection fraction and fractional shortening are commonly used global measures of 
myocardial performance. We also used speckle tracking based strain analysis, which 
may be more sensitive in detecting subtle differences,142 especially in regional 
function, to determine if any differences existed following Ang II treatment. Speckle 
tracking echocardiography has recently been applied to mouse studies and is shown 
as an efficient, reproducible method for regional and global assessment of left 
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ventricular function and is also directly comparable to magnetic resonance imaging, 
regarded as the gold standard.142 The current study was unable to detect differences 
in systolic strain or strain rate indices after treatment with subpressor Ang II, 
indicating a lack of even minor regional changes in systolic function in this model.  
Despite a lack of cardiac dysfunction in the subpressor Ang II study, it is anticipated 
that these recent advances in systolic and especially diastolic echocardiography will 
provide sensitive endpoints for subsequent mouse models of cardiac fibrosis and aid 
us in relating findings to the clinical setting.  
Taken together, the data in this chapter indicate a role for fibroblast NOX2 in the 
development of hypertension and interstitial cardiac fibrosis in response to chronic 
pressor doses of Ang II. The delayed onset of hypertension in fibroblast NOX2 KO 
mice could in part account for the reduction in fibrosis, requiring the use of a blood 
pressure-independent model of cardiac fibrosis. The chronic subpressor Ang II model 
was unable to show the development of cardiac fibrosis in wildtype mice, therefore 















CHAPTER 4: Contribution of 
Fibroblast NOX2 to Pressure 
Overload Remodelling induced by 
Transverse Aortic Constriction. 
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4.1 Introduction 
4.1.1 Models of Pressure Overload 
The aortic constriction model consists of a permanent ligature placed on the aorta 
either prior to the brachiocephalic branch (ascending aortic constriction – AAC),169 or 
between the brachiocephalic and left common carotid branches of the aortic arch 
(transverse aortic constriction – TAC; Figure 4-1), leading to chronic pressure 
overload, cardiac hypertrophy, remodelling and fibrosis.170 It is a crude model of 
aortic stenosis, where the chronic elevation of cardiac afterload causes mechanically-
induced stress.141, 171 An increase in cardiac fibroblast cell numbers has been 
reported,172 followed by severe cardiac fibrosis in as little as 1-week post-TAC, in 
addition to systolic and diastolic cardiac dysfunction.29, 31, 34, 170, 172  
Alternatively, the abdominal aortic banding/constriction (AAB) model places a 
permanent ligature on the abdominal aorta, often at the level of the suprarenal 
artery.152, 173 AAB is technically easier to perform and generally has a lower mortality 
rate, possible owing to avoidance of thoracic microsurgery. RAAS activation is 
apparent in pressure overload models, since RAAS inhibitors reduce the deleterious 
effects, such as the ACE inhibitor captopril.167 This is more pronounced in AAB, since 
constriction at the level of the suprarenal artery also creates a degree of renal 
ischaemia, an additional stimulus for renin release and full RAAS activation involving 
Ang II and an elevation in blood pressure.173 
Regardless of the model used, an important consideration in terms of pathological 
severity and speed of onset is the tightness of the ligature, often reported in 
reference to a needle gauge.   
4.1.2 NOX2 Activation after Pressure Overload 
Similar to chronic Ang II, pressure overload has been shown to induce the activation 
of NOX2 in cardiac tissue.118 Importantly, global NOX2 KO mice were shown to be 
protected from developing cardiac fibrosis using the AAB31, 152 and TAC118 models, 
indicating that this would be a suitable alternate model with which to address the 
hypothesis. 
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Grieve and colleagues showed profound systolic dysfunction in WT AAB mice by 
echocardiography, which was absent in global NOX2 KO AAB mice.31 Additionally, left 
ventricular pressure-volume analysis was used to show similar results for diastolic 
dysfunction.31 These differences in function (between WT and global NOX2 KO AAB 
mice) potentially provide a window through which to determine the functional role of 
fibroblast NOX2 specifically.118  
Recent work by Parajuli in 2014 showed an upregulation of NOX2 and oxidative stress 
in left ventricular tissue from failing human hearts, alongside evidence of adverse 
cardiac remodelling such as cardiac fibrosis and cardiomyocyte hypertrophy.118 These 
findings were recapitulated in TAC mice and, in agreement with Grieve and 
colleagues, global NOX2 KO mice were protected from adverse cardiac dysfunction 
and remodelling.118 Interestingly however, the majority of studies using global NOX2 
KO mice suggest that NOX2 is dispensable in the development of pressure overload-
induced cardiac hypertrophy.31, 152, 174 
Taken together, NOX2 is important for the development of cardiac fibrosis in both 
TAC and AAB pressure overload models, in addition to the Ang II models discussed in 
chapter 3. This suggested that a pressure overload model would be suitable for the 
investigation of cardiac fibrosis development in fibroblast NOX2 KO mice.  
4.1.3 Aims 
NOX2 activation in fibroblasts plays a significant role in Ang II-induced hypertension 
and is indicated to have a role in the development of Ang II-induced cardiac fibrosis. It 
is, however, difficult to separate these two roles using a pressor Ang II model. We 
therefore aimed to clarify the role of fibroblast NOX2 in the development of cardiac 
fibrosis by using an alternative model, namely TAC.    
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4.2 Methods 
4.2.1 Generation of Experimental Mice  
Male fibroblast NOX2 KO mice and their Cre-negative littermate controls were 
generated as described in chapter 3. 
4.2.2 Transverse Aortic Constriction (TAC) Surgery  
Minimally invasive TAC surgery without intubation was used to induce cardiac 
hypertrophy and fibrosis over 14 days, based on methods previously described 
(Figure 4-1).140 Briefly, mice were anaesthetised with isoflurane and maintained via 
nosecone at 1.5% at 1.5L/min. A small suprasternal incision was made, through which 
the thymus was retracted and the strap muscles were bluntly dissected to expose the 
aortic arch. A small, hook-shaped needle was used to pass a 6-0 silk suture under the 
aorta between the brachiocephalic (right common carotid) and left common carotid 
arteries. The needle was then removed. An angled 27-gauge needle was placed 
alongside the aorta and the 6-0 silk suture tied snugly around the 27-gauge needle to 
constrict the aorta. The needle was then promptly removed and the incision closed by 
suturing. Sham operated mice underwent the same procedure without constriction.  
4.2.3 Estimation of TAC Gradient by Forepaw Blood Pressure Assessment  
Successful aortic constriction was confirmed immediately after TAC surgery by 
estimation of trans-TAC gradient using measured blood pressure differential by 
plethysmography. Essentially, TAC leads to an increase in right carotid artery blood 
pressure relative to the left carotid and this will be reflected in peripheral blood 
pressure (Figure 4-1). Assessing systolic blood pressure in right and left forepaws 
would therefore give an indication of TAC gradient and the level of TAC. The average 
systolic blood pressure was measured from both the right and left forepaws of 
anaesthetised mice maintained with 1.5% isoflurane (5 measurements per forepaw), 
before mice were placed in a heated recovery chamber. The difference between right 
and left forepaw systolic blood pressures was calculated, thereby estimating the 
trans-TAC gradient.  
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Figure 4-1: Transverse aortic constriction (TAC) model. Constriction of the aorta 
between the right and left carotid arteries causes an increase in right carotid and 
right peripheral blood pressure relative to left. The right and left forepaw blood 
pressure differential gives an estimate of TAC gradient.  
4.2.4 Echocardiography 
Full echocardiographic assessment was performed for mice before (baseline) and 
after (7 and 14 days) TAC surgery, as described in chapter 2, to include systolic, 
diastolic, morphological, strain and strain rate indices. The trans-TAC pressure 
gradient was also estimated 1 day after TAC surgery (as described in chapter 2) and at 
7 and 14 days after. 
4.2.5 Tissue Harvest and Processing 
14 days following TAC surgery, mice were killed and organs harvested as described in 
chapter 2. Cardiac tissue was processed for histological and biochemical analysis as 
described. 
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4.3 Results 
Successful TAC surgery was confirmed by assessment of TAC blood pressure gradients 
using an immediate, indirect measure (peripheral blood pressure plethysmography) 
and later the trans-TAC Doppler imaging (echocardiography) up to 24 hours after 
surgery. 
The difference in right and left forepaw systolic blood pressure was significantly 
higher in mice receiving TAC compared to sham, with comparable values between 
flox and KO mice (Figure 4-2A). These data were supported by Doppler imaging 
echocardiography, showing significant TAC gradients of approximately 42-45mmHg 
for flox and KO TAC mice, respectively (Figure 4-2B) compared to sham. Taken 
together, data indicate that successful TAC was achieved and TAC surgery had 
comparable effects between genotypes. 
 
Figure 4-2: Assessment of TAC gradient by forepaw blood pressure 
plethysmography immediately after TAC surgery. A: Gradients are significantly 
increased after TAC surgery compared to sham for both groups. * indicates P<0.05 
with Bonferroni post-test; n=4, 11, 4, 10, respectively; 2-way ANOVA with Tukey post-
test. B: Central assessment of TAC gradient by Doppler echocardiography performed 
24 hours after surgery. Gradients are significantly increased after TAC surgery 
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4.3.1 Survival 
Deletion of NOX2 in fibroblasts had no effect on survival following TAC surgery (Figure 
4-3).  
 
Figure 4-3: Kaplan Meier survival curves for mice from 24 hours after surgery. 
Survival proportions are listed within, with no significant differences between surgery 
and genotype groups; P>0.05; n=10, 13, 11, 13, respectively.  
4.3.2 Cardiac Fibrosis and Hypertrophy  
Cardiac sections stained with Picrosirius red revealed profound interstitial and 
perivascular fibrosis in mice after 2 weeks of TAC, as compared to sham (Figure 4-4).  
Bright field analysis of Picrosirius red showed a significant total collagen proportion of 
5.57% and 5.52% for flox and KO TAC mice, respectively, representing a 360-440% 
increase vs. sham (Figure 4-4A). Circularly polarised light was also used as it is thought 
to be more specific for collagen, providing information about collagen fibre thickness, 
maturity and cross-linking and potentially capable of distinguishing types I and III.163-
165 Analysis indicated a more modest but nonetheless significant increase of 210-
220% in collagen (Figure 4-4B). Similar results are observed for perivascular fibrosis 
analysis (Figure 4-4C and D). Importantly, there appears to be no difference in the 
extent of cardiac interstitial or perivascular fibrosis between flox and fibroblast NOX2 
KO mice following 2 weeks of TAC.  
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Figure 4-4: Cardiac interstitial and perivascular fibrosis in mice 14 days after TAC 
surgery. Upper 2 rows: representative images for interstitial fibrosis (scale 300µm) 
and quantification (A and B). Bottom 2 rows: representative images for perivascular 
fibrosis (scale 100µm) and quantification (C and D). 2way ANOVA shows significant 
increase vs. sham for both groups.*P<0.05, **P<0.01 and ***P<0.001 vs. respective 
sham control; 2-way ANOVA with Bonferroni’s post-test; n=10, 12, 11, 11.  
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The observed cardiac fibrosis is supported by gene expression data, showing an 
increase in fibrotic gene markers in hearts of both flox and KO mice (Figure 4-5). In 
particular, analysis of collagen 1α1 and collagen 3α1 by qPCR showed an upregulation 
of between 200% to 300% for both flox and KO mice, however there is no difference 
between genotypes. Interestingly, in contrast to flox controls, fibronectin expression 
is not significantly increased in fibroblast NOX2 KO TAC mice, though the interaction 
is not regarded as statistically significant (Figure 4-5D).  
 
Figure 4-5: Increased expression of fibrotic gene markers in mice 14 days after TAC 
surgery. A: Collagen 1α1, B: Collagen 3α1, C: connective tissue growth factor (CTGF) 
and D: fibronectin. 2way ANOVA shows significant increase vs. sham for both groups. 
*P<0.05, **P<0.01, ***P<0.001 vs. respective sham control; 2way ANOVA with 
Bonferroni post-test; n=6.  
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In addition to cardiac fibrosis, cardiac hypertrophy was also observed following 2 
weeks of TAC (Figure 4-6). Flox and fibroblast NOX2 KO mice responded similarly with 
approximately 40-50% hypertrophy determined by whole heart weight and individual 
cardiac chambers.   
 
 
Figure 4-6: Cardiac hypertrophy determined by weight 14 days after TAC surgery. A: 
Whole heart weight (HW), B: left ventricle (LV), C: left atrium (LA), D: right ventricle 
(RV) and E: right atrium (RA) all normalised to left tibia length. ***P<0.001 vs. 
respective sham control; n=10, 12, 11, 11, respectively. 
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In support of cardiac weight analysis, echocardiography-derived cardiac dimensions 
indicated marked hypertrophy (Figure 4-7), which occurred to a similar extent in flox 
and fibroblast NOX2 KO TAC mice. In addition to left ventricular posterior and septal 
wall thickening, increases in left ventricular end systolic volume and internal diameter 
during systole indicate cardiac dilatation (Figure 4-7A and D).  
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Figure 4-7: Echocardiography-derived cardiac dimensions, indicative of 
hypertrophy, are increased to the same extent in flox and fibroblast NOX2 KO TAC 
mice. A: left ventricular end systolic volume, B: left ventricular posterior wall 
thickness, C: intraventricular septal wall thickness and D: left ventricular internal 
diameter during systole. *P<0.05, **P<0.01, ***P<0.001 vs. respective sham control; 
2way ANOVA with repeated measures and Bonferroni post-test; n=10, 12, 11, 11, 
respectively.  
The observed overall cardiac hypertrophy is likely to be a direct effect of 
cardiomyocyte hypertrophy, as indicated by left ventricular cardiomyocyte cross-
sectional area analysis (Figure 4-8). TAC surgery led to a similar increase in average 
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cardiomyocyte cross-sectional area in flox and KO mice of 43% and 39%, respectively 
(P<0.01 vs. respective sham controls).  
 
Figure 4-8: Cardiomyocyte hypertrophy determined by cross-sectional area analysis 
of wheat germ agglutinin- (WGA) stained cardiac tissue sections. Upper panels: 
representative images for WGA stained cardiac sections in mice 14 days after surgery. 
Lower graph: quantification showing enlarged cardiomyocytes in mice receiving TAC 
surgery. Data is from an average of ≥100 individual cardiomyocytes per mouse. 
**P<0.01 vs. respective sham control; scale 30µm; n=6, 6, 8, 8, respectively.  
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Taken together, flox and fibroblast NOX2 KO mice both underwent cardiac 
remodelling following 2 weeks of TAC and, importantly, this occurred to a comparable 
extent.  
4.3.3 Cardiac Function 
Chronic pressure overload in mice is known to cause cardiac dysfunction.29, 175 
Echocardiography was used to examine cardiac function both before and 1 and 2 
weeks after TAC. Indices of systolic dysfunction including ejection fraction, fractional 
shortening and cardiac output were significantly reduced in TAC mice at both 1 and 2 
week time points (Figure 4-9). The dysfunction was equivalent between flox and 
fibroblast NOX2 KO mice, with an approximate 33% reduction in ejection fraction in 
both groups (Figure 4-9A).  
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Figure 4-9: Systolic function is reduced to the same extent in flox and fibroblast 
NOX2 KO TAC mice as determined by echocardiography. A: Ejection fraction, B: 
fractional shortening, C: heart rate and D: cardiac output. *P<0.05, **P<0.01, 
***P<0.001 vs. respective sham control; 2way ANOVA with repeated measures and 
Bonferroni post-test; n=10, 12, 11, 11, respectively. 
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Diastolic dysfunction, for example reduced ventricular compliance, is seen on the 
progression to heart failure and can be caused by cardiac fibrosis.118, 176 Cardiac 
diastolic function was assessed by echocardiography, showing a similar extent of 
dysfunction in flox and fibroblast NOX2 KO mice (Figure 4-10). Here, the mitral valve 
E-wave deceleration time appears to be a highly sensitive measure in mice, reducing 
by about 50% with TAC (Figure 4-10D). Left atrial remodelling is also a reflection of 
left ventricular diastolic dysfunction, since a reduction in left ventricular compliance 
and relaxation capacity will increase filling pressures and therefore left atrial 
pressure. A similar ~85% increase in left atrial area was observed in both flox and 
fibroblast NOX2 KO TAC mice (Figure 4-10B).  
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Figure 4-10: Diastolic function was reduced to a similar extent in flox and fibroblast 
NOX2 KO TAC mice as determined by echocardiography. A: Isovolumic relaxation 
time, B: left atrial area, C: mitral valve ‘E’ wave velocity to annular motion ratio (E/E’) 
and D: mitral valve ‘E’ wave deceleration time. *P<0.05, ***P<0.001 vs. respective 
sham control; 2way ANOVA with repeated measures and Bonferroni post-test; n=10, 
12, 11, 11, respectively.  
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Sensitive strain and strain rate analysis in TAC mice revealed declines in cardiac 
function over time from baseline to 14 days after TAC (Figure 4-11). These declines in 
radial and longitudinal strain and strain rate were comparable between flox and 
fibroblast NOX2 KO mice, further confirming the lack of difference between 
genotypes. 
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Figure 4-11: Strain and strain rate echocardiography revealed comparable declines 
in cardiac function for flox and fibroblast NOX2 KO mice. A: Average radial strain as 
percentage of peak, B: average longitudinal strain as percentage of peak, C: Radial 
strain rate at peak per second, D: Longitudinal strain rate at peak per second. 
***P<0.001 from baseline (0) to 14 days after TAC; 2way ANOVA with repeated 
measures with Bonferroni post-test; n=12 and 11 for flox and KO, respectively.  
Taken together, these results indicate that fibroblast NOX2 does not contribute to the 
development of TAC-induced cardiac fibrosis, hypertrophy or systolic or diastolic 
dysfunction.  
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4.4 Discussion 
Previous studies have shown the importance of NOX2 in the development of cardiac 
fibrosis; however the cell-specific contribution remains unclear. In particular, 
fibroblast NOX2 is thought to be important, owing to the central role in extracellular 
matrix homeostasis. In the current study, fibroblast NOX2 KO mice subjected to TAC 
were comparable to flox controls in terms of cardiac fibrosis, remodelling, 
hypertrophy and systolic and diastolic function. This finding was perhaps unexpected 
and is in contrast to results obtained from the Ang II model.  This suggested stimulus-
dependent effects of fibroblast NOX2 as well as a non-critical role for fibroblast NOX2 
in the development of cardiac fibrosis in response to TAC.  
It is known that NOX2 contributes to both cardiac dysfunction and fibrosis in response 
to chronic Ang II35, 62 or pressure overload, but only plays a role in Ang II-induced left 
ventricular hypertrophy.31, 174 This showed that NOX2 activation is stimulus 
dependent and that NOX2 activity may be superseded by other ROS sources or other 
pathways for certain pressure overload-induced pathological effects. If the 
contribution of fibroblast NOX2 is also stimulus dependent, further experiments 
would be needed to confirm this. Since Ang II-treated fibroblast NOX2 KO mice have a 
delayed hypertensive response (chapter 3), a possible experiment could include the 
normalisation of blood pressure for both flox and KO mice. However, such an 
experiment would have to be carefully considered to avoid “preventing” cardiac 
fibrosis with an anti-hypertensive agent, effects often seen with resveratrol156 or 
losartan.177  
Activation of NOX2 by neurohumoral stimulation such as with Ang II is well 
characterized, involving Ang II receptor 1 (AT1R) activation, TGFβ signalling and  
phosphorylation of p47phox.178 In contrast, mechanical stimulation such as with 
pressure overload is less understood. What is known is that mechanical stretch of 
cardiomyocytes induces RAAS signalling and NOX2 activation179 and that stretched 
cardiac fibroblasts in vitro results in increased collagen deposition.180 ROS production 
in fibroblasts has also been reported in response to osmotic swelling, though this was 
deemed to be NOX4 mediated.181 Echocardiography data from this chapter showed 
development of cardiac strain and so stretch-induced activation of cardiac fibroblasts 
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is to be expected, but the extent, if any, of NOX2 activation in fibroblasts by this 
mechanism is unknown. As shown, in contrast to Ang II-stimulation, fibroblast NOX2 
deletion was unable to prevent cardiac fibrosis in TAC. This hints towards fibroblast 
NOX2 activation being most important in Ang II-mediated fibrosis and dispensable in 
TAC.  It is also worth noting that TAC is expected to cause less RAAS activation than 
AAB173 and as such, the loss of fibroblast NOX2 may be of little consequence in a 
system less reliant on Ang II-mediated signalling. 
Regardless, the absence of a reduction in cardiac fibrosis in fibroblast NOX2 KO mice 
suggested that NOX2 in non-fibroblasts is of greater importance in TAC. For example, 
it is known that inflammation occurs during TAC, leading to the recruitment of 
circulating leukocytes. These leukocytes are high expressers of NOX2 and rapidly 
increase their cardiac cell numbers after TAC, peaking at 3-7 days followed by a slow 
decline over time.182 Recent reports suggest some dependence on infiltrating 
leukocytes for the development of cardiac fibrosis in TAC. Phosphoinositide 3-kinase γ 
(PI3Kγ) is known to be essential for leukocyte recruitment during inflammation and 
kinase-dead mutant mice have been shown not to develop cardiac fibrosis following 
TAC.183 Similar results were obtained using a selective PI3Kγ inhibitor, but treatment 
had no effect when started 1 week after TAC, indicating that the initial leukocyte 
infiltration was most important.183 It is possible that a mechanical stimulus such as 
TAC is more dependent on leukocyte recruitment and leukocyte NOX2 activation for 
the development of cardiac fibrosis, since deletion of fibroblast NOX2 had no effect.  
Interestingly, this increase in leukocyte recruitment is also documented in response 
to chronic Ang II. Surprisingly however, it was shown that NOX2 from inflammatory 
cells was not essential for Ang II-induced cardiac fibrosis,53 highlighting both a 
stimulus and cell dependent effect.  
4.4.1 Transverse Aortic Constriction Model  
Transverse aortic constriction is a well-established murine model, repeatedly shown 
to induce cardiac hypertrophy and fibrosis.29, 118, 141 A major consideration for TAC 
studies is the degree of aortic constriction and the pressure differential generated as 
a result. It has been described that invasively measured trans-TAC pressure gradients 
correlate with TAC severity and left ventricular hypertrophy after 21 days.141 
Page | 103  
 
Importantly, non-invasively measured transverse aortic Doppler flow correlates with 
these invasive measures, providing an opportunity to prospectively assess TAC 
severity non-terminally.  
Here we measured blood pressure from the left and right foreleg immediately after 
TAC using non-invasive plethysmography. This method makes the assumption that 
the pressure measured peripherally in the right and left foreleg, is reflective of the 
pressures occurring proximal (transverse aorta) and distal (descending aorta) to the 
TAC site, respectively. We show an average 26mmHg pressure differential by 
plethysmography and close to 41mmHg measured by pulsed-wave Doppler 
echocardiography, the latter of which is comparable to catheter and Doppler-derived 
values previously reported.141 Given the vast variability in the TAC model, it is 
surprising that an indication of TAC severity or success is not included in many 
publications.29, 118, 184-186 In addition to a Doppler-based approach we present a 
plethysmography-based, and to our knowledge previously unreported, method for 
assessing TAC severity immediately post-surgery, which could be used in the absence 
of echocardiographic equipment. 
Taken together we can be confident in the TAC model effectiveness and 
reproducibility in our hands, giving strength to the conclusion that fibroblast NOX2 is 
dispensable in the development of TAC-induced cardiac fibrosis.  
4.4.2 Echocardiography and TAC 
In contrast to chronic Ang II models, TAC was capable of inducing significant systolic 
and diastolic dysfunction, as well as more profound cardiac fibrosis. As such, TAC 
provides a wider window through which to investigate subtle functional effects of 
gene deletion in vivo.  
Clinical echocardiography suggests that the E/A ratio is a very reliable and predictive 
index of diastolic function, however this is difficult to measure in mice due to higher 
heart rates. With a high heart rate, the mitral E and A waves can become fused, 
making it impossible to accurately distinguish the two components (Figure 4-12). This 
is a commonly reported problem in murine models and can be overcome either by 
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lowering heart rates artificially with increased isoflurane or by simply measuring 
alternative indices.   
 
Figure 4-12: Lower heart rates increase the probability of separate, measureable E 
and A waves. Left: Heart rate of 447 bpm compared to Right: heart rate of 540 bpm. 
Images are representative taken from a single mouse 7 days apart.  
Alternative indices include left atrial area and mitral E wave deceleration time, both 
of which have emerged as robust indicators of diastolic dysfunction by 
echocardiography, as well as IVRT and E/E’. The left atrium can be observed in an 
apical 4-chamber view probe orientation, and whilst difficult to achieve, is a way to 
determine the left atrial area. This index was found to be highly reproducible in TAC 
mice in this study and is clinically relevant, since it is commonly seen in patients with 
heart failure and can be an independent risk factor for death.168 Both the E wave 
deceleration time and IVRT are associated with left ventricular relaxation, becoming 
prolonged with impaired relaxation,153, 187 but also become shortened by increased 
filling pressures188 – a seemingly paradoxical event, explained by a U-shaped 
relationship.168 In the current study, TAC mice showed signs of impaired relaxation, 
denoted by an increased IVRT at day 7. However evidence predominantly points 
towards a more advanced pseudonormal or restrictive ventricular filling pattern due 
to severely increased atrial pressure (indicated by increased left atrial area), since the 
E wave deceleration time was reduced and IVRT appeared reduced in some mice. In 
addition, the E/E’ ratio increased (more negative). This occurs as the E wave tends to 
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increase with increased filling pressures, whereas mitral annular motion (E’) is 
reduced.168 
Collectively, echocardiography data presented in this chapter provide firm evidence 
for diastolic dysfunction following 14 days pressure overload by TAC in our own hands 
and is therefore a powerful tool for functional studies. 
4.4.3 Summary 
Data presented in this chapter strongly suggest that fibroblast NOX2 is dispensable in 
the development of TAC-induced cardiac fibrosis. This is in contrast to results from 
chapter 3 and taken together strongly supports the argument in chapter 3.5 for a 
pressor-dependent effect of fibroblast NOX2 in the development of cardiac fibrosis. In 
addition, these data could suggest a stimulus-dependent role for fibroblast NOX2, or 
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5.1 Introduction 
5.1.1 Endothelial Cells and the Endothelium 
The endothelium is a monolayer of cells, lining blood vessels and acting as a barrier 
between tissues and circulating blood. Endothelial cells are therefore critically 
positioned to be able to respond to physical and chemical stimuli in order to maintain 
vascular homeostasis.  
The endothelium-derived relaxing factor, identified as nitric oxide, mediates the 
quiescent state of the endothelium, including relaxation of underlying smooth muscle 
cells and a reduced tendency towards vascular inflammation, thrombosis and cell 
recruitment and adhesion.189 As such, nitric oxide signalling can be regarded as anti-
fibrotic. In fact, endothelial nitric oxide synthase KO mice are hypertensive190 and 
were more prone to develop cardiac hypertrophy and fibrosis.191 
Endothelial dysfunction is regarded as the activation of the endothelium coinciding 
with a switch from nitric oxide signalling towards reactive oxygen species.192 
Activation occurs in response to a range of stimuli, including abnormal shear stress, 
inflammatory mediators and agonists such as Ang II and results in inflammatory cell 
recruitment and adhesion, vasoconstriction and thrombosis.189 Reactive oxygen 
species, including NOX2-derived superoxide, can react and inactivate nitric oxide, 
reducing its bioavailability and thereby promoting fibrotic signalling.193 In addition, 
reactive oxygen species can directly activate neighbouring endothelial cells, leading to 
further fibrotic signalling via TGFβ.  
5.1.2 Endothelial Cells and Cardiac Fibrosis 
A number of studies have investigated the importance of endothelial cell signalling in 
the development of cardiac fibrosis.  
Endothelin-1 is secreted by activated endothelial cells for example during 
hypertension95 and is associated with the development of pulmonary and renal 
fibrosis.194 A role for endothelial cell endothelin-1 in the development of cardiac 
fibrosis has also been reported, since Endothelial cell endothelin-1 KO mice (Tie-2 
promoter) develop less interstitial and perivascular cardiac fibrosis following Ang II 
treatment.54 In addition, endothelial cell endothelin-1 KO mice had reduced fibrotic 
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gene expression for collagen 1, collagen 3 and connective tissue growth factor. 
Importantly, these effects were not due to differences in hypertension, since systolic 
blood pressure in KO mice was similar to that of wildtype controls.54 Similar results 
were found using a streptozotocin-induced model of diabetes in mice, giving further 
evidence for a pro-fibrotic role of endothelial cell-derived endothelin-1.52 
The tumour suppressor gene, p53, is elevated in heart failure patient biopsies.195 
Mice with endothelial cell-specific (Tie2 promoter) deletion of p53 were shown to 
have significantly lower basal cardiac collagen 1 and CTGF gene expression, 
suggesting that normal endothelial cell p53 signalling might be pro-fibrotic.196 
Furthermore, when these mice were subjected to TAC, they had greater survival, 
associated with reduced cardiac fibrosis and hypertrophy and with better cardiac 
function compared to wildtype controls.196  
A direct link between endothelial cell NOX2 activation and cardiac fibrosis was found 
by Murdoch and colleagues using an endothelial cell-specific transgenic NOX2 
overexpressing mouse.53 Transgenic mice had a 2-fold increase in NOX2,124 
accompanied by an approximate 2-fold increase in cardiac fibrosis following chronic 
angiotensin II treated compared to WT mice.53 Collagen 1 gene expression, overall 
NOX activity and diastolic stiffness were all increased in transgenic mice. The Ang II-
induced cardiac inflammatory cell infiltration (CD45+ and MAC3+ cells) was 
significantly increased in transgenic mice compared to wildtype, coinciding with 
increased endothelial cell expression of vascular cell adhesion molecule-1. It was 
therefore thought that these pro-fibrotic effects of endothelial NOX2 could be due to 
increased leukocyte recruitment. Surprisingly, inflammatory cell NOX2 was shown to 
be dispensable for the augmented cardiac fibrosis, but a role for NOX2-mediated 
endothelial-mesenchymal transition was reported.53 
5.1.3 Endothelial-Mesenchymal Transition 
Endothelial-mesenchymal transition (EndoMT) is a process by which cells lose their 
endothelial-specific markers, e.g. CD31 or CD144 and begin to express markers similar 
to fibroblasts (mesenchymal lineage), e.g. αSMA, vimentin, CD140α and DDR2. Cells 
will also change phenotype and may become motile and able to differentiate, such as 
from fibroblasts to myofibroblasts. This phenotypic switch is seen during the 
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development of the cardiac atrioventricular cushion in embryonic development,197 
but historically has not been documented in adult tissue. 
Evidence of EndoMT in cardiac tissue was first reported by Zeisberg and colleagues in 
2007, showing that up to 35% of fibroblasts were originally endothelial cells in a 
mouse model of chronic pressure overload (discussed in detail in chapter 6).30 
Murdoch and colleagues were also able to show that the augmented cardiac fibrosis 
in endothelial NOX2 transgenic mice coincided with cells undergoing EndoMT, as 
revealed by co-localisation of CD31 and αSMA markers in immunostained cardiac 
sections.53 Moreover, significantly less CD31 and significantly more αSMA and 
collagen 1 protein was detected in the hearts of Ang II-treated transgenic mice 
compared to wildtype, indicative of completed EndoMT.53 
In another experiment, human umbilical vein endothelial cells were stimulated to 
undergo EndoMT by hypoxia and subsequent re-oxygenation, leading to the loss of 
CD31 and CD144 markers and upregulation of αSMA.198 These cells were then 
assessed for their ability to produce collagen type I, showing only a mild contribution 
relative to that of either isolated cardiac fibroblasts or H9C2 rat cardiomyoblasts. It 
was then shown that conditioned medium from these EndoMT-derived cells could 
induce the transdifferentiation of cardiac fibroblasts into myofibroblasts.198 These 
data indicate that rather than just directly contributing to the fibroblast pool, 
endothelial cells undergoing EndoMT may stimulate resident fibroblasts via a 
paracrine signalling method, leading to increased collagen deposition and subsequent 
fibrosis.  
In summary, NOX2 overexpression in endothelial cells induces augmented cardiac 
fibrosis in Ang II-treated mice and increased EndoMT. In addition, the potential 
paracrine signalling between endothelial cells and fibroblasts further highlights this 
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5.1.4 Aims 
The aim of this chapter was to investigate the contribution of endothelial cell NOX2 in 
the development of TAC-induced cardiac fibrosis. Based on previous studies, it was 
anticipated that NOX2 is a key driver of endothelial to mesenchymal cell transition 
and so specific deletion of NOX2 would reduce the development of cardiac fibrosis.  
Page | 111  
 
5.2 Methods 
5.2.1 Generation of Experimental Mice 
Male Cre-positive Cdh5-CreER(T2) mice were crossed with Cre-negative female 
NOX2flox/flox mice to generate Cdh5-CreER(T2)/NOX2flox/y male or Cdh5-
CreER(T2)/NOX2flox/flox female mice respectively, or Cre-negative littermates. Cre-
positive progeny are deficient in endothelial cell NOX2 following daily i.p. injection 
with 1mg tamoxifen in peanut oil for 3 days.130  
As with the fibroblast NOX2 KO experiments, all experimental mice were NOX2 floxed 
and Cre-negative male littermates were used as flox controls. Recombination of 
disrupted NOX2 in heart tissue (following 3-day 1mg i.p. tamoxifen injections) was 
confirmed by the presence of a smaller PCR product (lower band, Figure 5-1). Mice 
with recombined NOX2 are referred to as endothelial cell NOX2 KO and those without 
are flox controls.  
 
Figure 5-1: PCR-based genotyping of mice using DNA gel analysis. Primers recognise 
WT NOX2 or recombined NOX2 in heart tissue following tamoxifen treatment. The 
upper band indicated WT NOX2, whereas the lower band indicated the presence of a 
disrupted (non-functional) NOX2 gene, so-called knockout. Recom. = recombined.  
Expression of NOX2 protein was significantly reduced by approximately 50-60% in 
aortae of endothelial cell NOX2 KO mice following three days tamoxifen treatment 
(Figure 5-2). Protein expression in aorta was analysed owing to the predicted low 
number of cardiac endothelial cells (<10%).172, 199 As such, any reduction in cardiac 
endothelial cell NOX2 protein might be masked by the contribution of cardiomyocyte 
and cardiac fibroblast NOX2.  
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Figure 5-2: NOX2 protein expression in aorta following mouse treatment with 
tamoxifen. A: Western blot for NOX2, with β-actin for normalisation, representative 
image. B: Quantification of western blot protein expression relative to flox controls. 
n=5; P<0.05; student’s t-test. Reproduced from Sag CM et al., 2016; manuscript 
submitted to Circulation Journal. 
Flox and KO mice were viable, had normal life expectancy, bred normally and did not 
show any obvious basal phenotype.  
5.2.2 Experimental Methods 
All other experiments were conducted exactly as for those described in chapter 4, 
excluding the estimation of adequate TAC gradient by forepaw blood pressure 
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5.3 Results 
5.3.1 Survival  
Mice subjected to TAC surgery had estimated trans-TAC gradients of between 40-
50mmHg, significantly higher than that of sham-operated mice (Figure 5-3). 
Importantly, there was no difference between flox and endothelial cell NOX2 KO 
mice. 
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Figure 5-3: Estimation of trans-TAC gradient by Doppler echocardiography 
performed 24 hours after surgery. Gradients are significantly increased after TAC 
surgery compared to sham ***P<0.001; n=8, 10, 8, 8, respectively; 2-way ANOVA 
with Tukey post-test. 
Deletion of NOX2 in endothelial cells had no effect on survival and all mice surviving 
the perioperative 24 hours went on to survive for the complete 2 week study 
duration (Figure 5-4). 
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Figure 5-4: Kaplan Meier survival curves for mice from 24 hours after surgery. 
Survival proportions are listed within, with no significant differences between surgery 
and genotype groups; P>0.05; n=8, 10, 8, 8, respectively. 
5.3.2 Cardiac Fibrosis and Hypertrophy 
Chronic transverse aortic constriction led to the development of significant interstitial 
and perivascular fibrosis in flox and endothelial cell NOX2 KO mice compared to 
sham-operated controls (Figure 5-5). Bright field analysis of cardiac sections stained 
with Picrosirius red revealed an increase in interstitial fibrosis of 7.72% and 9.83% for 
flox and endothelial cell NOX2 KO TAC mice, respectively (P<0.01), with similar values 
for perivascular fibrosis analysis (Figure 5-5A and C). Importantly, there was no 
difference in the extent of cardiac fibrosis for flox and endothelial cell NOX2 KO TAC 
mice, even with the more sensitive polarised light analysis method (Figure 5-5B and 
D).  




Figure 5-5: TAC induced comparable cardiac interstitial and perivascular fibrosis in 
flox and endothelial NOX2 KO mice 14 days after surgery. Upper 2 rows: 
representative images for interstitial fibrosis (scale 300µm) and quantification (A and 
B). Bottom 2 rows: representative images for perivascular fibrosis (scale 100µm) and 
quantification (C and D). 2way ANOVA shows significant increase vs. sham for both 
groups. *P<0.05, **P<0.01 and ***P<0.001 vs. respective sham control with 
Bonferroni’s post-test; n=8, 10, 8, 8, respectively.  
Page | 116  
 
The observed cardiac fibrosis was supported by gene expression by qPCR, showing a 
marked upregulation of the fibrotic gene markers collagen 1 and 3α1, connective 
tissue growth factor and fibronectin (Figure 5-6). Endothelial NOX2 KO mice had a 
similar or greater upregulation of fibrotic genes compared to flox controls. A 
significant interaction was observed for collagen 3α1 gene expression, with 
endothelial cell NOX2 KO mice having higher expression than floxed controls (Figure 
5-6B). This indicated a possible exacerbation of cardiac fibrosis signalling in these 
mice and is in agreement with the trend observed in Figure 5-5. 
 
Figure 5-6: Increased expression of fibrotic gene markers in mice 14 days after TAC 
surgery. A: Collagen 1α1, B: Collagen 3α1, C: connective tissue growth factor (CTGF) 
and D: fibronectin. 
#
P<0.05 for interaction between flox and endothelial cell NOX2 KO 
mice; *P<0.05, **P<0.01, ***P<0.001 vs. respective sham control; 2-way ANOVA with 
Bonferroni post-test; n=6, 5, 6, 6, respectively.  
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Reports suggest that endothelial cell undergoing EndoMT lose their specific markers 
such as CD31. Analysis of cardiac CD31 mRNA revealed that total CD31 expression 
levels were not changed by TAC, nor did they differ between flox and endothelial 
NOX2 KO mice (Figure 5-7). Any reduction in CD31 mRNA would have indicated 
evidence for EndoMT, especially in light of increased collagen 1α1 and collagen 3α1 
mRNA.  





































Figure 5-7: Unaltered cardiac CD31 gene expression in mice 14 days after TAC 
surgery. P>0.05; 2-way ANOVA with Bonferroni post-test; n=6, 5, 6, 6, respectively. 
An increase in whole heart weight: tibia length ratio was observed in both flox and 
endothelial cell NOX2 KO TAC mice (27.2% and 49.2% respectively; P>0.05; Figure 5-
8). This trend was also seen for left ventricular and left atrial weight: tibia length ratio 
(Figure 5-8B and C). Interestingly, cardiac hypertrophy in the current study did not 
extend to the right side of the heart, since right ventricular and right atrial weight: 
tibia length ratios were not increased in flox or endothelial cell NOX2 KO mice 
following TAC (Figure 5-8D and E). This is in contrast to results obtained in chapter 4, 
and possibly reflects a lower TAC severity in this chapter, since right ventricular 
remodelling and even dysfunction can be dependent on TAC severity.200 
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Figure 5-8: Comparable cardiac hypertrophy determined by weight 14 days after 
TAC surgery. A: Whole heart weight (HW), B: left ventricle (LV), C: left atrium (LA), D: 
right ventricle (RV) and E: right atrium (RA) all normalised to left tibia length (TL). 
**P<0.01 and ***P<0.001 vs. respective sham control; n=8, 10, 8, 8. 
In agreement with cardiac tissue weight analysis, echocardiography-derived cardiac 
dimensions indicated marked hypertrophy, which was to a similar extent in both flox 
and endothelial cell NOX2 KO TAC mice (Figure 5-9). Of particular note, both flox and 
endothelial cell NOX2 KO mice had approximately 50% hypertrophy, as determined 
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by echocardiography-derived LV mass (Figure 5-9D). Differences in left ventricular 
end diastolic volume were only detected between flox sham and endothelial cell 
NOX2 KO sham mice after 14 days; however this likely represents a sampling error, 
since all mice have much greater variability than for other parameters (Figure 5-9A).  
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Figure 5-9: Echocardiography-derived cardiac dimensions, indicative of 
hypertrophy, were increased to the same extent in flox and endothelial cell NOX2 
KO TAC mice. A: left ventricular end systolic volume, B: left ventricular posterior wall 
thickness during diastole, C: intraventricular septal wall thickness during diastole and 
D: left ventricular mass. **P<0.01, ***P<0.001 minimum vs. respective sham control 
for both groups; #P<0.05 for flox sham vs. endothelial cell NOX2 KO sham after 14 
days only; 2way ANOVA with repeated measures and Bonferroni post-test; n=8, 10, 8, 
8, respectively.  
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5.3.3 Cardiac Function 
TAC led to profound and sustained cardiac systolic dysfunction in both endothelial 
cell NOX2 KO mice and their controls, with no change or difference between groups 
in heart rate (Figure 5-10). Similar to that observed for fibroblast NOX2 flox and KO 
mice, an approximate 33% reduction in ejection fraction was observed here in TAC 
mice, mirroring changes in fractional shortening.  
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Figure 5-10: Systolic function was reduced to the same extent in flox and 
endothelial cell NOX2 KO TAC mice as determined by echocardiography. A: Ejection 
fraction, B: fractional shortening, C: heart rate and D: cardiac output. *P<0.05, 
**P<0.01, ***P<0.001 minimum vs. respective sham control for both flox and 
endothelial NOX2 KO TAC mice; 2way ANOVA with repeated measures and Bonferroni 
post-test; n=8, 10, 8, 8, respectively. 
Diastolic dysfunction was evident in both flox and endothelial cell NOX2 KO TAC mice, 
as determined by echocardiography-derived left atrial area and mitral valve 
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deceleration time which increase and decrease, respectively (P<0.05; Figure 5-11). 
Isovolumic relaxation time tended to increase in both TAC groups; however this was 
statistically insignificant (Figure 5-11A). Similar to data obtained in the fibroblast TAC 
study, E/E’ generally decreased in TAC mice, however statistical significance was only 
obtained for flox TAC mice.  
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Figure 5-11: Diastolic function was reduced in both flox and endothelial cell NOX2 
KO TAC mice as determined by echocardiography. A: Isovolumic relaxation time 
(IVRT), B: left atrial (LA) area, C: mitral valve ‘E’ wave velocity to annular motion ratio 
(E/E’) and D: mitral valve ‘E’ wave deceleration time. *P<0.05, **P<0.01 and 
***P<0.001 minimum vs. respective sham control; ‡‡P<0.01 vs. respective control for 
flox only; 2way ANOVA with repeated measures and Bonferroni post-test; n=8, 10, 8, 
8. 
Echocardiography-derived strain analysis showed profound cardiac dysfunction in 
TAC mice after surgery (Figure 5-12). Importantly, flox and endothelial NOX2 KO mice 
have almost identical function, both showed an approximate 40-50% decline in radial 
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and longitudinal strain and strain rate indices from baseline (day 0) to 14 days after 
TAC.  
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Figure 5-12: Strain and strain rate echocardiography revealed comparable declines 
in cardiac function for flox and endothelial cell NOX2 KO mice. A: Average radial 
strain as percentage of peak, B: average longitudinal strain as percentage of peak, C: 
Radial strain rate at peak per second, D: Longitudinal strain rate at peak per second. 
***P<0.001 from baseline (0) to 14 days after TAC; 2way ANOVA with repeated 
measures with Bonferroni post-test; n=6.  
Overall these data suggest that endothelial NOX2 does not play a role in the 
development of cardiac fibrosis, hypertrophy or systolic or diastolic dysfunction after 
chronic pressure overload due to TAC.  
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5.4 Discussion 
Endothelial cell ROS signalling is implicated in cardiac pathogenesis. As well as 
inducing endothelial cell activation, endothelial cell NOX2-derived ROS can react with 
nitric oxide (NO), causing NO inactivation and a reduction in bioavailability.201 This is 
important since endothelial-derived NO from endothelial nitric oxide synthase (eNOS) 
has paracrine actions on cardiomyocytes, limiting deleterious effects during 
pathology.193 In particular, eNOS KO mice were shown to have exacerbated left 
ventricular wall thickening, cardiac dysfunction and fibrosis following pressure 
overload compared to wildtype mice.202 Endothelial cell activation is also shown to 
upregulate vascular cell adhesion modelcule-1 expression,53 facilitating the 
attachment and infiltration of circulating leukocytes.  
In a previous study from our lab, the overexpression of endothelial cell NOX2 led to 
augmented cardiac fibrosis in mice subjected to chronic Ang II.53 With this in mind, it 
was expected that deletion of endothelial cell NOX2 would lead to a reduction in the 
development of cardiac fibrosis. In this chapter the TAC model was used to induce 
cardiac fibrosis, however it is indicated that endothelial cell NOX2 may be dispensable 
for the development of cardiac fibrosis in this model.  
One major consideration is the choice of mouse model. A direct comparison study has 
not yet been reported, however in general the TAC model might be considered as 
more severe than chronic Ang II. Chronic Ang II has been reported to cause mixed 
pressure and volume overload, with mild or negligible cardiac dysfunction,203 whereas 
the TAC model is acute onset and one of pressure overload, resulting in profound 
cardiac dysfunction as observed in the current study. Even so, both models would be 
expected to induce endothelial cell activation: TAC due to abnormal shear stress, 
particularly of coronary vessels, and Ang II due to direct endothelial cell activation 
and progressive hypertension. It is possible however, that the acute onset of pressure 
overload in the TAC model bypasses the need for endothelial cell NOX2 signalling for 
the development of cardiac fibrosis. This explanation could also apply to data 
obtained in chapter 4 for fibroblast NOX2 KO mice subjected to TAC. 
Interestingly, data presented here suggested an exacerbation of pro-fibrotic signalling 
in endothelial cell NOX2 KO mice compared to flox controls subjected to TAC. The 
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significant increase in collagen 3α1 gene expression is supported by trends towards 
collagen 1α1 and fibronectin expression, as well as overall fibrotic staining in cardiac 
section. This upregulation in fibrotic signalling appears to be in the absence of any 
systolic or diastolic functional consequences, but could nonetheless suggest a role for 
endothelial cell NOX2 in TAC. Whether this effect suggests a slight protective role for 
endothelial cell NOX2 or is just a consequence of greater overall hypertrophic 
remodelling in KO mice is difficult to say.  
5.4.1 Cardiac Cell Crosstalk 
Cardiac cells are in close proximity to each other and emerging evidence suggests that 
this enables crosstalk by paracrine actions.204 Whilst the role of endothelial-
cardiomyocyte crosstalk has been investigated, less is known about the role of 
endothelial-fibroblast signalling. In preliminary experiments using fibroblast and 
endothelial cell co-cultures, it was surprising that viral overexpression of endothelial 
cell NOX2 did not seem to increase collagen expression in fibroblasts, nor did it 
induce fibroblast-myofibroblast trans-differentiation, even with Ang II stimulation.53  
Further to paracrine effects of endothelial cell signalling, is the ability to change into 
fibroblasts through the process of EndoMT. This process was first reported in cardiac 
tissue by Zeisberg and colleagues, 30 showing up to 35% of fibroblasts as having 
endothelial cell origins in response to pressure overload. The net result is direct 
contribution of endothelial cells to the fibroblast pool30 and the promotion of 
fibroblast-myofibroblast trans-differentiation.198 Lee et al., showed that CTGF 
released from EndoMT-derived cells had paracrine actions on fibroblasts, leading to 
trans-differentiation to myofibroblasts in vitro.198  
Murdoch and colleagues indicated that the augmented fibrotic response to chronic 
Ang II corresponded to increased EndoMT in endothelial cell NOX2 overexpressing 
mice.53 The process of EndoMT was not measured directly in the current study; 
however an increase in collagen 1α1 and collagen 3α1 mRNA was observed, likely 
corresponding to increased fibroblast numbers and/or activity. In addition, quantified 
CD31 mRNA, used as a marker for endothelial cells, was unchanged after TAC for both 
genotypes, which suggested that total endothelial cell numbers are not altered by 
TAC after 14 days. This points towards a lack of EndoMT, though it is a weak method 
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and firm conclusions cannot be drawn. Another consideration is the time frame of 
EndoMT; a detailed study showed that endothelial cell numbers are only decreased in 
the initial 2-3 days following TAC, returning to baseline levels by 7 days.172 If this 
study is correct, then a 14 day snapshot would not be expected to provide evidence 
of EndoMT.  
5.4.2 Tie2 vs. Cdh5 
Both tunica intima endothelial kinase 2 (Tie2) and VE-cadherin (Cdh5) Cre-
recombinase promoters have been used for endothelial cell-specific recombination. 
The endothelial NOX2 overexpression study by Murdoch53 took advantage of the Tie2 
promoter, whereas the Cdh5 promoter was used in the current study. Recently, it has 
been described that Tie2 will also target cells of haematopoietic origin, such as 
leukocyte subsets.205 In contrast, the Cdh5-CreER(T2) construct is reported to have 
minimal leakage into the haematopoietic lineage, labelling less than 1% of bone 
marrow cells.130 Considering this difference, it is possible that NOX2 overexpression 
using the Tie2 promoter53, 124 may, in addition to endothelial cells, target leukocytes 
which are known to infiltrate during chronic Ang II stimulation. As such, in the case of 
augmented cardiac fibrosis, leukocyte-specific effects could be mistaken for 
endothelial-specific effects. This is an important consideration, though the 
dependence on bone marrow-derived cells for the development of cardiac fibrosis 
was ruled out using a global NOX2 KO bone marrow transplant approach.53 
5.4.3 Future Directions 
As discussed, endothelial cell NOX2 KO mice were not protected from developing 
cardiac fibrosis, dysfunction or any other deleterious effect of TAC, similar to results 
obtained for fibroblast NOX2 KO mice. Taking these two studies together, one 
conclusion is that in TAC, NOX2 from a range of cellular sources combine to produce 
fibrosis and dysfunction and as such, single cell-specific NOX2 deletion may not lead 
to noticeable protective effects. This would be technically challenging to determine, 
since a combination of double and possibly triple cell-specific knockouts would be 
required.  
A key experiment would be to investigate the effects of endothelial NOX2 deletion in 
a chronic Ang II model. Fibroblast NOX2 was shown as important in the development 
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of Ang II-induced hypertension and cardiac fibrosis and it would be interesting to see 
if endothelial cell NOX2 KO mice respond in the same way. If endothelial cell NOX2 KO 
mice were protected from Ang II-induced fibrosis and hypertension, this would add 
further strength to the idea of stimulus-dependent NOX2 activity.  
5.4.4 Summary 
Data presented in this chapter strongly suggest that endothelial cell NOX2 is 
dispensable in the development of TAC-induced cardiac fibrosis. This is somewhat 
unexpected owing to the reported effects of endothelial cell NOX2 overexpression in 
Ang II-treated mice; however the stimulus difference is likely to be a determining 
factor. Studies are ongoing to determine the effect of endothelial cell NOX2 deletion 
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6.1 Introduction 
Fibroblasts play a key role in extracellular matrix homeostasis and as such, are 
thought to be responsible for the generation of fibrosis. The exact origin of these 
fibroblasts remains disputed, however, with some evidence suggesting that 
endothelial-mesenchymal transition (EndoMT) gives rise to a large proportion of 
proliferative and fibrosis-inducing fibroblasts, mediated by TGFβ.5, 30 As discussed in 
chapter 5, EndoMT is a process by which cells lose their endothelial-specific markers, 
e.g. CD31, in favour of mesenchymal markers similar to fibroblasts, e.g. alpha smooth 
muscle actin. EndoMT-derived cells appear spindle-shaped, similar to that of 
fibroblasts, and also express collagen 1 and fibronectin.30  
This phenotypic switch has recently become an area of research interest with a 
number of reports across a variety of tissues and disease models, including renal 
fibrosis,206 liver fibrosis,207 pulmonary fibrosis208 and cardiac fibrosis induced by 
experimental hypoxia,209 diabetes,52 chronic neurohumoral stimulation,53 pressure 
overload30 and myocardial infarction.210 
6.1.1 EndoMT in Cardiac Fibrosis  
In a landmark study by Zeisberg and colleagues in 2007 it was found that up to 35% of 
fibroblasts in fibrotic myocardium were of endothelial origin in mice subjected to 
chronic pressure overload.30 In this study, the authors performed lineage tracing of 
mouse endothelial cells by labelling them with LacZ via a Tie1-promoted Cre 
recombinase. The authors claim that these mice permanently express LacZ specifically 
in endothelial cells, such that LacZ will still persist following subsequent proliferation, 
transition or differentiation. Following TAC pressure overload, LacZ expressing 
endothelial cells were found distributed throughout the fibrotic regions of the 
myocardium and also stained positive for fibroblast-specific marker-1 (FSP-1), in 
contrast to sham-operated mice. Flow cytometry of cardiac single cell suspensions 
revealed a reduction in LacZ+CD31+ cells in favour of LacZ+CD31- cells. Furthermore 
these LacZ+CD31- cells had greater expression of αSMA, FSP-1, DDR2 and collagen 1α1 
fibroblast markers, indicating endothelial cells were losing their specific markers in 
favour of mesenchymal markers.30 Importantly, the authors were able to show a 
dependence on TGFβ1 signalling via Smad3, both in vitro and in vivo. 
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6.1.2 Involvement of Reactive Oxygen Species  
Owing to the ROS-dependent activation of TGFβ, it is logical to suggest that NOX2 
activation may contribute to EndoMT and subsequent cardiac fibrosis. In a transgenic 
endothelial cell-specific NOX2 overexpression model, mice were found to have 
increased cardiac fibrosis vs. wildtype following chronic treatment with pressor Ang 
II.53 In addition, transgenic hearts also had increased αSMA and collagen 1 protein 
expression, as well as reduced CD31 expression vs. wildtype. There was also 
enhanced co-localisation of endothelial and mesenchymal markers in transgenic heart 
sections compared to wildtype and similar results were found using cultured human 
aortic endothelial cells.53 These data suggest an increase in EndoMT as a direct result 
of enhanced endothelial cell NOX2 activation following chronic Ang II stimulation.53 
6.1.3 Lineage Tracing 
In the absence of a truly fibroblast-specific marker, many previous reports have 
identified fibroblasts using αSMA,30, 53 FSP-1,30, 53 DDR230 and vimentin,211 all of which 
have now been shown to label other lineages, in particular endothelial cells (CD31+),5, 
197, 212 smooth muscle cells (SM22+) and leukocytes (CD45+).212 Cellular co-expression 
of a fibroblast and an endothelial cell marker indicated evidence of ongoing EndoMT; 
however the lack of marker specificity will have no doubt clouded conclusions, since 
these so-called fibroblast markers were in fact already labelling endothelial cells.  
A better approach is to use lineage-specific reporter mice to permanently label cells 
of interest, prior to applying a disease model. For example, endothelial cells can be 
tagged with a fluorescent protein using the Cre-LoxP system and then subjected to 
pressure overload.213 The behaviour of so-called lineage traced cells can be tracked 
across its lifetime, including gene expression patterns, tissue location and distribution 
patterns, morphology, activity and in addition, cells will pass on the fluorescent label 
to all progeny following proliferation.133 In the context of EndoMT, lineage traced 
endothelial cells can be examined for evidence of phenotype switching, i.e. the 
expression of fibroblast markers and morphological changes, making this a very 
powerful tool.  
A further advantage of permanently tagging cells is to give an indirect measure of 
Cre-recombinase efficiency, or in other words, how effective the extent of knockout 
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is.205 This can be estimated by crossing an established Cre-recombinase mouse line 
with a STOP-floxed reporter line. A common reporter is LacZ (β-galactosidase/X-gal 
reaction to produce 5,5'-dibromo-4,4'-dichloro-indigo), used in the characterization of 
both Col1α2132 and Cdh5130 Cre-recombinase mice, but simpler reporters are now 
used, including green fluorescent protein (GFP) and tdTomato.134, 135, 213 Upon 
tamoxifen induction, the percentage of lineage marker+ cells also expressing the 
reporter protein gives an estimation of Cre-recombinase efficiency. This approach can 
be applied to flow cytometry, giving a quantitative readout of estimated Cre-
recombinase efficiency. This data is useful when considering the magnitude of effect 
of gene deletion in Cre-LoxP gene knockout studies.  
6.1.4 EndoMT in Cardiac Fibrosis or Myth?  
Despite evidence in support of EndoMT, recent and thorough research from Moore-
Morris and colleagues suggested that EndoMT did not occur in the context of 
pressure overload-induced cardiac fibrosis.213 Instead, the authors propose that 
fibroblasts arise from resident fibroblast lineages. Collagen 1α1 (Col1α1)-GFP reporter 
mice were characterized for their ability to identify cardiac fibroblasts, showing 
strong co-localisation of GFP+ cells with the fibroblast markers CD140α and vimentin. 
These fibroblast reporter mice were then crossed with Tie2 or VE-Cadherin Cre-
tdTomato reporter mice, meaning that fibroblasts were tagged green and endothelial 
cells were tagged red. Small subsets of fibroblasts were found to be of endothelial 
origin in naive mice, thought to represent EndoMT-driven atrioventricular cushion 
development. Importantly, when these mice were subjected to TAC, the authors 
showed no evidence for EndoMT, since the proportion of lineage traced Tie2-
tdTomato+Col1α2-GFP+ cells did not increase and GFP+ VE-Cadherin lineage traced 
cells were extremely rare in cardiac tissue devoid of developmental EndoMT-derived 
cells.213 
This work has been supported by another laboratory, who concluded that cardiac 
myofibroblasts arise from tissue-resident fibroblasts following acute myocardial 
infarction.129 In this study Kanisicak and colleagues linage traced myofibroblasts 
(eGFP+) using the periostin (Postn) Cre, showing that these cells did not arise from 
endothelial lineages.129 To further complicate matters, there is recent evidence in 
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support of mesenchymal-endothelial cell transition following ischaemia-reperfusion 
cardiac injury, the reverse process of EndoMT, although this is the only report of its 
kind so far.135 
In light of recent lineage tracing advances and an increased interest in EndoMT, this 
chapter describes the establishment, characterization and use of tdTomato-labelled 
mice in the laboratory.  
6.1.5 Aims 
The first aim of this chapter was to use tdTomato mice to determine an estimation for 
the degree of Col1α2 and Cdh5 Cre-mediated NOX2 deletion in mice (chapters 3, 4 
and 5), so-called Cre efficiency. It is known that low and/or non-specific Cre 
recombinase activity can explain the absence of a phenotype in KO mice and it was 
deemed important to rule this out.  
The second aim was to quantify the extent of EndoMT in TAC mice, using tdTomato 
lineage tracing of endothelial cells and flow cytometry. This aim also required the 
accurate estimation of Cdh5 Cre efficiency.  
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6.2 Methods 
6.2.1 In Vivo Methods 
Generation of Experimental Mice 
Male Cdh5CreER(T2) or Col1α2CreER(T) mice were crossed with female ROSA26R-
tdTomatoflox/flox mice to generate experimental Cdh5CreER(T2):ROSA26R-
tdTomatoflox/flox (EndoTom) or Col1α2CreER(T):ROSA26R-tdTomatoflox/flox (FibroTom) 
reporter mice, respectively. Cre-positive progeny were expected to have permanent 
tdTomato-labelled endothelial cells or fibroblasts following daily i.p. injection with 
1mg tamoxifen in peanut oil for 3 or 10 days, respectively.  
Mice were genotyped by ear biopsy as described in chapter 2 and homozygous 
tdTomato “STOP” floxed mice were used for experiments (Figure 6-1). 
 
Figure 6-1: PCR-based genotyping of reporter mice using DNA gel analysis. Primers 
recognised the wildtype (WT) ROSA26 and mutant ROSA26-tdTomato alleles. A single 
upper band (297 bp) indicated wildtype (WT), a single lower band (196 bp) indicated 
homozygous “STOP” flox and both bands together (297 bp + 196 bp) indicated 
heterozygous “STOP” flox mice.  
Transverse Aortic Constriction  
Transverse aortic constriction (2 weeks) was performed as described in chapter 2, 
with echocardiography used to determine successful TAC 1 day later as described.  
Primary Cardiac Cell Isolation 
FibroTom or EndoTom reporter mice were killed by cervical dislocation. An abdominal 
incision was made and continued up to the thorax to expose the heart. The right 
atrium was cut and the left ventricle perfused with approximately 1mL saline or PBS 
to remove circulating blood. The atria were removed and the remaining heart excised 
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and placed into a pot of ice cold PBS. Heart tissue was disrupted to small (1mm2) 
pieces using scissors. Collagenase type II (Worthington Biochemicals; Lakewood, NJ) 
was reconstituted to 1200 units/mL in pre-warmed serum-free growth medium 
(Dulbecco’s Modified Eagle’s Medium (DMEM); Cat# D6546, Sigma, UK). PBS was 
aspirated from the disrupted tissue and replaced with 1.5mL collagenase media 
before being incubated with agitation (200rpm) at 37°C for 10 minutes. A further 
1.5mL of fresh collagenase was added and tissue chunks were triturated to aid 
digestion. The suspension was then further incubated for an additional 30 minutes. 
Enzymatic digestion was arrested by doubling the volume with media containing 10% 
foetal bovine serum (FBS). Avoiding frothing, cells and remaining tissue chunks were 
triturated ≥10 times by passing through a 21G needle, followed by a 23G needle to 
further promote a single cell suspension. Cells were centrifuged at 1200 rpm for 5 
minutes, then resuspended in 2mL cold flow cytometry buffer (PBS with 0.4% EDTA 
and 0.4% FBS) per heart, maintained on ice throughout and protected from light 
where possible. 
Alternatively, cells were resuspended in 5mL fresh warm growth medium with 10% 
FBS, supplemented with penicillin and streptomycin and transferred to a T25 cell 
culture flask and incubated at 37°C. 
6.2.2 Flow Cytometry 
Flow Cytometry Concepts 
Flow cytometry is a powerful tool for the quantitative analysis of the optical 
properties of single cells within a suspension. A flow cytometer can be broken down 
to 3 essential systems (Figure 6-2). Firstly, the fluidics system uses sheath fluid to 
hydrodynamically focus the cell suspension into a single cell beam, which is presented 
to the flow cell. The flow cell is an interrogation point where the optical properties of 
a cell are analysed. Secondly, the optics system has two components; excitation 
optics and collection optics. The excitation optics system uses a range of lasers to 
introduce light to the flow cell and the collection optics systems collects scattered 
light from the flow cell as a result of light-cell interactions. In addition, the collection 
optics system uses dichroic mirrors and specific wavelength filters to direct light to 
specific detectors. Lastly, the electronics system amplifies and converts the optical 
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signals reaching the detectors into proportional electronic signals, detailing the 
optical footprint of the cell.  
 
Figure 6-2: Fluidics, optics and electronic components of a typical flow cytometer. 
The single cell suspension is hydrodynamically focussed and passed through the flow 
cell via the fluidics system. Scattered light from coloured lasers reaches specific 
detectors and the information is converted to a digital signal via the electronics. After 
passing through the flow cell, cells are discarded or can be sorted based on 
fluorescence for downstream applications. The FSC and SSC detectors report the size 
and granularity of each cell, respectively. 
Scattered light is detected in terms of forward and side scattered light (FSC and SSC, 
respectively) for size and granularity analysis. In addition, flow cytometers use a 
range of colour lasers which emit excitation light of a specific wavelength. In a typical 
flow cytometry experiment, cell suspensions are stained with fluorophore-conjugated 
antibodies against proteins of interest, which ideally have a distinct, narrow range of 
excitation/emission wavelength properties. Further to this, optical filters have a 
specific wavelength median and range for the passage of light, and will absorb or 
reflect non-suited light. For example a 530/30 filter allows scattered light of 
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wavelength 515nm-545nm to be detected. As such a 488nm laser used with a 530/30 
filter will excite and detect fluorescein isothiocyanate (FITC)-conjugated antibodies, 
but not allophycocyanin (APC)-conjugated antibodies (Table 6-1). Cells can therefore 
be stained with multiple conjugated antibodies, enabling multicolour analysis.  
Table 6-1: List of conjugated fluorophores used in flow cytometry experiments and 
the lasers by which they were excited. Note that tdTomato was detected as a 
phycoerythrin (PE) fluorophore. 
Flow Cytometer Laser (Colour) Filter/ Fluorophore 
BD Accuri C6 488nm (Blue) 533/30 FITC 
  585/40 PE 
 640nm (Red) 675/25 APC 
    
BD FACSCanto II 488nm (Blue) 530/30 FITC 
  585/42 PE 
 633nm (Red) 660/20 APC 
    




 633nm (Red) 670/30 APC 
 
Cell Staining 
Flow cytometry was performed in round-bottomed flow cytometry tubes (Falcon, 
Corning, UK) on a 200µL aliquot of cells per sample, including an unstained control. 
Cells were incubated with primary antibody (see Table 6-2) for 30 minutes. Non-
specific staining was removed by washing via the addition of 2mL cold flow cytometry 
buffer and centrifugation at 1200 rpm. Cells were then resuspended in 200µL cold 
flow cytometry buffer before running samples on the flow cytometer (BD Accuri C6, 
BD FACSCanto II, or BD Fortessa, BD Biosciences). Note that for DDR2 staining, cells 
underwent a second incubation with Alexa Fluor® 488-conjugated anti-goat 
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secondary antibody (A-11078, ThermoFisher Scientific, UK; excitation/emission max 
495/519nm). 
Samples were run initially at slow speed (14µL/minute) using a maximum threshold of 
1,000,000 cells. Data was analysed and presented using FlowJo software (FlowJo LLC, 
OR, USA). 
Table 6-2: List of primary conjugated antibodies and their dilutions used in flow 
cytometry experiments. All antibodies are anti-mouse and developed in rat, except 
where stated*. Additionally, the reporter, tdTomato, is similar to PE and discosoma 
sp. red (DsRed) and has maximum excitation at 554nm and maximum emission at 
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Voltage Setting 
Detected cells are recorded as voltages in flow cytometry. When using the BD 
FACSCanto or BD Fortessa, an unstained control sample was used to adjust cellular 
event voltages on FSC-A and SSC-A and for each colour channel used. This was to 
optimise the signal to noise ratio for recorded events, meaning that negative 
populations were recorded on the far left of the graph, allowing easy detection of 
positive populations. A single stained control was then used to further optimise the 
detection of positive populations. Voltages were then kept constant for each 
experiment.  
Voltage setting was not necessary on the BD Accuri C6 and negative events usually 
arose before the third log decade.  
Flow Cytometry Compensation 
Although flow cytometry detectors are aligned to detect specific wavelengths, it is 
common for fluorescence emitted from a single fluorophore to spill over into another 
detectors channel. This is known as spectral overlap and leads to false positives in 
multicolour experiments. The effect of spectral overlap can be eliminated by using 
appropriate compensation controls in every experiment.214 Compensation was 
performed manually using single-stained control samples on the BD Accuri C6, an 
example compensation matrix is detailed in Table 6-3 (note that channel 3 is not used 
owing to high spectral overlap between channel 2 and 3). Compensation was applied 
automatically using single-stained controls on the BD FACSCanto or BD Fortessa via 
the BD FACSDiva™ acquisition software (BD Biosciences, v8).  
Table 6-3: Commonly used compensation matrix for BD Accuri C6 flow cytometer. 
Values represent the percentage spectral overlap from channel to channel, e.g. 
channel 2 spills into channel 4 by 5%. Note that the compensation matrix changed 
slightly for each experiment.  
 Channel 1-A Channel 2-A Channel 4-A 
Channel 1-A 100% 7% 0.4% 
Channel 2-A 7% 100% 5% 
Channel 4-A 0% 0% 100% 
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Flow Cytometry Gating and Analysis of Cardiac Cells 
All flow cytometry events were registered on FSC-A and SSC-A for x- and y-axis, 
respectively. Cardiac cells were gated according to the schematic shown in Figure 6-3. 
For each round of gating, the main populations of events were manually selected and 
taken forward. For round one, cells were gated on FSC-A and SSC-A (Figure 6-3A – 
“cells”) for debris exclusion. For round two, cells were gated on FSC-A and FSC-H 
(Figure 6-3B – “single cells”) for doublet exclusion. For the final round, cells were 
gated on SSC-A and SSC-H (Figure 6-3C) – “single cells”) for a second doublet 
exclusion. Lastly, positive/negative gates were placed on histograms for each 
fluorescence channel, ensuring less than 1% positivity on an unstained sample (Figure 
6-3D-F). This gating strategy was then applied to all samples in the experiment and 
further adjusted if needed for analysis. 
 
Figure 6-3: Basic flow cytometry gating strategy for cardiac cells. Main populations 
of cells are selected and taken forward on FSC-A vs. SSC-A (A), FSC-A vs. FSC-H (B) and 
SSC-A vs. SSC-H (C). Positive/negative gates were then placed on fluorescence-specific 
channel histograms for FITC/Alexa 488 (D), tdTomato (E) and APC/Alexa 647 (F).  
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During cell isolation and staining steps, some cells may die and begin to take up 
fluorescent dye non-specifically. This skews data and gives false positives. Dead cells 
were excluded from initial experiments using the dead cell stain 7AAD in fluorescence 
channel 3 (Figure 6-4). Analysis showed that there was generally less than 1% dead 
cells on average. Dead cell exclusion was not performed in subsequent experiments, 
owing to the high spectral overlap between channels 2 and 3, as discussed above. 
 
Figure 6-4: Dead cell exclusion using the dead cell marker 7AAD. An unstained 
control (upper panel) was used to set a positive gate for 7AAD+ (dead) cells (lower 
panels) showing an average of less than 1% dead cells. Data is taken from 3 separate 
experiments. 
For experiments involving multiple fluorophores, fluorescence minus one (FMO) 
control samples were used to set positive and negative gates. Essentially, these 
controls contain all experimental fluorophores except for the named fluorophore. For 
example, positive and negative gates will be set for the FITC channel using a FITC FMO 
sample (containing FITC and APC). Using such controls is more accurate, since the 
presence of multiple fluorophores in one sample can artificially augment the 
fluorescence signal. 
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Col1α2 Cre-recombinase Efficiency 
Cell suspensions from FibroTom reporter mice were single stained with a fibroblast 
antibody: CD140α-FITC or CD90-FITC.  
Alternatively, freshly isolated cardiac cells from FibroTom reporter mice were seeded 
onto a T25 flask and allowed to adhere for up to 72 hours. The flask was washed with 
PBS and non-adherent cells discarded. Remaining cells were detached using trypsin 
(ThermoFisher Scientific, UK) and washed in growth medium, before being 
centrifuged and re-suspended as above. Flow cytometry was then performed on 
these cells as described. 
The Col1α2 Cre-recombinase efficiency was defined as the percentage of fibroblast 
marker+ cells also expressing tdTomato fluorescence (e.g. CD140α+tdTomato+).  
Cdh5 Cre-recombinase Efficiency 
Cell suspensions from EndoTom reporter mice were stained with an endothelial cell 
antibody: CD31-APC, CD31-FITC, CD201-APC or CD144-APC. Flow cytometry was 
performed and analysed as described. The Cdh5 Cre-recombinase efficiency was 
defined as the percentage of endothelial cell marker+ cells also expressing tdTomato 
fluorescence (e.g. CD31+tdTomato+). Cre-recombinase specificity was defined as the 
percentage of tdTomato+ cells also expressing an endothelial cell marker (e.g. 
tdTomato+CD31+). This measure reflects how specific the Cdh5-driven Cre-
recombinase is at targeting tdTomato expression to endothelial cells. 
Determination of Endothelial-Mesenchymal Transition 
Male EndoTom reporter mice subjected to 14 days TAC were killed by cervical 
dislocation and cardiac cells isolated as described. Cardiac cells were stained with 
CD31-APC and CD140α-FITC or CD201-APC and CD90-FITC antibodies, followed by 
flow cytometry and analysis as described. The experimental overview and possible 
outcomes are detailed in Figure 6-5. In brief, tdTomato+ cells from TAC mice were 
assessed for their expression of fibroblast markers. The percentage of tdTomato+ 
fibroblast marker+ cells was compared to EndoTom reporter sham controls. In 
addition, lungs were excised and processed as described for cardiac tissue, including 
isolation of lung cells, staining and flow cytometry. 




Figure 6-5: Experimental plan to determine the extent of endothelial-mesenchymal 
transition in EndoTom reporter mice subjected to TAC. A: Experimental timeline, 
including day 1 echocardiography for the estimation of TAC gradient. B: tdTomato+ 
cells are identified and C: examined for expression of the fibroblast marker CD140α. 
Cells falling into the upper right quadrant would be regarded as fibroblasts with 
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6.3 Results 
6.3.1 FibroTom Reporter Mice 
Further Characterization 
Following tamoxifen treatment for 10 days, exposed skin of FibroTom reporter mice 
was visibly pink/red and with quantitatively higher tdTomato fluorescence compared 
to Cre-negative controls when placed in a bioluminescence scanner (Figure 6-6). This 
indicated successful Cre-recombinase activity and recombination in skin fibroblasts.  
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Figure 6-6: Successful Cre-recombinase activity in Col1α2CreER(T):ROSA26-
tdTomatoflox/flox (FibroTom) mouse skin fibroblasts. Left: Cre-negative and right: 
Cre-positive mice were scanned in a bioluminescence scanner set to detect tdTomato 
fluorescence. Fluorescence counts were quantified and are shown on the right-hand 
bar chart. Data represents mean counts of tdTomato fluorescence in 1 second; 
***P<0.001 vs. Cre-negative control by t-test; n=3.  
Successful recombination in heart and lung tissue was shown qualitatively by the 
detection of tdTomato fluorescence in excised FibroTom heart and lungs using 
fluorescence microscopy (Figure 6-7). Importantly, this highlighted sustained 
expression, as heart and lung tissues were excised approximately 12 weeks following 
cessation of tamoxifen treatment. Additionally, tdTomato fluorescence was not 
detected in Cre-negative mice.  
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Figure 6-7: Successful recombination in heart and lungs of FibroTom reporter mice. 
Representative bright-field and fluorescence microscopy images of whole excised 
heart (upper images) and lung (lower images) in a FibroTom reporter mouse 12 
weeks after cessation of tamoxifen (right on each image) and Cre-negative control 
(left on each image).  
Furthermore, florescence microscopy of cardiac sections from FibroTom reporter 
mice showed diffuse tdTomato fluorescence throughout heart tissue (Figure 6-8B). In 
contrast, Cre-negative hearts did not have any tdTomato fluorescence (Figure 6-8A).  
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Figure 6-8: Diffuse tdTomato fluorescence throughout cardiac sections of FibroTom 
reporter mice. A: Cre-negative control as seen using transmitted light. B: Diffuse 
tdTomato fluorescence in Cre-positive cardiac section. Scale bars 100µm. Images 
captured on a Leica TCS SP5 Confocal Microscope (Leica Microsystems LTD, UK).  
Cardiac sections were fixed and prepared for staining with DDR2 or vimentin 
fibroblast-specific antibodies, however processing led to the rapid loss of tdTomato 
fluorescence. This included fixation with 4% PFA or acetone, as well as the application 
of cover slips with commercial mounting media. 
Regardless, taken together tdTomato is expressed in fibroblasts in a range of tissues, 
indicating Col1α2 Cre-recombinase activity. 
Cardiac Fibroblast Labelling and Col1α2 Cre Efficiency 
Despite qualitative evidence to suggest successful expression of tdTomato in 
fibroblasts, cardiac cell suspensions from FibroTom mice frequently yielded a very 
low percentage (<2%) of tdTomato+ cells (Figure 6-9 and 6-10). This could suggest an 
effect of the collagenase digestion enzyme used, which may affect the fluorescence 
of fibroblast-derived tdTomato. It is worth noting that collagenase digestion may also 
affect the binding of fibroblast markers used here. In contrast, fibroblasts were found 
to represent up to 27% of total cardiac cells, as determined by CD140α, CD90 or DDR2 
antibody staining (Figure 6-10). There was a significant difference in the proportion of 
cells indicated to be fibroblasts depending on the antibody used. In addition to 
CD140α and DDR2, CD90 was used since it is a surface marker, shown to be expressed 
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by the majority of cardiac fibroblasts.215, 216 CD140α, CD90 and DDR2 stained on 
average 6%, 15% and 27% respectively, indicating that these antibodies were unlikely 
to be labelling all fibroblasts. 
 
Figure 6-9: Flow cytometry of FibroTom cardiac cells yielded a very low percentage 
of tdTomato+ cells. Plots are from 3 separate experiments comparing Cre-negative 
(wildtype) and Cre-positive (FibroTom) mice treated with tamoxifen. Positive 
percentages are shown inside gates, ranging from 0.11% to 0.75%. 
F lo w  C y to m e tr y
































td T o m a to C D 1 4 0
F IT C
C D 9 0
F IT C
D D R 2






Figure 6-10: Flow cytometry of cardiac cells revealed differential labelling of 
fibroblasts with CD140α, CD90 or DDR2 antibodies. Antibody targets and conjugated 
fluorophores are shown. Horizontal lines represent significant differences in staining 
proportions by flow cytometry P<0.05; 1way ANOVA with Tukey’s post-test for 
multiple comparison; n=6, 8, 7, 2, respectively. 
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Taken together, a low percentage of tdTomato+ cells would indicate a very low Cre-
recombinase efficiency; however this was unlikely to be true (e.g. based on 
assessment of whole heart or heart sections). For further investigation, flow 
cytometry experiments were then performed on adhered cardiac fibroblasts. Firstly, 
isolated cardiac cells seeded in T25 flasks attached and grew to confluency. 
Fibroblasts were identified by their elongated morphology, whereas contaminating 
cardiomyocytes and other cells were identified as weakly auto-fluorescent, rounded 
shapes. Fluorescence microscopy of cardiac cells from FibroTom mice showed 
tdTomato florescence in the majority of fibroblasts (Figure 6-11). In contrast, 
tdTomato fluorescence was absent in cardiac cells isolated from Cre negative mice, 
confirming Cre-recombinase dependency.  
 
Figure 6-11: tdTomato fluorescence in seeded fibroblasts isolated from FibroTom 
mouse cardiac tissue. Bright field (left) and fluorescence (right) images from cardiac 
cells in culture. Fibroblasts were identified by morphology. Representative images 
using 20x objective. 
Adhered cells were detached, stained and subjected to flow cytometry and showed 
that 30-40% of adhered cardiac cells were tdTomato+ (Figure 6-12). Additionally, on 
average 44% of cells were CD140α+, of which nearly 70% were also tdTomato+ in 
FibroTom-derived cells (Figure 6-13).  
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Figure 6-12: Adhered cardiac cells subjected to flow cytometry. Two separate 
experimental cultures are shown, with FibroTom cells shown on the right and Cre-
negative control cells on the left.  
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Figure 6-13: Flow cytometry of adhered cardiac cells from FibroTom and Cre-
negative mice. CD140α+ cells represent approximately 44% of adhered cells and 
nearly 70% of CD140α+ cells were also tdTomato+.  
Assuming similar Col1α2 Cre-recombinase activity in fibroblast NOX2 KO mice, these 
data suggest that the Cre-recombinase efficiency was up to approximately 70%. It 
was therefore inferred that the lack of phenotype in fibroblast NOX2 KO mice in 
response to TAC was not due to inadequate knockdown. 
6.3.2 EndoTom Reporter Mice 
Further Characterization 
Following tamoxifen treatment for 3 days, EndoTom mice had tdTomato fluorescence 
in cardiac sections (Figure 6-14). Fluorescence microscopy at low magnification 
showed a speckled tdTomato fluorescence appearance throughout the heart (Figure 
6-14B). Higher magnification showed that tdTomato fluorescence was found in 
between cardiomyocytes at cell junctions, suggestive of small capillaries (6.14C). In 
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addition, larger coronary vessels were tdTomato-positive in areas corresponding to 
the vessel wall (6.14D). Lastly, Cre-negative controls did not express tdTomato and 
are only visible using transmitted light (6.14A).  
 
Figure 6-14: Fluorescence microscopy of cardiac sections from EndoTom reporter 
mice show tdTomato fluorescence in areas corresponding to cardiac endothelial 
cells. A: Cre-negative control as seen using transmitted light. B: Low magnification 
(20x objective) of Cre-positive cardiac section showing speckled tdTomato 
fluorescence. C: High magnification (63x objective) showing tdTomato cells in 
between cardiomyocytes, with a tube-like appearance similar to that of small 
capillaries. D: Large coronary vessel (63x objective) with tdTomato fluorescence in the 
luminal lining. Scale bars 100µm. Images captured on a Leica TCS SP5 Confocal 
Microscope (Leica Microsystems LTD, UK). 
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Cardiac sections were fixed and prepared for staining with CD31 antibody, however 
processing led to the rapid loss of tdTomato fluorescence. This included fixation with 
4% PFA or acetone, as well as the application of cover slips with commercial 
mounting media. 
Cardiac Endothelial Cell Labelling and Cdh5 Cre Efficiency 
Results show that tdTomato+ cells represented approximately 6-7% of total cardiac 
cells from EndoTom mice. From this, it was anticipated that endothelial cell markers 
would provide a similar proportion, assuming high Cre recombinase efficiency.  
In contrast to tdTomato, the proportion of endothelial cell marker+ cells was higher 
and varied significantly depending on the antibody and fluorophore used (Figure 6-
15). 13% of total cardiac cells stained positive for the commonly used endothelial cell 
marker, CD31. 20% of total cardiac cells stained positive for CD144, another 
commonly used endothelial cell marker. CD201 is suggested to play a key role in the 
prevention of thrombosis by interaction with Protein C217 and is expressed by 
endothelial cells in the heart and lungs and in large vessels.218 Furthermore, CD201 
was shown not to be expressed in fibroblast cultures in vitro.219 Here, CD201 was 
similar to CD31-FITC, staining approximately 11% of total cardiac cells.  
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Figure 6-15: Flow cytometry of cardiac cells reveals differential labelling with 
endothelial cell specific markers. Antibody targets and conjugated fluorophores are 
shown. Horizontal lines above bars represent significant differences in staining 
proportions by flow cytometry P<0.05; 1way ANOVA with Tukey’s post-test for 
multiple comparison; n=13 for tdTomato and n=6, 3, 6, respectively for conjugated 
antibodies.  
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The majority (approximately 85%) of tdTomato+ cells also expressed CD31 (Figure 6-
16), which indicated highly specific targeting of the Cdh5-driven Cre recombinase to 
endothelial cells. In contrast, of the CD31+ cells, only 15-40% were also tdTomato+, 
suggestive of low Cdh5 Cre-recombinase efficiency. This, however, most likely reflects 
non-endothelial cell staining by CD31, since endothelial cells are reported to only 
account for approximately 5-10% of all cardiac cells and CD31 is also expressed by 
other cells including leukocytes and platelets. The CD144 and CD201 antibodies also 
estimated a low Cre-recombinase efficiency, however in contrast to CD31, very few 
tdTomato+ cells were positive for these markers (approximately 17-28%; Figure 6-16). 
Since the majority of tdTomato Cdh5-derived “endothelial cells” in cardiac tissue do 
not express CD144 and CD201 in the current study, these markers might not be best 
suited to determine Cdh5 Cre-recombinase efficiency.  
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Figure 6-16: Cdh5 Cre-recombinase efficiency and specificity varies depending on 
the endothelial cell-specific marker used. The percentage of endothelial cell marker 
positive cells also expressing tdTomato (efficiency) or tdTomato positive cells also 
expressing an endothelial cell marker (specificity) is shown. **P<0.01 vs. CD31 (FITC) 
efficiency; †††P<0.001 vs. CD31 (FITC) specificity; 2way ANOVA with Tukey’s post-test 
for multiple comparison; n=3. 
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Since CD31 is also expressed by non-endothelial cells, it is difficult to accurately 
determine the Cdh5 Cre-recombinase efficiency in this experiment. However, more 
than 80% of tdTomato+ cells express CD31, suggesting high Cre specificity for 
targeting endothelial cells.  
Endothelial-Mesenchymal Transition in TAC 
Male EndoTom mice subjected to TAC developed trans-TAC pressure gradients of 
greater than 40mmHg, similar to those generated in chapters 4 and 5 (Figure 6-17). 
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Figure 6-17: EndoTom mice developed significant echocardiography-derived trans-
TAC pressure gradients of between 50-60mmHg, indicative of successful TAC 
surgery. Student’s t-test; *P<0.05 vs. sham control; n=3. 
Flow cytometry of sham operated EndoTom mouse hearts suggested a basal 
population of fibroblasts with endothelial origin, since approximately 21% of 
tdTomato+ cells also express the fibroblast marker CD140α (Figure 6-18). It is possible 
that CD140α might have labelled endothelial cells, giving rise to this subpopulation of 
fibroblasts with endothelial origin. Most importantly, TAC did not significantly 
augment this percentage, with approximately 26% of tdTomato+ cells also CD140α+ 
cells (P=0.34), suggesting an absence of TAC-induced EndoMT.  
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Figure 6-18: TAC did not lead to an increase in cardiac tdTomato+ cells expressing 
the fibroblast marker CD140α. Representative plots from flow cytometry of 
EndoTom mouse hearts. P=0.34 vs. sham; student’s t-test; n=3.  
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Similar to cardiac tissue, the lungs also contain endothelial cells and fibroblasts, and 
evidence suggested that EndoMT may contribute towards the development of 
pulmonary fibrosis.208 In parallel experiments, lung tissue was collected and 
processed for flow cytometry following TAC. Virtually all lung tdTomato+ cells 
expressed CD31 (92-96%). Importantly, 35% of tdTomato cells expressed CD140α, 
which was not augmented by TAC (P=0.95; Figure 6-19). This is again suggestive of a 
lack of EndoMT following TAC and a possible lack of fibroblast specificity for CD140α.  
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Figure 6-19: TAC did not lead to an increase in lung tdTomato+ cells expressing the 
fibroblast marker CD140α. Flow cytometry of lung tissue from EndoTom mice. 
Approximately 92-96% of tdTomato+ cells were positive for CD31. Approximately 35% 
of tdTomato+ cells express CD140α, both prior to and after TAC. P=0.95 vs. sham; 
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6.4 Discussion 
A key report regarding cardiac EndoMT in 2007 provided a potentially new and 
exciting target for preventing the development of cardiac fibrosis.30 There is now a 
larger body of evidence supporting the process of EndoMT in cardiac fibrosis from a 
range of stimuli.52, 53, 198, 211 This is alongside reports detailing a reduction in 
endothelial cells and an increase in fibroblast numbers following pressure 
overload.172, 212 Despite this, emerging research disputes these claims, suggesting that 
EndoMT does not occur.129, 213, 216 The data presented in this chapter, although 
preliminary, are in support of the recent and thorough report by Moore-Morris and 
colleagues,213 showing no evidence of cardiac EndoMT in mice subjected to chronic 
pressure overload.  
6.4.1 Fibroblast-Specific Markers? 
A truly fibroblast-specific marker has yet to be identified. FSP-1 appears to be a 
misnomer, since up to 45% of FSP-1+ cells also express CD31, indicating that FSP-1 
antibodies label endothelial cells and leukocytes.212 Furthermore, FSP-1+ cells were 
not detected during neonatal cardiac remodelling in mice, a process involving the 
proliferation of fibroblasts, further limiting the credibility of FSP-1.212 αSMA is also 
often used in the detection of fibroblasts or myofibroblasts,30, 53 but is actually a 
smooth muscle cell marker, with very little fibroblasts labelled in healthy cardiac 
tissue.213 
Other fibroblast markers include CD140α, CD90, DDR2 and vimentin, all of which are 
reported to be expressed by other cell types.213 Further difficulty arises since 
fibroblasts have varied origins and form subsets between different tissues and even 
within tissues. For example, a thorough examination of CD90+ fibroblasts showed 
different marker profiles between mouse tail skin and cardiac populations.215 There is 
also low co-expression of multiple fibroblast markers, including CD140α and CD90 
which are only co-expressed by approximately 28% of cardiac fibroblasts.215 As such, 
it can be now accepted that not all fibroblasts express all fibroblast markers, however 
in non-haematopoietic CD90+ cardiac cells, up to 80% expressed collagen 1, DDR2 or 
CD140α, suggesting that populations can be enriched prior to analysis.216 In this 
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chapter, CD140α was selected, since it is regarded as the most robust cardiac 
fibroblast marker and its surface location allows for easy antibody staining.220  
Regardless of the antibody used, it seems that the use of αSMA and FSP-1 as 
fibroblast markers is now ill-suited. Unfortunately, many of the earlier studies on 
EndoMT were based on the use of these markers.30, 52, 53 
6.4.2 Fibroblast Origins and Changes during Pressure Overload  
Interestingly, data in this chapter showed that under basal conditions, up to 20% of 
CD140α+ cardiac cells (fibroblasts) were of endothelial origin. This percentage is in 
agreement with a previous study using double transgenic mice with Tie2-tdTomato 
lineage traced endothelial cells and Col1α1-GFP lineage traced fibroblasts.213 The 
report concluded that up to 19% of fibroblasts had endothelial cell origins in naïve 
mice. In the current study however, tdTomato expression was induced during 
adulthood in mice. This would suggest that tdTomato+CD140α+ cells only became 
fibroblasts following induction at between 6-8 weeks of age, an unlikely occurrence. 
Alternatively, data presented here suggested that CD140α was also expressed on a 
subset of mature endothelial cells. This may also be true for CD90, another fibroblast 
marker. In a study using tamoxifen-induced Tie2-GFP lineage traced endothelial cells 
and CD90 as a fibroblast marker, approximately 20% of cardiac fibroblasts were 
shown to be of endothelial origin in naive mice. Importantly, this percentage did not 
change following TAC-induced fibroblast proliferation and fibrosis, similar to results 
obtained here.216 Data in this chapter suggested a lack of EndoMT in chronic pressure 
overload, supported by reports using two different approaches. Furthermore, 
CD140α and CD90, similar to FSP-1 and αSMA, might not be best suited for the study 
of EndoMT. 
6.4.3 Determination of Cre-Recombinase Efficiency 
A significant phenotype of delayed Ang II-induced hypertension was observed in 
fibroblast NOX2 KO mice in chapter 3. As such, and considering the previous 
characterization of the Col1α2 promoter,132, 136, 162 the Cre efficiency was never called 
into question. Using an indirect reporter mouse cross approach on isolated cells, it 
was estimated here that the Col1α2 Cre-recombinase efficiency was approximately 
70% in cardiac tissue following 10 consecutive days of tamoxifen.  
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In EndoTom reporter mice, the Cre efficiency could not be accurately estimated, 
owing to predicted non-endothelial targeting by the CD31 antibody. Encouragingly, 
tdTomato+ cells represented 6-7% of all cardiac cells, similar to that reported by two 
reports using CD31 as a marker.172, 199 Although care was taken to remove blood from 
excised hearts, contamination by platelets in particular may be responsible for the 
increased CD31+ proportions. With this in mind, the percentage of tdTomato+CD31+ 
(rather than CD31+tdTomato+) cells may provide a better efficiency estimate. A high 
efficiency is therefore predicted, since up to 90% of tdTomato+ cells also expressed 
CD31, with a higher percentage (close to 100%) in lung tissue. 
6.4.4 Study Limitations 
As discussed, the lack of a specific fibroblast marker has hampered research into this 
cell type for decades. Previous studies have highlighted the use of CD140α as a robust 
fibroblast marker, despite it being known to be expressed by endothelial cells.213 Here 
it was found that CD140α might be expressed by approximately 20% of endothelial 
cells, which potentially makes it difficult to detect low levels of EndoMT. In fact, 
EndoTom mice which underwent TAC appeared to have a modest increase in cardiac 
tdTomato+CD140α+ cells compared to sham (26% vs 21%). Therefore statistical 
analysis could represent a type II error, though the number of replicates used here is 
in line with previous reports of this type.30, 213 Regardless, despite emerging strategies 
for identifying fibroblasts, a more robust and specific marker is desperately needed. 
In addition, experiments carried out in this chapter were not without further 
challenges and limitations.  
In initial stages, tdTomato was selected owing to its superior brightness, stability and 
fluorescence persistence following various processing steps including fixation.133, 221 
In contrast to reports, tdTomato fluorescence was almost immediately lost from 
cardiac sections following fixation with 4% PFA or acetone. Even the application of 
commercial DAPI mounting medium led to the loss of tdTomato fluorescence. This led 
to difficulty in characterising FibroTom and EndoTom reporter mice by 
immunohistochemistry. Antibodies directed to tdTomato are available; however this 
avenue was not pursued.  
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In determining the Col1α2 Cre-recombinase efficiency, FibroTom hearts yielded very 
low proportions of tdTomato+ cells. This was despite up to 27% of cells being labelled 
as fibroblasts with DDR2, in agreement with current literature for mouse cardiac 
fibroblasts.199 As a consequence, the Col1α2 Cre-recombinase efficiency was 
determined using adhered cardiac cells in culture. This may have led to inaccuracies, 
since it is feasible that tdTomato fibroblasts may have different proliferation rates to 
that of non-reporter fibroblasts, thereby increasing or decreasing the relative 
numbers and therefore estimated efficiency. Culture time was limited to 72 hours in 
an attempt to limit this, whilst allowing adequate time for adhesion. It is possible that 
the loss of tdTomato fluorescence following collagenase digestion may be due to 
enzymatic modification of the fluorophore.  
6.4.5 Summary 
In summary, this chapter provides more evidence against the process of cardiac 
EndoMT in response to chronic pressure overload, in agreement with other recent 
reports.  
  












CHAPTER 7: General Discussion 
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7.1 Cardiac Fibrosis and Cardiac Dysfunction 
Cardiac fibrosis leads to cardiac dysfunction via mechanical and electrical defects. This 
is exemplified by heart failure with preserved ejection fraction (HFpEF), which 
represents around half of all heart failure cases.12 There is currently no specific 
therapy for cardiac fibrosis and the best commonly used treatments target signalling 
pathways relating to the renin angiotensin system, such as Ang II receptor blockers, 
angiotensin converting enzyme inhibitors and beta blockers, all of which take an 
indirect approach. 10  
Since cardiac fibrosis is central to the development and persistence of diastolic 
dysfunction and therefore HFpEF, anti-fibrotic therapies are highly desirable. Clinical 
trials involving MMP inhibition have been largely unsuccessful, likely owing to off-
target systemic effects and a possible dependence on duration of use.24, 222 Recent 
work indicates that serelaxin, a recombinant form of the human hormone relaxin-2, is 
an effective anti-fibrotic agent in experimental models of heart failure.223 It has also 
been shown to provide positive benefits in clinical trials, including reduction of 
hemodynamic load, dyspnoea and death after 180 days,224, 225 though questions over 
efficacy have halted progression to approval. Resveratrol is another drug which has 
gained much attention in recent years for its combined anti-hypertensive and 
antioxidant properties in mouse studies, shown to improve cardiac fibrosis.156, 226 
Unfortunately such studies have not been successfully translated to the clinical 
setting and an anti-cardiac fibrosis therapy still seems a long way off. It is common for 
promising pre-clinical candidates to fail in clinical trials, highlighting the need for 
more basic research. Furthermore, owing to an aging population, the burden of heart 
failure with preserved ejection fraction is expected to rise in the near future, since 
cardiac aging is associated with pathological stiffening and dysfunction.16  
NOX2 is expressed in a range of tissues and cell types, including cardiac fibroblasts, 
endothelial cells, cardiomyocytes and inflammatory cells. It has been repeatedly 
shown to play a key role in mediating cardiac remodelling and dysfunction in 
response to pathological stimuli such as infarction,32 chronic neurohumoral35, 62 or 
mechanical stimulation.118 Global NOX2 KO mice were shown to be resistant to 
hypertrophy and cardiac fibrosis, making it an attractive target for clinical research; 
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however the pleiotropic role of NOX2, not just as a pathological signalling molecule, 
makes it unsuitable to target indiscriminately. With this in mind, research has shifted 
towards trying to elucidate the cell-specific contribution of NOX2 to the development 
of these pathologies, yielding largely positive results. Fibroblasts are central to the 
production of cardiac fibrosis, and preliminary data suggested that fibroblast NOX2 is 
essential in a rat model of ethanol-induced fibrosis, though the lack of a fibroblast-
specific deletion approach makes it difficult to attribute NOX2 activity to fibroblasts 
specifically.227 In another recent report, NOX2 was overexpressed in mouse 
endothelial cells, showing an augmentation of cardiac fibrosis in response to chronic 
Ang II in vivo.53 This, along with other evidence, suggested that disrupting fibroblast 
or endothelial cell NOX2 activity may prevent the development of cardiac fibrosis.  
7.2 Thesis Summary 
The studies described in this thesis used novel NOX2 floxed mice to develop cell-
specific NOX2 KO mice and in particular, sought to determine the role of fibroblast 
and endothelial cell NOX2 in the development of cardiac fibrosis. The NOX2 floxed 
mice have essential regions of exons 1 and 2 flanked by LoxP sites, rendering NOX2 
dysfunctional upon Cre recombinase-mediated excision. Both cell-specific Cre 
recombinase promoters have been previously used and characterized130, 132 and the 
Cre recombinase efficiency was further investigated in chapter 6. Additional 
characterisation in terms of ROS production was not performed in the current study, 
but could have provided greater reassurance regarding NOX2 gene deletion. Although 
basal levels of superoxide production would not be expected to differ, since a 
lucigenin chemiluminescence-based approach in global NOX2 KO mouse heart 
homogenates showed similar production to that of wildtype mice,62 analysis following 
angiotensin II or pressure overload may have been beneficial. Other methods include 
spin trapping and dihydroethidium staining coupled with high performance liquid 
chromatography.228 
The possibility that deletion of NOX2 in fibroblasts or endothelial cells could be 
compensated for by upregulation of other NOX isoforms was not investigated in the 
current study, however our lab has previously shown that global NOX2 KO mice have 
unaltered NOX4 expression levels compared to wildtype.32 Similarly, in NOX4 KO mice 
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the expression of NOX2 was unaltered, suggesting that NOX2 and NOX4 can be 
deleted without affecting the expression of each other.34 In addition, the expression 
of p22phox and p47phox were unaltered in KO mice compared to flox. While this 
provides some support, if the loss fibroblast NOX2 is indeed compensated for by 
NOX4, then any effects on cardiac fibrosis would be masked.  
In chapter 3 it was found that NOX2 in fibroblasts is essential in the proper 
development of hypertension in response to chronic Ang II in vivo. Further to this, the 
development of cardiac fibrosis was found to be blunted in fibroblast NOX2 KO mice, 
supporting the hypothesis that fibroblast NOX2 plays a key, pathological role.  
It is known that hypertension in isolation promotes the development of cardiac 
fibrosis and as such, the delayed hypertensive response in fibroblast NOX2 KO mice 
could contribute towards the decreased development of cardiac fibrosis in these 
mice. The blood pressure component of chronic angiotensin II was therefore removed 
by the use of a chronic subpressor dose in mice, however this coincided with an 
absence of cardiac fibrosis and other cardiac pathology even in wild-type mice. A 
thorough review of current literature revealed a range of conflicting data with 
subpressor Ang II, most likely reflecting different routes of administration, strain 
differences and other variables. Taken together, chapter 3 suggested a possible 
indirect, pressor-dependent effect on the development of cardiac fibrosis in fibroblast 
NOX2 KO mice. In support of this, A novel potential mechanism for fibroblast NOX2-
mediated hypertension and vascular remodelling in response to chronic Ang II has 
been elucidated (Harrison et al., 2017; manuscript in preparation).  
Investigations were then focussed on determining this using a non-RAAS, blood 
pressure-independent model of fibrosis. 
Chapter 4 sought to determine the role of fibroblast NOX2 in a relatively blood 
pressure-independent mouse model of pressure overload induced by transverse 
aortic constriction. Curiously and in contrast to chronic Ang II, it was found that 
deletion of NOX2 in fibroblasts was not cardioprotective in terms of cardiac fibrosis 
following TAC. There was also no prevention of other cardiac remodelling and cardiac 
dysfunction. It was concluded that fibroblast NOX2 was either dispensable in the 
development of TAC-induced cardiac fibrosis – suggesting stimulus dependent NOX2 
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effects, or that there is a general non-essential role for fibroblast NOX2 in isolation. 
Taken together, chapters 3 and 4 suggested that fibroblast NOX2 led to cardiac 
fibrosis via a blood-pressure dependent mechanism. Experiments then moved 
towards investigating NOX2 derived from another cell type, namely endothelial cells. 
The role of endothelial cell NOX2 was investigated in chapter 5, again using TAC. 
Work from our own lab inferred that deletion of endothelial cell NOX2 would be 
beneficial, leading to a reduction in cardiac fibrosis and dysfunction. This was not the 
case, and endothelial cell NOX2 also seemed to be dispensable in the development of 
TAC-induced cardiac fibrosis. One obvious question remains unanswered and as such 
work is ongoing to determine the effect of endothelial cell NOX2 deletion in Ang II-
induced cardiac fibrosis, which would greatly compliment the experiments in chapter 
3. Such a study would also compliment work published by Murdoch et al., in 2014, 
which showed augmented cardiac fibrosis in Ang II-treated transgenic mice 
overexpressing endothelial cell NOX2. Interestingly, similar to fibroblast NOX2, the 
role of endothelial cell NOX2 appears to also be stimulus dependent. Very recent 
research from our laboratory has shown that transgenic mice overexpressing NOX2 in 
endothelial cells do not have augmented cardiac fibrosis in response to acute 
myocardial infarction.123 In addition, infarct sizes, survival and cardiac function is 
comparable to wildtype controls in these transgenic mice. These findings could have 
implications regarding how NOX2 might be targeted in both different cell types and 
different pathologies; however it must be considered that transgenic and knockout 
mouse model approaches might not always be comparable.  
Since endothelial cells have been repeatedly shown to be involved in the 
development of cardiac fibrosis, experiments were designed to investigate EndoMT 
as a possible mechanism. 
Recent research suggested a role for EndoMT in the development of cardiac fibrosis 
by contributing to the fibroblast pool and or promoting the conversion of resident 
fibroblasts to myofibroblasts.30, 52, 198 To test this, reporter mice were generated in 
which endothelial cells could be lineage traced with tdTomato. Reporter mice 
subjected to TAC showed no evidence of cardiac or lung EndoMT, since the 
proportion of fibroblasts with endothelial (tdTomato) origins was similar in TAC and 
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sham-operated mice. This was in agreement with more recent reports.213, 216 Evidence 
of EndoMT using the tdTomato reporter system would have allowed further 
investigation into the possible role of NOX2 in this process. For example, the effect of 
global NOX2 deletion on the extent of EndoMT could be investigated. Further still, the 
effect of fibroblast or endothelial cell-specific NOX2 deletion could then be 
investigated. Such experiments were not deemed necessary owing to the lack of 
evidence for EndoMT in standard reporter mice following TAC. 
7.3 Clinical Implications 
The clinical impact of cardiac fibrosis is well described, involving diastolic dysfunction 
and an eventual progression to systolic dysfunction and death. As discussed above, 
both cardiac fibrosis and diastolic dysfunction lack specific treatments, though there 
are a number of promising pre-clinical agents.10  
Various signalling pathways have been targeted in an attempt to attenuate the 
pathological development of cardiac fibrosis, discussed in chapter 1.5. In addition, 
there is a role for natriuretic peptides in the development of cardiac fibrosis. Secreted 
by ventricles, B-type natriuretic peptide is increased during cardiac stress and appears 
to be anti-fibrotic. B-type natriuretic peptide KO mice were shown to have significant 
basal fibrotic lesions compared to wildtype, and an exacerbation following pressure 
overload.229, 230 
The involvement of NOX2 in these pathologies provides an additional target, however 
a universal NOX2 blocker is anticipated to have severe detrimental effects in terms of 
leukocyte host defence. In addition, general antioxidant clinical studies have been 
largely unsuccessful. Whilst NOX2 activity is often regarded as pathological, other 
ROS sources can be beneficial. An example of this includes NOX4 signalling in 
cardiomyocytes, which is shown to limit adverse cardiac remodelling and fibrosis in 
response to pressure overload, as well as promoting angiogenesis.34 This offered 
some explanation as to why many antioxidant therapies failed to show significant 
benefits.  
Selective inhibition of NOX2 over NOX4 is therefore of interest. A small peptide, PR-
39, was shown to prevent transient cardiac dysfunction in a rat model of ischaemia-
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reperfusion.231 This peptide binds to p47phox, thereby preventing its interaction with 
p22phox and subsequent NOX2 enzyme assembly. Selectivity is a problem however, 
since the SH3 binding domain required for inhibition is also present in other 
proteins.232  
In contrast, the peptide inhibitor NOX2ds-tat is currently regarded as being NOX2 
isoform specific. The in vivo Inhibition of NOX2 by NOX2ds-tat was shown as 
beneficial in mice receiving chronic Ang II, leading to reduced superoxide production 
and systolic blood pressure.233 The extent of cardiac fibrosis was not reported, though 
a reduction in systolic blood pressure would be expected to alleviate its development. 
Furthermore, assays designed to monitor the interaction of p22phox and p47phox for 
NOX2 assembly have highlighted a number of opportunities for small molecule 
inhibition. In vitro experiments identified ebselen and a range of its analogues as 
selective inhibitors of NOX2 over NOX4, though these small molecules were also 
shown to target NOX1.234  
Despite these advances, it is known that not only is the ROS producing NOX isoform 
important, but also the cell type on which NOX is active. For example NOX2 activity in 
endothelial cells is detrimental in chronic Ang II, but appears to be merely 
coincidental in inflammatory cells.53  
Data in this thesis adds another layer of complexity, since NOX2 signalling is essential 
in fibroblasts for Ang II-induced hypertension and subsequent cardiac fibrosis, but is 
dispensable in TAC-induced adverse remodelling and dysfunction. This potential 
stimulus-dependent effect of cell-specific NOX2 activation requires further 
investigation.  
7.4 Study Limitations and Considerations 
The experiments presented in this thesis were conducted on mice and used mouse 
tissue in hopes of translation to human disease. Using mice has some drawbacks 
owing to species differences. In particular, cellular composition of cardiac tissue may 
differ significantly. There are a few reports stating that fibroblasts represent up to 
30% of the total cells in mouse cardiac tissue,172, 199 whereas this figure is estimated 
to be closer to 60% in rat hearts.199 This highlights significant species variation and 
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similar differences may exist between mouse and human hearts. Differing fibroblast 
proportions between species may alter the relative dependence on cell-specific ROS 
signalling or even the extent of EndoMT. This study used single cell suspensions from 
mouse hearts and estimated cardiac fibroblast proportions to be up to 27%. A 
comparable study in humans and especially one encompassing lineage tracing, is not 
feasible, making it difficult to bridge the gap between pre-clinical and clinical settings. 
Careful consideration is therefore required when attempting to conduct translational 
research.  
In the studies outlined here, the TAC model was extensively used in mice. TAC is a 
crude model of aortic stenosis, which simulates common clinical symptoms, including 
systolic and diastolic cardiac dysfunction, as well as severe cardiac fibrosis and 
hypertrophy. Despite this, owing to the rapid onset of stenosis and subsequent 
dysfunction, the TAC model is often regarded as lacking direct clinical relevance.170 A 
number of other mouse models leading to the development of cardiac fibrosis with 
slower onset are routinely used, such as chronic drug administration (e.g. Ang II or 
doxorubicin).35, 235 However, as seen in the experiments performed here, it is possible 
for cell-specific NOX2 to have stimulus dependent effects, requiring consideration of 
the mechanism of fibrosis development in these models.   
A final consideration is the fact that the development of cardiac fibrosis is complex 
and involves a range of cell types. Here, efforts were towards elucidating the role of 
fibroblast and endothelial cell NOX2, owing to their involvement in extracellular 
matrix production or EndoMT. It must be considered however, that a concerted 
activation of NOX2 from a range of cell types might be at play in response to chronic 
pressure overload. As such, whilst fibroblast and endothelial cell NOX2 will be 
activated following TAC, NOX2 from infiltrating inflammatory cells and even 
cardiomyocytes is also important, as well as cell-cell communication and cross 
activation. To investigate further, challenging double and or triple cell-specific 
knockout mice would have to be generated, as discussed in chapter 5. 
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7.5 Future Work 
Experiments to investigate the effect of endothelial cell NOX2 deletion on Ang II-
induced cardiac fibrosis would greatly compliment the studies described in this thesis. 
Work is already ongoing in the lab to determine this, though preliminary data 
suggests that endothelial NOX2 KO mice have a blunted hypertensive response, 
similar to that observed in fibroblast NOX2 KO mice. The extent of cardiac interstitial 
and perivascular fibrosis was determined using both brightfield and polarized light 
microscopy for most studies detailed in this thesis. The exception is for experiments 
in chapter 3.3.1, at which time a reproducible method was still under development. 
Thorough analysis is ongoing to make these data consistent with those reported in 
chapters 4.3.2 and 5.3.2 for use in publication. 
Collagen 1α2-promoted Cre recombinase was used in the current study to confer 
fibroblast specificity, but this promoter will target all fibroblasts, not just cardiac. 
Periostin is expressed by cardiac fibroblasts during development and in adult tissue in 
response to pressure overload.184 As such it identifies activated fibroblasts and is a 
useful tool for the study of cardiac fibrosis development. Deletion of NOX2 in 
activated fibroblasts using a periostin-driven Cre recombinase might provide more 
specific insights, especially considering that collagen 1α2 is expressed by cells other 
than fibroblasts.129  
7.6 Final Summary 
In summary, this thesis has built on knowledge of NOX2 in cardiac remodelling. Here, 
a role for fibroblast NOX2 specifically has been described in the development of 
angiotensin II-induced hypertension and cardiac fibrosis. The importance of fibroblast 
NOX2 may also be stimulus dependent, since mechanically-induced pressure overload 
did not require NOX2 in this cell type for detrimental cardiac effects. There is also a 
non-essential role for endothelial cell NOX2 in TAC and contrary to early reports, 
EndoMT is shown not to occur in cardiac or lung tissue in response to TAC.  
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